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This dissertation is the result of my own work and includes nothing which is the 
outcome of work done in collaboration except as declared in the preface and specified in 
the text.  It is not substantially the same as any work that has already been submitted 
before for any degree or other qualification except as declared in the preface and specified 
in the text. It does not exceed the prescribed word limit of 60,000 words, exclusive of 
figures, tables, footnotes, bibliography, and appendices as set by the Degree Committee.  
On the 23rd of March 2020, during the final year of this PhD, the Prime Minister placed 
the United Kingdom on a police-enforced lockdown to prevent the spread of Coronavirus 
(COVID19). This lockdown was enforced for several months, and as a result of the 
financial pressure arising as a result of the pandemic, my host institute the Animal Health 
Trust closed from the 23rd of March, entering compulsory liquidation on the 31st July 
2020. As such some aspects of the thesis were not completed.  
However, the majority of the work presented on the transcriptomic differences between 
adult, fetal and ESC-derived tenocytes described in chapter 3 has been published in 
(Paterson et al. 2020; Stem Cell Research & Therapy). Likewise, the bulk of the work 
describing the effect of knocking down scleraxis in adult, fetal and ESC-derived tenocytes 
outlined in chapter 4 & 5 has been published in (Paterson et al. 2020; Mechanisms of 
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Tendon injuries occur commonly in equine athletes. Adult tendons undergo poor natural 
regeneration, resulting in scar-tissue which is prone to re-injury. Fetal tendons however 
are capable of completely scar-less regeneration, a property which is intrinsic to the fetal 
cells themselves. Novel cell therapies should therefore try to recapitulate this scar-less 
fetal tendon regeneration. This thesis builds on previous research into the use of horse 
embryonic stem cells (ESCs) to aid tendon regeneration. The aim of this thesis was to 
determine if tendon cells derived from ESCs were more similar to fetal or adult tendon 
cells, as well as try to understand if scleraxis (SCX), an essential gene in tendon 
formation, has different roles at different stages of tendon development. 
Equine adult, fetal and ESC-derived tenocytes were cultured in a three-dimensional 
environment, with histological, morphological and transcriptomic differences compared. 
Additionally, the effects on gene expression of culturing adult and fetal tenocytes in either 
conventional two-dimensional monolayer culture or three-dimensional culture was 
compared using RNA-sequencing. No qualitative differences in three-dimensional tendon 
constructs generated from adult, fetal and ESCs were found using histological and 
morphological analysis. However, genome wide transcriptomic analysis using RNA-
sequencing revealed that ESC-derived tenocytes transcriptomic profile more closely 
resembled fetal tenocytes as opposed to adult tenocytes. Furthermore, this thesis adds to 
the growing evidence that monolayer cultured cells gene expression profiles converge, 
with adult and fetal tenocytes having only 10 differentially expressed (DE) genes when 
cultured in this manner. In contrast, when adult and fetal tenocytes were cultured in three-
dimensional culture, large distinctions in gene expression between these two 
developmental stages were found, with 542 genes being DE. 
The effects of knocking down the expression of SCX on gene expression in adult, fetal 
and ESC-derived tenocytes was then determined using RNA-sequencing and qPCR. SCX 
knockdown had a larger effect on gene expression in fetal tenocytes, affecting 477 genes 
in comparison to the 183 genes effected in adult tenocytes, indicating that scleraxis-
dependent processes differ in these two developmental stages. Gene ontology, network 




remodelling processes within both comparisons. These included several matrix 
metalloproteinases, proteoglycans and collagens, some of which were also investigated 
in SCX knockdown tenocytes from young postnatal foals. Using chromatin 
immunoprecipitation, novel genes that SCX differentially interacts with in adult and fetal 
tenocytes were identified. SCX knockdown in ESCs resulted in upregulation of cartilage 
markers, a result which still needs to be confirmed in further biological replicates.  
In summary, the data presented in this thesis provides an unprecedented insight into some 
of the differences between fetal regenerative and adult reparative tenocytes. It also 
indicated that ESC-derived tenocytes are more similar to fetal rather than adult tenocytes, 
highlighting their potential as a therapeutic cell source. The results presented also indicate 
a role for SCX in modulating ECM synthesis and breakdown and provides a useful dataset 
for further study into SCX gene regulation. Taken together this data is likely to be 
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 Chapter 1 – Introduction 
Orthopaedic injuries are the most common cause of wastage in the performance horse 
accounting for 82% of injuries in horses competing in National Hunt and flat races (1–3). 
Of these 46% are involved in overstrain and traumatic tendon and ligament injuries, with 
the superficial digital flexor tendon (SDFT) being particularly at risk (3). Current 
treatment methodologies are unsatisfactory, resulting in incomplete recovery and high re-
injury rates. Tendon injuries therefore remain a significant clinical challenge.  
1.1 Tendon structure and function 
1.1.1. Tendon composition  
Tendons are highly organised, dense, fibrous tissue structures which serve to transmit 
contractile forces from skeletal muscle to bone. The composition of the tendon is not 
homogeneous along the entire tendon axis, having different cellular and structural 
properties at both the interface between muscle (myotendinous junction) and between 
bone (enthesis) (4). Here however, I will focus on the tendon proper or tendon mid-
substance.  
Type I collagen fibrils are the predominant component of the tendon proper, making up 
65-80% of its dry weight (5). These fibrils are composed of a triple helix made up of two
α1 chains and oneα2 chain of molecules which align uniformly in the direction of force 
(6). The collagen molecules, encoded by the COL1A1 and COL1A2 genes, are organised 
into distinct hierarchical levels (Figure 1.1) and are stabilised by intermolecular 
crosslinks, primarily composed of proteoglycans (2). Decorin (DCN), hyaluronan (HA), 
lumican (LUM), biglycan (BGN) and fibromodulin (Fmod) are just some of the 
proteoglycans present. These proteoglycans have specialised carbohydrate 
glycosaminoglycan (GAG) side chains which allows them to link to other proteoglycans 
in order to maintain collagen fibril diameter and fibril distances, thereby providing 





structural strength (7–9). The synthesis of these extracellular matrix (ECM) components 
is conducted by a small population of resident tendon fibroblasts (referred to as 
tenocytes), which make up 95% of the cells within the tendon (10,11). Tenocytes in 
adults, although not a homogenous population, are predominantly characterised as 
elongated, spindle-shaped cells, whose large cytoplasmic extensions allow them to link 
to each other via gap junctions to form extensive communicative networks within the 
ECM (2,12,13). In general these tenocytes primary function is to remodel and control 
ECM production by producing collagens, proteoglycans and matrix metalloproteinases 
(MMPs) in response to mechanical stimulus (14).  
 
Figure 1.1. Tendon architecture. Structure of the tendon showing the interface between the 
tendon and bone (enthesis) moving into the tendon proper or tendon midsection. The tendon 
proper is composed of a hierarchical structure which spans from a single collagen fibre up to 
fibrils, fascicles and whole tendon. These collagen fibres arrange in parallel in the orientation of 
the applied force as displayed in the microstructure insert. Looking closer at the tendon 
microstructure (displayed in the cell niche insert), resident tenocytes populations (pink) are 
situated between the collagen fibres (yellow) and associate with proteoglycans (grey) which help 
to maintain the structural strength. The cellular population is however not homogeneous and other 
cell types are found between collagen fascicles and within the endotenon although they are not 
well characterised.  
 





The remaining 5% of cells include endothelial cells, chondrocytes and tendon 
stem/progenitor cells (TSCs) (10). TSCs are believed to differ from their terminally 
differentiated tenocyte counterparts by having multi-differentiation potential and self-
renewal capabilities, and have been identified in human, mouse, rabbit and equine 
tendons (15–17). However, the concept of tenocytes as being terminally differentiated is 
being challenged, with studies showing tendon-derived fibroblasts can also differentiate 
into chondrocytes, adipocytes and osteocytes suggesting instead that tenocytes may have 
trans-differentiation potential (18,19). This trans-differentiation potential is not unique to 
tenocytes, with fibroblasts derived from other tissues including the skin, lungs, heart as 
well as many others having also been demonstrated to have multilineage potential as 
outlined in Ichim et al., 2018 (20).  
Thorough comparison of tendon cell populations, in particular between tenocytes and 
TSCs, are scarce within the literature, with those that have been conducted showing 
conflicting results (21). One study in rabbits showed large differences in TSCs and 
tenocytes isolated from patellar and Achilles tendons, with TSCs having expression of 
stem cell markers octamer binding transcription factor-4 (OCT4), stage specific 
embryonic antigen-4 (SSEA4) and nucleostemin, which were absent in tenocytes (19). 
Similarly, a study comparing mouse TSCs and tenocytes showed increased expression of 
stem cell markers (Nanog and cluster of differentiation-73 (CD73)) in TSCs, although 
these were different markers than that observed in the rabbit study (21). In contrast 
comparison between TSCs and tenocytes isolated from the equine SDFT showed few 
differences in stem and tenogenic gene expression (22). Taken together, the lack of 
consensus data and molecular markers available to allow precise identification and 
isolation of tendon cell subsets at present impedes our understanding of their exact 
locations and functions. 
1.1.2. Tendon function 
The force transmitting SDFT shares remarkable similarities with the human Achilles 
tendon (AT) in terms of its composition and function (23,24). These tendons serve not 
only to connect skeletal muscle to bone, but also provide a means of energy-storing to 
facilitate high-speed locomotion. In simple terms, this system works by storing the 
potential and kinetic energy generated during the loading phase (i.e. as the foot hits the 





ground). This stored energy is then released back as elastic energy when the foot leaves 
the ground (i.e. the elastic recoil phase), thus reducing the muscular effort required (23). 
As such, these tendons are often referred to as biomechanical springs and in the galloping 
horse this elastic energy saving results in an up to 36% recovery of mechanical work (25). 
The efficiency of this energy return system has been calculated to be approximately 93%, 
with around 5% of energy being lost as heat (hysteresis) (23,26). This rise in temperature 
in the tendon core can reach up to 46ºC, a temperature in which fibroblasts from other 
locations would not survive (12,27). As the tendon is relatively avascular this heat is then 
very slowly dissipated. The tendon is therefore subjected to some of the most intense 
mechanical demands in the body (28), with strains of up to 16% in the equine SDFT 
having been recorded from horses at a gallop. This degree of strain is extremely close to 
the in vitro calculated tendon failure rate of 15-17% (2,29). However caution should be 
taken when comparing calculated strains from in vivo and in vitro experiments as they do 
not always corroborate (30). Regardless, the exposure of such high strains can put tendon 
tissue at risk of damage. 
1.2 Tendon injury and repair 
1.2.1. Pathogenesis of tendon injury 
Overstrain injuries are the most common form of tendon injury and occur either by a 
sudden overloading of the tendon or more frequently by a progressive build-up of 
microdamage due to repetitive exposure to high strains (12). Whilst it is not fully 
understood when these micro-degenerative changes progress into macroscale damage, 
this gradual weakening eventually overwhelms its structural integrity leading to 
irreversible damage (31). In the SDFT this damage most commonly presents in the central 
core region, which can be visualised ultrasonographically as a centrally located ‘hole’ 
(12).  
Modelling overstrain injuries has been conducted to try and explore the impacts of cyclic 
mechanical loading on tendon ECM and inflammatory protein production. Applying 
cyclic loading from 2-12% uniaxial strain to isolated equine SDFTs results in increased 
expression of interleukin-6 (IL-6) and cyclooxygenase-2 (COX2) inflammatory 





mediators, collagen degradation markers C1 and C2 as well as MMP13, albeit at 
relatively low levels (32). Similarly, loaded ex vivo bovine tendons exposed to cyclic 
strain from 1-10% show collagen fibre disruption as well as increased expression of IL-
6, COX2, MMP-1, 3 and 13 (33). Cell culture models echo these results, with human 
tenocytes exposed to 3.5% cyclic strain for 2 hours showing upregulation of MMP3 and 
interleukin 1 beta (IL1-β), a cytokine which can induce MMP expression (34). Such 
evidence suggests that it is this increased production of matrix degrading enzymes and 
low levels of inflammation, resulting from cyclic overloading of the tendon that 
ultimately results in the degenerative changes seen in tendinopathies.  
1.2.2. Tendon repair process 
Once the tendon presents with clinical injury the healing process is thought to comprise 
of three main stages (Figure 1.2). Firstly there is an acute and local inflammatory 
response, where inflammatory cells such as macrophages, monocytes and neutrophils are 
attracted to the injury via signalling from pro-inflammatory cytokines (35). Recruited 
inflammatory cells secrete growth factors which in turn activate tenocytes (36). In adults, 
there is then rapid cellular proliferation and a delayed but excessive accumulation of 
unorganised ECM, composed predominantly of type III collagen. Remodelling of the 
tissue then occurs over a number of weeks and months to consolidate the tissue, through 
gradually decreasing cellularity and increasing the fibrous matrix by replacing collagen 
type III with type I. Finally the maturation stage occurs, to stiffen and restore the tendons 
tensile strength (35). However, this newly remodelled scar tissue is functionally inferior 
in comparison to that of normal tendon. Although it tends to be on the whole stronger 
than that of the original tissue it is much stiffer, with this stiffness leading to reduced 
efficiency of the tendon acting as a spring which results in substantial risk of re-injury of 
up to 67% in racehorses and 31% in human athletes (23,37–39).  






Figure 1.2. Adult tendon repair process. Tendon healing passes through three main overlapping 
stages. Some of the most commonly cited matrix and molecular changes are listed in the figure 
above which is adapted from Schneider et al., 2018 (40). 
In contrast, fetal tendon wounds regenerate with non-disrupted collagen ECM through 
simultaneous proliferation and synthesis of organised collagen (41). Although the exact 
mechanisms of fetal scar-less healing are unknown, various studies suggest this 
difference in regenerative ability is partly explained by intrinsic differences between adult 
and fetal fibroblasts themselves. Comparative studies have indicated that differences in 
the migratory activity, inflammatory responses, cellular mediated expression of 
chemokine, cytokines and growth factors, and deposition of components of the ECM may 
play a vital role (41–44). The concept of fetal regeneration will be explored further in 
chapter 3.  
1.3 Therapies for tendon injury  
Many proposed treatments for tendon injuries have been developed and tested over the 
years, with most showing indistinguishable or even damaging results (12). The standard 
treatment for tendon injuries however remains to subject the horse to lengthy periods of 
confinement and controlled exercise programmes, which may be required for up to 12 
months post injury (45,46). Some alternative treatments are discussed below.  





1.3.1. Surgical intervention  
Surgical interventions during the acute inflammatory stage can be conducted in the horse, 
such as by percutaneous tendon splitting. Here a puncture is created with a scalpel or 
needle and typically intratendinous polysulfated glycosaminoglycans, a pharmacological 
agent which in vitro has been shown to inhibit prostaglandin E2 (PGE2) production, is 
injected in to reduce the pressure in the wound and promote vascularisation (47). This 
therapy has been shown to more rapidly decrease the lesion size in the tendon core, 
however functionally the tendon is not vastly improved in comparison to controlled 
exercise alone (47,48). Similarly, desmotomy of the accessory ligaments is often 
performed in conjunction with tendon splitting to allow lengthening of the SDFT 
muscle/tendon unit which is thought to protect the repairing SDFT from peak strain. 
However, although initial evidence suggested a beneficial effect by increasing the rate of 
return to racing, others have demonstrated it also results in an increased incidence of 
suspensory ligament strains and desmitis (47,49–51).  
1.3.2. Growth factors and biologics 
Newer treatment methods are starting to emerge focusing on enhancing tendon 
regeneration through the delivery of various growth factors. Growth factors are important 
signalling molecules that play a role in tendon healing and development, with growth 
factors such as insulin growth factor-1 (IGF-1), transforming growth factor beta (TGF-
b), basic fibroblastic growth factor (bFGF), platelet derived growth factor (PDGF), 
vascular endothelial growth factor (VEGF), to name a few, being of particular interest 
therapeutically (35,52). Typically these are applied by local injection, or by implanting 
biomaterial scaffolds or even suture material to allow for a more sustained release (35,52–
54). Overall, growth factor treatments appear to provide some beneficial effects for 
tendon healing. For example, treatment with PDGF has been shown to increase collagen 
production and crosslinking as well as hyaluronic acid content leading to improved 
functional movement in a canine model of intrasynovial flexor tendon repair (55). 
Similarly, bFGF has been shown to accelerate wound closure through stimulation of cell 
proliferation in rat patellar tendon injury models (56). Likewise the addition of IGF-1, 
bFGF and PDGF in rabbit flexor tendon injuries also resulted in a marked increase in cell 





proliferation rates (57). However, for many of these treatments the long-term benefits still 
remain to be seen, with mixed success being reported (58). 
Platelet rich plasma (PRP) treatment has gained much popularity in the last decade. This 
involves drawing peripheral blood from the patient and, using centrifugation or gravity 
filtration, red blood cells are removed, and the resulting concentrated plasma/platelet mix 
is then injected into the tendon. This PRP mix contains a rich source of growth factors 
which are believed to stimulate cell proliferation and ECM production (12). Evidence 
regarding PRP’s effectiveness is developing, however of the clinical trials conducted thus 
far, many include study biases with multiple factors contributing to this lack of evidence. 
Study biases and issues include the significant patient to patient variability in the 
constitution of PRP produced, differences in how vendors isolate PRP as well as the 
delivery method used, all of which make it difficult to draw strong conclusions (52). 
Systematic reviews on PRP have therefore failed to find solid evidence of its efficacy 
(59).  
1.3.3. Cell-based therapies  
The use of growth factors and biologics may be inadequate if the resident tendon cells 
cannot be manipulated to reduce the scarring. As such this has led to research into cell-
based therapies, to harness the powers of cells which do potentially possess such 
regenerative properties. One such strategy is the use of adult derived mesenchymal 
stromal cells (MSCs), which have the capacity to differentiate into tenocytes (Figure 1.3). 
To date the most commonly investigated MSC source is bone marrow-derived MSCs 
(BMSCs), which are increasingly being used in the veterinary field for transplantation 
into injured tendons and ligaments (60). This therapy has shown promising results, with 
one study showing a reduction in re-injury rates from 56% down to 18% following 
autologous implantation of BMSCs into injured SDFTs (61), with others showing similar 
reductions (39). However, the true efficacy of these studies is difficult to assess. Many 
clinical trials do not include adequate control animals, which likely reflects the reluctance 
of horse owners to enrol valuable horses into controlled studies where they may only 
receive a placebo. Similarly, comparisons between studies is difficult due to the many 
differences in the treatment itself such as whether the MSCs have been combined with 





other biologics such as serum, the number of MSCs injected, the age of the horses treated, 
the treatment follow up time and the post treatment recovery plan.  
Although the results from clinical trials of MSCs is encouraging there is still a number of 
limitations to their use. Firstly, each patient has to undergo an invasive tissue isolation 
procedure, typically bone marrow aspiration of the sternum, in order to collect the 
required cells. Of this aspirate only 0.001-0.01% of the total cell population contains 
BMSCs, which then need to be expanded in culture for 2-4 weeks before sufficient 
numbers are obtained for therapeutic use, which can result in loss of stemness (35). This 
long delay therefore prevents the immediate treatment of acute injury. Several clinical 
trials in surgical or collagenase induced tendon lesions in rats, rabbits and horses have 
demonstrated improved rates of healing and maturation as a result of BMSC treatment 
(62–65). However, in many small animal models ectopic bone formation was also 
described (66–68). In comparison to date, no ectopic bone formation has been described 
following MSC injection in the horse, highlighting that small animal studies often act as 
poor models for the horse (69). Similarly, the long-term effects on tendon strength and 
functional performance post injury remain unclear and proper follow up studies are 
required. 
Adipose tissue derived MSCs (ASCs) and umbilical cord blood (UCB) or tissue (UCT) 
MSCs have also been investigated as potential therapeutics. Adipose tissue in particular 
present as a much more accessible, abundant source of MSCs. Trials in equine 
collagenase induced SDFT injury have shown increased collagen fibre organisation as a 
result of ASC treatment (70). Peripheral blood is equally becoming an increasingly 
popular source of MSCs, which using techniques such as gradient separation, can lead to 
isolation of fibroblastic cells which display mesenchymal differentiation potential. 
Equine peripheral blood-derived MSCs have however been demonstrated to be more 
restricted in their differentiation potential compared to BMSCs (71). Similarly, studies 
using ASCs, UCB/UTC and peripheral blood MSCs are limited, and again like any 
autologous therapy, age, patient to patient variability and expansion time are a concern.  
Due to the various practical limitations related to autologous MSC treatments, 
investigations have been conducted into the use of allogeneic MSCs (i.e. those derived 
from a different horse than the recipient), with previous work from our group and others 
showing that MSCs are immune privileged in vitro (72–75). These in vitro studies have 





typically used mixed lymphocyte reactions (MLRs) to show that allogeneic MSCs inhibit 
the proliferation of major histocompatibility complex (MHC) mismatched lymphocytes, 
demonstrating also that MSCs secrete a variety of immunomodulatory cytokines in order 
to modulate this effect (76). In a clinical setting, MSC therapy has generally been 
regarded as safe following systematic reviewing of clinical trial data (77), however 
adverse clinical events such as cytotoxicity and allograft rejection has been observed in 
several horse, mouse, pig and macaques in vivo studies (78–86). This discrepancy is likely 
due to the fact that few clinical studies properly control for MHC matched or mismatched 
molecule expression or conduct a thorough immune response analysis, such as cell-
mediated functional assays, humoral assays and in vivo imaging to track MSC survival 
(76).  
Regardless, many companies are now offering “off the shelf” sources of MSCs to be used 
allogeneically in horses, including Arti-Cell® (of which the MSC source is not stated) and 
HorStem (UCT- derived MSCs) (87–89). However, questions regarding their efficacy in 
tendon injuries remain, with the concept of how exogenously applied MSCs function in 
the injured tendon changing considerable over the years (90). Where MSCs were first 
thought to migrate to the injury site, differentiate into functional tendon cells and engraft 
into the injured tissue, cell tracking techniques and follow up studies have disproven this 
theory. The survival rate of injected MSCs is in fact very poor (91–93) and as such it is 
now hypothesised that rather than actively contributing to tissue regeneration, MSCs may 
instead work via modulation of the inflammatory environment (72,94). As well as their 
ability to modulate the immune system response, in vivo studies have also demonstrated 
their ability to promote the growth and differentiation of resident progenitor and immune 
cells at the wound site (76,95,96). It is likely that in order for exogenous MSCs to have a 
full therapeutic effect via these indirect mechanisms, treatment would be best given 
during the acute inflammatory stage of tendon injury and further studies to assess the 
potential of allogeneic MSCs is needed.  
 





1.4 Pluripotent stem cells1 
Embryonic Stem Cells (ESCs) may offer an alternative solution to the drawbacks 
encountered when using MSCs for tissue repair. Here I will briefly discuss their history 
as well as the characteristics which make them an interesting candidate for tendon injury 
repair.  
1.4.1. A brief history of ESCs 
Although it is difficult to pinpoint when and who first discovered what we now call “stem 
cells”, the first scientists to thoroughly define their key characteristics were Ernest 
McCulloch and James Till in the 1960s. Their work led them to discover the blood-
forming stem cell, the haemopoietic stem cell (HSC), a cell type which could self-renew 
in culture and give rise to multiple cell types (98). This discovery would ultimately lead 
to the clinical application of bone marrow transplantations for haematopoietic disorders 
(98). This, and other key advancements in the field, led to the isolation and 
characterisation of many different stem cell types. The differentiation potential of stem 
cells is very dependent on the stage of embryonic development and are highlighted in 
Figure 1.3.  
 
1 Section modified and/or reprinted from Y Z Paterson, C Kafarnik and D J Guest, Characterization of 
Companion Animal Pluripotent Stem Cells, 137-148, © 2018, with permission from Wiley Online Library. 
https://onlinelibrary.wiley.com/doi/full/10.1002/cyto.a.23163.  






Figure 1.3. Stem cell differentiation pathway. At the base of the stem cell hierarchy is the 
fertilised oocyte, which is totipotent, having the ability to differentiate into extra-embryonic tissue 
as well as the embryo itself. Following this, during the initial days of mammalian embryonic 
development the first stem cells arise, derived from the inner cell mass of the pre-implantation 
embryo. These cells are termed embryonic stem cells (ESCs) and are pluripotent in nature, being 
able to differentiate into any cell type that arises from the three embryonic germ layers – 
endoderm, mesoderm and ectoderm. Fibroblasts can also be reprogrammed back into a state of 
pluripotency by introducing a number of reprogramming factors such as Oct4, sex determining 
region Y-box2 (Sox2), Kruppel-like factor-4 (Klf4) and cMyc (Yamanaka factors). The 
mesodermal lineage then gives rise to a number of progenitor lineages including MSCs which are 
multipotent, being able to give rise to a restricted number of specialised lineages.  





One of the major advancements was the discovery of pluripotent embryonic stem cells 
which were first cultured in mice in 1981 and in humans 17 years later (99–101). These 
cells, unlike those derived from adults, can differentiate into derivatives of all three germ 
layers, be propagated extensively in culture (102–104), and have a degree of immune 
privilege (72,105–107). Pluripotent stem cells were later obtained from inducing adult 
somatic cells back into a state of induced pluripotency through a process termed as cell 
reprogramming (108). Similarly to ESCs, these induced pluripotent cells (iPSCs) are 
capable of self-renewal and differentiation into derivatives of all three germ layers and 
also provide a more ethical approach to studying pluripotency without the need to destroy 
an embryo (102).  
To date human and mouse ESCs are still the most commonly used and studied pluripotent 
stem cell source, providing the standard against which all other species are compared. 
Much of our current knowledge on the molecular basis of pluripotency, differentiation 
and self-renewal has been drawn from the murine model. The core triad of transcription 
factors Oct4, Sox2 and Nanog, markers which are expressed in all pluripotent stages and 
are required for the maintenance of pluripotency and self-renewal, have been 
demonstrated to be highly conserved  between species, giving credit to the continued use 
of murine models in aiding our understanding of pluripotency across species (97).  
However, some clear differences do exist, with variations in molecular signalling 
pathways, morphology and developmental potential occurring (109). Murine ESCs 
(mESCs), originally derived from the blastocyst of early embryos, can be easily isolated 
and maintained in a naïve state, express the cell surface markers SSEA-1 and SSEA-3, 
are karyotypically stable and are unable to differentiate into trophectoderm (109). In 
comparison, human ESCs (hESCs), similarly derived from the preimplantation embryo, 
have marked characteristic deviations from mESCs being isolated and maintained in a 
primed pluripotent state meaning that they are in a later stage of pluripotency compared 
to their naïve counterparts. Accordingly they express the cell surface markers SSEA-3, 
SSEA-4, TRA-1-60 and TRA-1-81, are karyotypically less stable than mESCs, and can 
differentiate into trophectoderm (109). Such differences highlight the need to continue 
research on species specific pluripotent cells alongside that of murine models. 





1.4.2. Equine pluripotent stem cells 
Deriving and studying pluripotent cells in other species has lagged somewhat behind that 
of mice and humans and there are only limited numbers of reports on their derivation. 
The first equine derived ESC-like cells were reported in 2002 (110). These cells were 
maintained in vitro for more than 56 passages and could be induced to differentiate into 
neural, haematopoietic and endothelial precursors (110). This was later replicated by two 
further independent groups in 2006 and 2010 (111,112). Although the aforementioned 
equine ESCs displayed many of the key characteristics of pluripotency, unlike in human 
and mouse studies they have not yet been shown to be capable of forming interspecies 
chimeras such as described in human cells (113), nor do they form teratomas following 
injection of putative stem cells into immunodeficient mice. Although teratoma assays are 
a common measure of pluripotency, there are several limitations to their use. Such 
limitations include the lack of consistency between laboratories in terms of inoculation 
site, number of cells injected, mouse strain used, number of injections per animal and 
time in vivo, all of which affect whether or not a teratoma will form (114–116). Given the 
aforementioned limitations it is therefore difficult to interpret if the negative results 
displayed are the result of experimental variations or truly due to an inability of the cells 
to form a teratoma.  
The stark number of publications on equine ESC derivation is in complete contrast to the 
large numbers of publications researching the application of adult stem cells for their 
regenerative potential in horses. This difference likely reflects the difficulties in both 
equine ESC isolation and culture, as well as the ethical concerns regarding embryo 
destruction required in order to isolate ESCs. Not only this, research using horses is 
particularly expensive and breeding is seasonal, therefore having access to sufficient 
numbers of horse embryos with which to successfully isolate ESCs can be a limitation. 
Similar to the success rates of deriving ESCs from human embryos (117), our group has 
found that only up to 20% of horse embryos will successfully give rise to an ESC line 
which further highlights these difficulties.  
Following the successful derivation of human (118) and mouse iPSCs (119), investigation 
into the derivation of equine iPSCs commenced as a means to remove the aforementioned 
limitations. The first report of equine iPSCs was in 2011 where a piggyback transposon 
system was used, containing murine Oct4, Sox2, Klf4, and Myc reprogramming factors 





(120). Several other publications have followed this, the majority of which have used 
viral expression vectors to mediate genome integration of the reprogramming gene 
sequences (121–127). In order for an iPSC treatment to be deemed clinically safe it is 
important that the viral transgenes which are integrated during reprogramming are 
silenced (128). However, in many of the equine iPSCs generated to date, continued 
variable expression of the transgenes remain. In the first publication on the generation of 
equine iPSCs transgenes were required to be constitutively expressed to maintain 
pluripotency (120,122–125), with only one other study demonstrating that the transgenes 
were silenced (127). Although the equine iPSCs reported share many of the features of 
equine ESCs and iPSCs reported in other species, their differentiation potential has been 
shown to be limited in their ability to differentiate down the tendon lineage (121). Further 
research to understand this is required before iPSCs can be considered as a therapeutic 
for tendon regeneration.  
1.4.3. ESCs as a therapeutic 
ESCs could provide an unlimited source of allogeneic cells for treating tendon injuries. 
However, what makes ESCs so favourable for clinical use also brings a note of caution. 
Whether ESCs will succumb to immune rejection when used therapeutically has proven 
controversial. MHC cell surface proteins are important components of the immune 
system. The expression of MHC antigens on cellular surfaces mediate the outcome of 
alloantigen-specific T-cell responses. There are two classes, class I molecules which 
activate CD8+ (cluster of differentiation 8 positive) cytotoxic T-cells, and class II 
molecules which activate CD4+ (cluster of differentiation 4 positive) helper T-cells (129). 
Mouse ESCs have been shown to have no MHC class I or class II gene expression 
(130,131), whereas both human and equine ESCs express low levels of MHC class I but 
no MHC class II gene expression (132,133). Several studies have shown that both human 
and equine ESCs do not trigger a T-cell response in vitro or in vivo 
(72,91,97,106,134,135), highlighting their potential low immunogenicity.  
However, despite this lack of T-cell response, immune rejection has been demonstrated 
in several studies, with allogeneic natural killer (NK) cells being shown to be capable of 
eliminating mouse and human ESCs using chromium release and cytotoxicity assays 
(129,136,137). Kofidis et al., 2005 (138), also found that following injection of labelled 





undifferentiated mESCs into damaged myocardium of allogeneic recipients, a strong 
immune response was generated with 75% of injected cells dying within 48 hours. 
Likewise, transplantation of undifferentiated mESCs into allogeneic hosts resulted in 
infiltration of immune cells and subsequent rejection within 28 days of intramuscular 
injection (139).  
Contrary to this, our group has shown that injecting labelled equine ESCs into 
mechanically induced SDFT injuries has a different effect, with ESCs being found after 
10, 30, 60 and 90 day periods at the injection site and other distant induced mechanical 
lesions (91). Injected ESCs were found to take on the correct orientation and tendon 
morphology and had a high survival rate of at least 60% (91,140). A gradual decrease in 
leukocyte numbers at the injection site was noted, and that coupled with the ESCs high 
survival rate suggests that the ESCs did not induce immune cell stimulation. Although no 
other studies to date have been performed to look at the immune-privileged status of horse 
ESCs, several other studies using human ESCs have similarly shown a lack of 
inflammatory response and tolerance to ESC engraftment following injection into 
immunocompetent mice (141,142).  
It is difficult to know whether ESC survival and immunogenicity is species specific or a 
result of the particular environment in which they are injected. Evidence of this site 
specific immune-privilege can be found in the eye, where stem cell grafts in the subretinal 
space of the rat eye show much better cell integration and migration compared to that of 
the vitreous cavity (143,144). However, it must be noted that in a diseased state even so 
called immune privileged sites are often compromised due to breakdown of blood-tissue 
barriers (145). Further research on the effects of differentiation and the specific host tissue 
receiving the cells under a diseased state is therefore required.  
Another limitation is that current clinical trials using ESCs have only been monitored 
short term, with trials in horse tendons having only been monitored for up to 90 days post 
injection (91). The long term survival/rejection of these cells is therefore unknown, and 
studies in human and mouse models have indicated a high likelihood of teratoma 
formation based on injection into other transplantation sites (146). To avoid this risk, 
strategies to induce human and mouse ESCs towards the appropriate lineage prior to 
clinical application have been investigated (147–152). One preliminary report on the use 
of human ESCs differentiated retinal pigment epithelium cells for the treatment of 





macular degeneration showed no apparent rejection, tumorigenicity or ectopic tissue 
formation after 4 months of injection with some improvements to vision noted (153). 
Similarly, human ESC differentiated cardiac progenitors embedded in fibrin scaffolds 
and surgically delivered to infarct areas of the heart have shown no adverse immune 
effects or tumour formation after a 3-month period. Yet, again here long term follow up 
data is not available in either case. Moving pluripotent cells to the clinic will therefore 
require robust assessment of in vitro differentiation and long term monitoring to ensure 
that the differentiated cells are functional (121,124,154).  
1.5 Transcription factors in tendon development  
In order to decipher the most robust methods for ESCs differentiation in vitro, it is first 
important to have a better understanding of the mechanisms and transcription factors 
involved in tendon development. Better understanding of basic tendon biology should 
lead to better identification of effective treatments.  
1.5.1. Scleraxis 
Unlike in skeletal muscle or cartilage, to date the master tendon regulator or regulators 
have not been identified. At present, scleraxis (SCX), a basic helix-loop-helix 
transcription factor, is the most widely studied tendon marker, upon which much of the 
information regarding tendon development and tenocyte behaviour has been built (155). 
SCX gene expression is first detected between mouse embryonic day (E) 10 and 11, in 
which SCX positive cells condense to form a complex structure between developing 
cartilage and muscle tissue by E12.5 (155–157). This induction occurs through the 
interplay between fibroblastic growth factors (FGFs) and sonic hedgehog (Shh) signalling 
(Figure 1.4) and later by TGF-b in the developing limbs (155,158–160). By E14.5 
embryonic tendons are distinctly characterised by SCX expression, which continues into 
late development as well as postnatally, also being upregulated during adult injury repair 
(155,156,161,162).  
Although not exclusively expressed in tendons, being expressed in other ECM rich tissues 
such as the heart, periodontal ligaments and muscle, SCX has an indispensable role in the 
development of force transmitting and intramuscular tendons, which are severely 





disrupted in SCX knockout mice (163). Interestingly, short-range anchoring tendons are 
only moderately affected by SCX absence (163). Upon examination of the flexor 
digitorum profoundum (FDP) of SCX knockout mice, ECM organisation, as visualised 
by electron microscopy and histological staining, was severely disrupted with a complete 
loss of collagen alpha-1(XIV) (COL14A1) and tenomodulin (TNMD) expression and 
disorganised microfibrils being apparent (163). SCX therefore, although not a single, 
master regulator of tendon development, clearly plays an important role in differentiation 
down the tenogenic lineage as well as in ECM structural organisation in the tendon.  
 
Figure 1.4. Embryonic limb tendon development. FGF signalling in the myotome activates the 
inducers PEA3/ERM (polyoma enhancer activator protein-3 & ezrin radixin moesin proteins 
respectively) to upregulate SCX which induces cells of the sclerotome to become tendon cells. 
Inhibition of SCX occurs via SOX9 upregulation of the sclerotomal factors SOX5/6 and paired 
box protein-1 (PAX1), which allows cartilage to develop. In the limb, SCX is the first signal for 
tendon progenitor cell initiation. Mohawk (MKX), early growth response-1 and 2 (Egr1/2) are 
secondary signals required for tendon differentiation and maturation leading to eventual 
expression of ECM molecules at various stages of tendon development. Figure adapted from Liu 
et al., 2011 (58). 






Mohawk (MKX) is a member of the three-amino acid loop (TALE) superclass of atypical 
homeobox genes whose expression is first detected in E12.5 mouse limb and tail tendons 
(164). It is however, most robustly expressed during E13.5 to E14.5 when tendon 
progenitors begin to condense and differentiate, with it then dramatically decreasing by 
E16.5 (165). Although MKX is expressed postnatally, it is much weaker than during 
embryonic development, being mostly localised to the cells of the limb tendon sheath 
(165). Interestingly like SCX, MKX has been shown to be mechanosensitive and is 
upregulated in adult mice subjected to mechanical loading, leading to increased collagen 
fibrinogenesis and collagen cross-linking (166,167). MKX mutant knockout mice have 
also demonstrated that MKX is essential for normal tendon morphology and function of 
the forelimbs, tail and trunk, with knockout mice displaying smaller, paler, hypoplastic 
tendons which have decreased tensile strength (165,168,169). Tendon gene expression is 
also significantly altered, with E16.5 mice displaying reduced COL1A1, TNMD, Fmod, 
LUM and DCN expression, with many of these genes being required to regulate collagen 
fibril growth (165,168,169). Histologically, MKX knockout tendons had an overall lower 
density of collagen fibres, as determined using aniline blue staining and electron 
microscopy, compared to the wildtype control (168). Similarly, MKX null tendons had 
decreased total soluble collagen and decreased collagen I protein content, as determined 
by soluble collagen assays and western blotting techniques (168). 
Interestingly, when comparing SCX to MKX knockout mice no direct interaction is 
apparent, as the lack of one gene does not affect the expression of the other throughout 
embryonic tendon development (163,164). It therefore appears that SCX and MKX take 
part in distinct signalling cascades during tendon development, with MKX having a more 
pronounced role in collagen fibril growth and regulation. MKX expression, like SCX, is 
not restricted to tendons, being expressed in progenitor populations of cartilage, skeletal 
muscle and bone in early somites (164). Studies utilising MKX gain and loss of function 
techniques in mice and zebrafish have highlighted MKX’s ability to suppress myoblast 
determination protein-1 (MyoD) transcription, thereby inhibiting muscle differentiation 
and development suggesting a role of MKX in promoting tendon differentiation via 
repression of muscle development (4,164,170,171). Further work is required to validate 





this however, as MKX knockout mice do not display any clear skeletal muscle changes 
(169).  
1.5.3. Early growth response 1 and 2  
Early growth response 1 and 2 (Egr1 and Egr2) are members of the early growth response 
family of zinc finger transcription factors which have been implicated in tendon 
development (172). Egr1 is first detected at E12.5 in the developing mouse forelimb 
tendons at the attachment between the tendon and muscle tissue, whereas Egr2 is first 
detected at E14.5 in all limb tendon regions (172). Activation of both Egr1 and Egr2 
occurs through FGF4, via unknown mechanisms during vertebrate tendon development 
(172). Upon activation both proteins are capable of transactivating the tendon regulatory 
regions of the COL1A1 proximal promoter, with Egr1 also directly binding to the 
COL1A2 promoter to regulate gene expression (172,173). Although both Egr1 and Egr2 
are expressed during tendon development and regulate COL1A1, Egr1 seems to play the 
leading role. Egr1 knockout mice display significantly reduced expression of key tendon 
markers, SCX, and TNMD, as well as a variety of tendon associated collagens (COL1A1, 
COL1A2, COL14A1, COL3A1 and COL5A1) and tendon associated ECM components 
(BGN) (172,173). These mice also display defects in collagen fibrils, which are present 
in smaller numbers, with smaller diameters and reduced function, leading to a lower 
ultimate tensile strength compared to their wild type (WT) littermate controls (172,173). 
Egr1 and Egr2 may also function to maintain SCX expression during embryonic 
development, as overexpression of both induces SCX expression in ectoderm and 
mesoderm-derived tissue (172). However, the mechanisms of SCX and TNMD activation 
are not well defined, as Egr1 does not directly transactivate these genes. It is thought that 
Egr1 may activate expression through the known downstream binding partner TGF-b2, 
which is consistent with the recognised role of TGF-b signalling in tendon gene 
expression (Figure 1.5) (174,175).  






Figure 1.5. Proposed Egr1 signalling cascade in tendon cells. Diagrammatic representation of 
the Egr1 downstream regulation of tendon gene expression through proposed downstream binding 
partner TGF-b2 (Tgfb2). Adapted from Havis et al., 2020 [131]. 
1.6 Strategies for tenogenic differentiation in vitro  
1.6.1. Transcription factors 
As previously described, it is likely that stem cells may need to be pre-differentiated in 
vitro prior to clinical application. Transcription factors identified as key for tendon 
development in vivo have been investigated as a means to facilitate this process.  
Forced expression of SCX for example, has been used to differentiate human BMSCs to 
TSCs (176). In doing so tendon-related gene expression (COL1A1, DCN, Fmod, LUM, 
TNMD and alpha smooth muscle actin (α-SMA)) increased, with the resulting cells 
having decreased self-renewal potential and restricted multipotentiality (176). Similarly, 
human ESCs have also been shown to be capable of stepwise differentiation down the 
tendon-lineage (177). ESCs were first differentiated into MSCs via the replacement of 
pluripotency medium with 20% serum medium, the resulting ESC derived MSCs were 
then subjected to SCX-overexpression via lentiviral infection (177). Resulting cells 
displayed tenocyte morphology and had upregulated COL1A1 and tenascin C (TNC) 
tendon gene expression and downregulated SOX9 (cartilage gene) and alkaline 





phosphatase (ALP) (pluripotency gene) expression (177).  In vivo studies have also shown 
that SCX transduced MSCs, when used to treat rat supraspinatus induced tendon injuries, 
improved the tendons overall tensile strength compared to the non-transduced MSC 
controls suggesting SCX induction leads to improved regeneration (178). Taken together 
this suggests that SCX has a role in promoting tendon differentiation in vitro, the 
mechanisms of which will be further explored in chapters 4 and 5. 
MKX overexpression has also been shown to induce tenogenic gene expression in MSC, 
showing upregulation of several tendon-associated genes including COL1A1, TNMD and 
TNC (179,180). Moreover, ectopic MKX overexpression in MSCs was found to be more 
efficient at promoting tenogenesis than SCX overexpression, showing significantly 
greater expression of tenogenic genes and improved collagen fibril growth (180). They 
also showed that MKX indirectly regulated SCX expression via TGF-b2 expression, 
much like that of Egr1 as previously described in section 1.5.3. It therefore appears that 
maintenance of SCX expression during tendon development is achieved in part via 
transcriptional activation of the TGF-b signalling pathway. Using MKX to induce tendon 
differentiation has also been conducted in equine BMSCs and iPSCs resulting in 
increased expression of SCX, Egr1, COL1A2, COL14A1, DCN, elastin (ELN), Fmod and 
TNC.  
Similarly, Egr1 has also been tested as a strategy to induce tendon differentiation in 
MSCs. Following its forced expression cells have a reduced capacity to differentiate into 
fat and bone lineages as well as an increased expression of several tendon-associated 
molecules including COL1A1, TNMD and TNC (173). This result has been further 
demonstrated in rabbit tendon stem cells, with forced Egr1 expression leading to 
increased tendon gene expression and an inhibition of non-tenocyte differentiation (181).  
1.6.2. Growth factors  
Growth factors are produced throughout tendon development and differentiation as well 
as during tendon healing. To differentiate stem cells into bone and cartilage lineages, 
fairly well-defined growth factor formulations are used which produce reproducible 
results, however the same has not yet been achieved for tendon differentiation.  





The most widely reported growth factors used come from the transforming growth factor 
beta family, which forms part of the most significantly upregulated signalling pathway 
expressed during embryonic limb development (159). TGF-b1, 2 and 3 have all been 
investigated, and show robust induction of SCX both in vitro and in vivo, as well as other 
tendon-related marker genes. Its suitability can be drawn from studies in which TGF-b 
signalling is disrupted in the mesenchyme of mouse limb buds, which leads to prevention 
of tendon formation (175). Similarly, TGF-b signalling also appears to be required for 
the continuous maintenance of the tendon cell fate, as without this tenocytes revert into a 
more stem/progenitor like state which can be rescued by its reintroduction (182).  
A whole host of other growth factors and growth factor combinations, including 
connective tissue growth factors (CTGFs), growth differentiation factors (GDFs), basic 
fibroblastic growth factors (bFGFs) and insulin growth factors (IGFs) have been utilised 
in tenogenic induction protocols. However, a consensus on the optimal combination has 
not been reached, which likely comes from the lack of definitive markers to define the 
different tendon cell populations. Table 1.1 summarises some of the current in vitro 
growth factor strategies that have been used for tenogenic differentiation





Table 1.1. Growth factor strategies for tendon differentiation. Adapted and updated from Zhang et al., 2018 and Shojaee et al.,2019 (60,183). Acronyms 
not previously defined are:- cartilage oligomeric matrix protein (COMP), thrombospondidn-4 (THBS4), fibronectin (FN), vimentin (VIM), aggrecan (ACAN), 
mothers against decapentaplegic homolog-8 (SMAD8).  
Growth 











10 or 100 ng/ml 3D collagen gel 24, 48 hours 
⇧SCX, MKX, BGN, COL V, COL XII, Serpine1 
⇩MMP16, DCN gene expression 
(184) 
Horse ESC 20 ng/ul  7 to 14 days ⇧COLIA1, COMP, TNC, TNMD, THBS4 protein expression (140) 
Horse BMSC 5 ng/ml 3D collagen gel 10 days ⇧SCX gene expression (185) 
Human ASC 50 ng/ml 50 μg/ml Ascorbic Acid 14 days 
⇧SCX, MKX, COMP, THBS4, TNC, COL1A1, COL1A2, 
COL3A1 gene expression (186) 
TGF-β2 
Mouse MSC 20 ng/ml 3D collagen culture 1, 24 hours ⇧COLIA1, SCX gene expression (173) 
Horse ESC 20 ng/ml  7 to 14 days ⇧COLIA1, COMP, TNC, TNMD, THBS4 protein expression (140) 
Mouse TSC and 
MSC 20 ng/ml 
Culture in cell 
sheets 
12, 24, 48 






20 ng/ml 3D fibrin gel 7 days Synthesis of collagen fibrils and appearance of fibripositors (187) 





Horse ESC 20 ng/ml  1, 2, 3, 7, 14 days 
⇧SCX, TNC, COMP gene expression between 24 -72 
hours of induction 
⇧COLIA1, COMP, TNC, TNMD, THBS4 protein 
expression 
(140) 
Human BMSC 10 ng/ml 




24 hours, 5, 
10 days 
⇧COL1A1, TNMD gene expression 
⇧COL I protein production 
(188) 
Horse ESC 20 ng/ml 3D collagen gel 1, 2, 3, 7, 14 days 
⇧COL1A1, COMP and induction of THBS4, TNMD 
gene expression 
⇧SCX, COLIA1, COMP, TNC, TNMD, THBS4 protein 
expression 
(154) 
Horse iPSC 20 ng/ml 2D or 3D collagen gel 
1, 3, 7, 14 
days 
⇧COL1A1, COMP, SCX gene expression 




Human BMSC 100 ng/ml 50 μg/ml Ascorbic Acid 4 weeks ⇧COLI, TNC gene expression (189) 
Human BMSC 100 ng/ml 50 μg/ml Ascorbic Acid 4 weeks 
⇧COLI, COLIII, TNC, FN, VIM, MMP1, gene expression 
⇧COLI and TNC protein expression 
(190) 
Rat TSC 25 ng/ml 
25 μM/L Ascorbic 
Acid 
Culture in cell sheet 
2 weeks 
⇧COL1A1, SCX, THBS4, TNMD, ELN, DCN, BGN gene 
expression 
⇧TNMD, COL1, COLIII protein expression 
(191) 
Rat TSC 25 ng/ml 
25 μM/L Ascorbic 
Acid 
Culture in cell sheet 
 
⇧COL1A1, TNMD 
⇩ACAN, COL2A1, ALP gene expression 
(192) 







Rat ASC 100 ng/ml  3, 6, 9, 12 days 
⇧COLI, DCN, ACAN, SCX, TNMD, TNC gene expression 
and 
⇧TNMD, TNC, SMAD8, MMP13 protein expression 
(193) 
Human BMSC 10 ng/ μl  14 days 
⇧DCN, COLIII, TNC gene expression 
⇧TNC, DCN, COL1, COL III protein expression 
(194) 
Human BMSC 100 ng/ml  4 days ⇧COLI, SCX, TNC gene expression (195) 
Human BMSC 




environment 3 days ⇧COL1A1, COL3A1 DCN, SCX, TNC gene expression (196) 
Rat BMSC 50 ng/ml  2, 5, 7 days ⇧COLI, COLIII SCX gene expression (197) 
GDF-6 
(BMP13) 
Mouse BMSC 100 nM  3 days ⇧COLI, THBS4 gene expression (198) 
Rat BMSC 20 ng/ml  2 weeks 
⇧SCX, TNMD gene expression 




Horse BMSC 50 ng/ml  14-21 days ⇧DCN, TNMD gene expression (200) 
Mouse BMSC 100 nM  3 days ⇧COLI, THBS4 gene expression (198) 
Rat BMSC 10 ng/ml 2D or 3D collagen scaffolds 12 hours ⇧COLI, TNMD, TNC, SCX gene expression (201) 
Rat BMSC 50 ng/ml  2 weeks 
⇧ TNMD, TNC, SCX gene expression 
⇧TNMD protein expression 
(202) 





Dog/Mouse ASC 50 ng/ml  2 weeks ⇧TNMD, SCX gene and protein expression (203) 
Horse amniotic 
fluid MSC 50 ng/ml  14 days ⇧TNMD, DCN gene and protein expression (204) 
Horse UCB-MSC 50 ng/ml  10 days 
⇧TNMD, MKX, SCX, COL1A1, DCN gene expression 
⇧TNMD, DCN protein expression 
(205) 
Rat TSC 50 ng/ml  14 days ⇧TNMD, SCX, COLI, TNC gene and protein expression (206) 
Human ASC 100 ng/ml  7 days 
⇧SCX, MKX gene expression 
⇧MKX, COLI protein expression 
(207) 
Horse BMSC 5 ng/ml 3D collagen gel 10 days ⇧SCX, DCN, COLIII gene expression (185) 
Human ASC 50 ng/ml 50 μg/ml Ascorbic Acid 14 days ⇧SCX, MKX, COMP, THBS4, DCN gene expression (186) 
FGF-2 (bFGF) 
Human BMSC 3 ng/ml  14 days ⇧COLI, COLIII, FN gene expression (208) 
Rabbit BMSC 
Dosed released – 
variable 
concentrations 
Nanofiber scaffold 10, 14 days 
⇧COLI, COLIII gene expression 
⇧TNC, COLI, COLIII protein expression 
(209) 
Human BMSC 10 ng/ μl  14 days 
⇧SCX, DCN, COLI, COLIII, TNC gene expression 
⇧TNC, DCN, COL1, COL III protein expression 
(194) 
IGF-1 Human BMSC 10 ng/ μl  14 days 
⇧SCX, DCN, TNC, COLIII gene expression 
⇧TNC, DCN protein expression 
(194) 





Horse TSC 100 ng/ml Acellular tendon matrix 7 days 
Increase proliferation with COL and GAG synthesis 
increased (210) 





10 ng/ml Low-level laser therapy 5 days ⇧Egr1, DCN, TNC gene expression (211) 
GDF-5, GDF-6, 
GDF-7 Horse ASC 
10 ng/μl GDF-5 & 6, 
100 ng/μl GDF-7 
3D collagen gel in 
bioreactor 21 days ⇧COL1, COLIII gene expression (212) 
GDF-6, GDF7 Human ESC 10 ng/ml  40 days ⇧COL1A2, TCN, COL3A1, THBS4, TNMD, DCN gene expression and ⇧TNMD protein expression (213) 
GDF-7, CTGF, 
TGF-β3 Human ASC 
50 ng/ml GDF-7, 100 
ng/ml CTFC, 10 ng/ml 
TGF-β3 
50 μg/ml Ascorbic 
Acid, collagen 
coated plates 
1, 3, 7 and 14 
days 
⇧SCX, COL1A1, COL3A1, COMP, MMP3, MMP13 gene 
expression 
⇧SCX, TNMD protein expression 
(214) 
TGF-β1, CTGF Rat BMSC 10 ng/ml 
50 μg/ml Ascorbic 
Acid, stepwise 
approach 
7 days with 
TGF-β1, 7 days 
with CTGF 
⇧SCX, COL1, Egr1, COMP, TNC, THBS4, Fmod, TNMD 
gene expression (215) 
TGF-β2, TGF-
β3 Mouse MSC 20 ng/ml  24, 48 hours ⇧COL1A1, SCX gene expression (159) 





1.6.3. Three-dimensional culture and mechanical stimulation  
As suggested in Table 1.1 the use of scaffolds and three-dimensional (3D) cell culture is 
commonly utilised to assist in tendon differentiation. Tension and mechanical stimuli is 
a major part of the tendon cell niche, with mechanical stimulation controlling the 
formation of all musculoskeletal tissue during embryonic development (4,216). Tendons 
are particularly mechanosensitive, and tendon tissue does not form in the absence of 
muscle (155,217). Similarly in vitro, tenocytes are said to de-differentiate when cultured 
in traditional two-dimensional (2D) monolayer culture, with loss of tension in tenocyte 
culture being associated with apoptosis (218,219). In contrast, when tenocytes are 
exposed to mechanical force or strain, tendon related gene expression is promoted and 
cell proliferation increases (220–226). Due to the clear importance of mechanical 
stimulation, researchers sought to try to improve tenogenic differentiation by designing 
ECM-like scaffolds and 3D culture methods to better recapitulate the in vivo environment. 
In doing so both cell alignment and migration can be better observed, as well as changes 
to the ECM organisation and ECM protein deposition.  
Culturing cells in 3D constructs was first reported in 1972, here fibroblasts were seeded 
into a collagen gel which contracted over time down to 1/10th of its original size by 
rearranging the collagen matrix (227). Since its publication, collagen gels have become a 
popular scaffold for studying tendon development, differentiation and wound healing 
(63,154,173,184,185,201,212,228). For these gels collagen I is typically used, due to it 
being the most abundant collage in the native tendon. The gels are then grown either 
under “static” tension (121,154,177,187,229,230), where tension is applied by 
suspending the gel between two fixed point and intrinsic force applied by the matrix of 
cell themselves (140), “uniaxial applied tension” (231), where a constant one dimensional 
tension is applied externally, or under “cyclic tension”, (231), where a recurrent cycling 
tension is applied externally (229,232,233). Fibrin (prepared from fibrinogen and 
thrombin) alone or in combination with hyaluronan or collagen is another popular 
scaffold system used to produce tendon-like constructs (187,222,234). Utilising these 
methods has been reported to enhance tenogenic differentiation in comparison to 2D 
culture, with 3D culture alone being a potent driver of ESC and MSC differentiation 
towards the tendon cell fate (140,229,235).  





New bioengineering strategies including electrospun collagen scaffolds, de-cellularised 
tendon hydrogels, poly(glycolic acid) (PGA) scaffolds, knitted silk and collagen matrices 
are also being investigated, and may provide a more “in vivo” like environment for tendon 
differentiation and culture (236). However further research, as well as thorough 
characterisation of cells grown in these culture systems is required.  
1.7 Determining tendon differentiation  
1.7.1. Tendon associated markers 
As described in section 1.6 a huge array of methods have been proposed to differentiate 
stem cells down the tenogenic lineage, with no clear consensus on the most efficient and 
robust protocol. One of the main reasons for this is the clear lack of definitive markers 
defining the tendon cell lineage, unlike that of cartilage, muscle and bone. Typically, for 
tendon differentiation studies only a small panel of tendon-related genes are investigated 
in order to evaluate the efficiency of the protocol as highlighted in Table 1.1. However, 
caution needs to be taken with this approach as many of the common markers, including 
COMP, TNC, Fmod, BGN are highly expressed in both cartilage and tendon tissue (237–
240). Similarly, SCX, TNMD and THBS4 which are often regarded as the most specific 
tendon markers are widely expressed in a variety of tissue fibroblasts (241,242). 
Therefore, it is equally possible that many in vitro differentiation protocols, which only 
assess a small number of candidate genes, result in the generation of other cell types. This 
highlights the need for more global high throughput gene expression approaches to be 
taken in order to identify the best tenocyte differentiation protocols. Such global 
techniques, including their inception and development will be discussed below. 
1.7.2. From microarrays to next generation sequencing 
High throughput transcriptomics first became possible with the invention of the 
microarray in the 1990s (243). These small analytical devices, typically composed of a 
glass chip printed with thousands of microscopic spots of known DNA sequence at 
defined positions (probes), allowed genomic exploration of vast numbers of genes at high 
speed. Microarrays work by first converting sample RNA into complementary DNA 





(cDNA) labelled with fluorescent tags. Molecules in the fluorescent sample then bind to 
complementary probes on the microarray through a process called hybridization leading 
to emission of light upon stimulation with a laser, the intensity of which is proportional 
to the level of gene expression (243). Microarrays are particularly useful in clinical 
research and drug development due to their ability to rapidly assess gene expression in 
thousands of different samples at relatively low cost. However, microarrays are only 
capable of detecting known sequences, with chips needing to be constantly updated in 
order to contain the latest sequence information, which limits their ability to detect novel 
transcripts (244). Similarly, the hybridization process can often result in background, with 
probe saturation interference making low and high-level detection more difficult. 
Although microarray technology continues to evolve, with regards to dyes, probes, 
platforms, algorithms etc, RNA-sequencing (RNA-seq) is now considered the leader in 
high throughput technologies for transcriptome analysis. A comparison of microarray and 
RNA-seq techniques is displayed in Figure 1.6. 
The power of RNA-seq lies in the fact that it provides a method for both mapping and 
quantifying entire transcriptomes all in a single assay. RNA-seq generally works by first 
converting an RNA sample into cDNA fragments, otherwise known as a cDNA library. 
Adapter sequence containing functional elements required for the sequencing are added 
to the ends of each fragment in the cDNA library before subjecting it to next generation 
sequencing (NGS). The principle behind NGS is similar to that of Sanger sequencing, in 
which capillary electrophoresis is used, with different companies offering different 
sequencing methods from pyrosequencing to sequencing by ligation (SOLiD). Illumina 
sequencing however, which uses a sequencing method adapted from Sanger sequencing 
called sequencing by synthesis (SBS), has dominated the sequencing industry and is 
described in Figure 1.6. One of the key benefits RNA-seq has over microarrays include 
the fact than no prior knowledge of the reference genome is required, which opens the 
technology up to scientists working on unusual model organisms allowing them to 
construct de novo transcriptomes without the need for a sequenced genome (245). 
Similarly, unlike microarrays, minimal background signal occurs, allowing greater 
detection of low abundance transcripts if the sequencing is done at a high enough depth. 
RNA-seq also does not have an upper limit for quantifying highly expressed genes 
meaning it has a much broader range of detection. Finally, RNA-seq requires very little 
starting material and has also been shown to be extremely robust, producing reproducible 





results for both technical and biological replicates. Taken together it is clear why this 
technology has become so popular, becoming widely used in place of microarrays.  
 
Figure 1.6. Comparison of microarrays and RNA-sequencing technologies. For microarrays 
the RNA sample is reverse transcribed to produce cDNA incorporating a fluorescent tag. The 
labelled cDNA is then added to the DNA microarray where it hybridises with cDNA probes that 
are attached to the microarray slide. Following a series of wash steps to remove unbound 
fragments, a laser is used to excite the bound fluorescently labelled target sequences and a 
fluorescent signal emitted. The intensity of signal represents the amount of target sample bound 
to each probe, which is subsequently quantified to give the level of gene expression. For RNA-
seq the RNA sample is again fragmented and converted into cDNA, this time with the addition 
of adapters on both sides of the fragments. Bridge PCR is then used to amplify the cDNA library, 
which is performed on the flow cell, with each fragment being linked to it via the adapters. This 
results in clusters of identical DNA fragments which act as primers for the sequencing reaction. 
During the sequencing reaction each of the four nucleotides, each linked with different fluorescent 
tags, and a terminator group is added alongside polymerase. These nucleotides then bind to their 
complementary nucleotide and due to the terminator sequence further synthesis is not possible. A 
picture is then captured of the flow cell and the colour of the probe detected. The tag and 
terminator are then cleaved, and the process repeats until each sequence of nucleotides is 
determined. The sequences generated are then aligned to a reference genome or transcriptome to 
determine gene expression. 





1.7.3. RNA-sequencing experimental design  
Before any RNA-seq experiment is performed it is crucial that good experimental 
planning is conducted to ensure the biological question of interest can be properly 
answered. This can include how many replicates are required, library type, sequencing 
depth as well as how the data will be analysed. The first aspect to consider is the RNA-
extraction protocol used. Typically for differential gene expression studies it is the 
messenger RNA (mRNA) that we are interested in, rather than the more abundant 
ribosomal RNA (rRNA) (1-2% versus > 90% of the total RNA) (246). The right RNA-
extraction protocol therefore needs to be considered in order to enrich the mRNA from 
the rRNA. This can be in the form of poly(A) selection, which is typically performed on 
samples which have high RNA integrity or by rRNA depletion which is more suitable for 
samples which have decreased RNA integrity. With poly(A) selection a greater exonic 
coverage is obtained versus RNA depletion methods, with fewer pre-mRNA reads 
generated. However it does mean that any non-poly(A) transcripts, including small 
nucleolar RNAs (sno-RNAs), microRNAs (miRNAs) and some long non-coding 
(lncRNAs) are not detected and so poly(A) selection should not be used if these 
components are of interest (246).  
Another factor which should be considered is read length. This can be particularly 
important for large transcriptomes, such as the horse being composed of 59,087 gene 
transcripts, in which if reads are too short they may map to multiple locations in the 
genome (247). Therefore, careful consideration needs to be taken on whether the cheaper 
single-end (SE) shorter reads or the longer more expensive pair-end (PE) read method is 
chosen. Similarly, the depth of sequencing coverage is an important consideration which 
has implications on the overall cost. In general the greater the sequencing depth the more 
coverage provided, with more complex transcriptomes requiring more sequencing depth 
in order to provide adequate coverage (247). Finally, one key aspect of experimental 
design is the number of replicates used. The number of replicates required will depend 
on how much technical variability there is in the RNA-seq procedure as well as the 
amount of biological variability in your system. Power calculations are typically used to 
determine how many replicates are needed, which work by making inferences from 
publicly available prototype data in order to calculate the best trade-off between replicate 
number and sequencing depth in order to detect your chosen power.  





1.7.4. Data analysis 
With transcriptomic analysis rapidly becoming standard practice in life science research 
this has led to a tremendous amount of data being generated. In order to turn this data into 
something with biological meaning it has meant that computational tools have had to be 
developed and updated at an exceptional rate to keep up (248). As such there is a whole 
host of different software available to analyse RNA-seq data. However, regardless of the 
software chosen the general principles remain the same. These include firstly quality 
control checking and pre-processing the generated reads, assembling the reads into a 
transcriptome either using a reference genome, reference transcriptome or by de novo 
assembly, a quantification step to estimate gene and transcript expression, and a statistical 
analysis step such as conducting differential gene expression analysis (245).  
Describing these steps in more detail, firstly when sequencing reads are generated, they 
are assigned a Phred score (Q), this is a measure of the accuracy of base calling (245). 
Similarly, GC content, PCR duplicates, untrimmed adapter sequence and other PCR 
artifacts or contamination all need to be assessed prior to analysis to prevent inaccuracies 
in the downstream analysis and data interpretation (245). Once this is determined 
software can be used to trim or remove low quality sequence and remove any 
contaminating sequence or adapters. Once trimmed, reads then need to be aligned and 
assembled into transcripts. If a reference genome is available, this will typically involve 
aligning the reads onto the reference genome or transcriptome (246). This is clearly 
computationally challenging, considering that RNA-seq reads are relatively short and 
have the potential to map to multiple location within the reference genome or 
transcriptome with many spanning exon-exon junctions (249). To solve this, two main 
algorithmic approaches can be taken. Firstly, an unspliced read aligner can be used, which 
aligns reads without any large gaps, meaning only known exonic regions are considered 
as alignment is done to reference cDNA (transcriptome) rather than genomic DNA 
(genome). This method is computationally quicker and useful if you are only interested 
in quantifying known genes. The second option is to use a spliced aligner, which instead 
aligns reads to the entire genome, including intron spanning reads (249). This therefore 
allows the identification of novel splice sites. However, if no reference sequence is 
available then de novo assembly is performed, which involves constructing transcripts 





directly from overlapping reads, and typically needs to be performed with longer PE reads 
with high sequencing depth in order to generate a reliable assembly.  
Once the reads are assembled into transcripts, gene expression can be estimated. To do 
so several sources of variability need to be taken into account, with read counts needing 
to be properly normalised to minimise the effects of these variables. Firstly, there is the 
variability caused by the fragmentation process during library construction where longer 
transcripts will generate more reads than shorter ones regardless of whether they have the 
same abundance in the sample (249). Secondly, the number of reads generated and the 
length of reads for each sample, as well as the GC content between genes can fluctuate 
and must be taken into consideration. Several normalisation methods including the 
trimmed mean of M-values (TMM) normalisation factor, total count normalisation factor 
and median of ratio normalisation factor can be used to account for these biases (245).  
Once the normalisation factor is chosen and transcript expression is quantified, typically 
the next step is to determine how these expression values differ between experimental 
conditions. Many different tools have been developed to detect differentially expressed 
genes, which continue to be made at an expeditious rate. In its simplest form, these 
methods use a test statistic to identify genes which have statistically significant changes 
in gene expression in one sample condition compared to another. Different differential 
expression analysis tools do so by using various statistical models based on, for example, 
Poisson distribution or normal or negative binomial distributions in order to 
accommodate the count-based nature of RNA-seq data (249). Which tool and model is 
best is not clear and depends on the biological variability, number of conditions and 
number of samples per condition; with multiple studies having been performed to 
compare available tools (250–253). As such no one standard protocol is used for RNA-
seq analysis which can make data less comparable across platforms (244).  
Once a list of generated differentially expressed (DE) genes is obtained, a number of tools 
can be utilised in order to gain some biological insight into what biological pathways are 
up or downregulated between comparisons. This includes the use of biological gene 
ontology analysis, pathway and network analysis software, which allow for the 
investigation of the biological processes and pathways that are enriched within your list 
of DE genes.  





RNA-seq techniques and methodologies continue to evolve, playing an indispensable role 
for studying gene expression. Although I have focused on bulk RNA-seq techniques here, 
newer techniques such as single cell RNA-seq (scRNA-seq) are starting to push to the 
forefront, with ever more sensitive and automated methods being developed. With time, 
such techniques will become more accessible and should allow for a more robust 
understanding of many aspects of biology, including studies into stem cell differentiation.  
  





1.8 Research aims  
In summary, tendon injuries occur commonly in human and equine athletes. Adult 
tendons undergo poor natural regeneration, resulting in scar-tissue which is prone to re-
injury. Novel cell therapies are being developed to facilitate adult tendon healing. 
However, for a cell-based therapy to be effective it is important that the cells used 
represent a viable regenerative cell type.  
Fetal tendon injuries undergo completely scar-less regeneration (254). This regenerative 
ability is intrinsic to the fetal cells themselves, as fetal tendons, once transplanted into an 
adult environment, retain their regenerative capacity (255–259). Although fetal tenocytes 
are being considered as a cellular therapy (260), accessing fetal tissue is an issue when 
considering their use in clinical practice. Stem cell therapies are therefore being 
considered as stem cells can turn into tenocytes, however, during normal adult tendon 
repair there is already an influx of tenocytes into the injury site which result in scarring. 
It is therefore important that stem cell therapies mimic fetal regenerative tenocytes and 
recapitulate the properties of fetal scar-less healing.  
This thesis builds on previous research into the use of horse ESCs to aid tendon 
regeneration. It will determine if tendon cells derived from ESCs represent the fetal or 
adult stage of tendon development and begin to determine if scleraxis, an essential gene 
in tendon formation, has different roles at different stages of development. To achieve 
this the following specific objectives were set:  
1) To determine if ESCs differentiate into tenocytes which represent the fetal or adult 
stage of development by comparing their global gene expression profiles with those of 
adult and fetal tenocytes.  
2) To identify and compare how gene expression is affected by knocking-down the 
tendon-related gene scleraxis in adult, fetal and ESC-derived tenocytes. 
3) To identify novel genes which are the direct targets of scleraxis regulation in adult, 
fetal and ESC-derived tenocytes.  
 









Chapter 2 - Materials and Methods 
2.1 Tissue isolation 
2.1.1. Tendon and tenocyte isolation 
Tenocytes used in this study were either freshly isolated from tendon tissue or obtained 
from previously derived cryopreserved stocks. Equine (Equus caballus) tissue was 
harvested with the approval of the Animal Health Trust ethical review committee 
(AHT02_2012). Tendon tissue was collected from healthy SDFTs of eight adult 
Thoroughbred horses (aged 2-10 years) and three Thoroughbred foals (aged 54 days – 84 
day postpartum), euthanised for reasons unrelated to this project, and from seven 
spontaneously aborted Thoroughbred fetuses which were 271, 289, 316, 319, 320, 321 
and 340 days through gestation (full term = 322-387 days). As the sex was not determined 
at the time of tissue collection, polymerase chain reaction (PCR) was conducted using 
primers specific for the SRY gene (sex-determining gene on the Y chromosome) and sex 
chromosome-encoding zinc finger ZFX-ZFY genes (261) as described in section 2.4. 
Tendon tissue was collected in tenocyte culture medium (Dulbecco’s Modified Eagle’s 
Medium (DMEM) (Gibco, Invitrogen, Carlsbad, CA, USA) containing 10% Fetal Bovine 
Serum (FBS) (Gibco), 2 mM L-glutamine (L-Q) (Gibco) and 1% penicillin-streptomycin 
(P/S) (Gibco)), supplemented with 2.5 μg/ml of fungizone (Gibco). Tenocytes were 
isolated from the mid-metacarpal region of the SDFT, ensuring the peritenon was 
removed and only the central tendon core was used (Figure 2.1). Dissected tendon tissue 
was then cut into small pieces and digested in 1 mg/ml type I collagenase produced by 
Clostridium histolyticum (Sigma, Poole, Dorset, UK) in tenocyte culture medium at 37°C 
overnight. The culture digest was then pelleted by centrifugation (161 x g, 5minutes) and 
washed three times before re-plating in fresh tenocyte culture medium.  





Figure 2.1. Tendon dissection and tenocytes isolation. Tendon tissue from the mid-metacarpal 
region of the equine forelimb was obtained. The SDFT, identified as the semi-circular tendon 
located laterally, was extracted and the peritenon removed. The central core was then digested in 
order to extract the tenocytes.  
2.1.2. Cartilage isolation 
Articular cartilage was harvested with the approval of the Animal Health Trust ethical 
review committee (AHT02_2012) under sterile conditions from both forelimb fetlock 
joints of one warmblood mare aged approximately 10 years. The horse was euthanised 
for reasons unrelated to this project, and no joint disease was detected. Both forelimb 
fetlock joints were disarticulated, and the cartilage removed from the articular surfaces 
using a scalpel blade before storing in RNAlaterÒ stabilization solution (Invitrogen, 
Renfrewshire, UK) at -20°C.  
2.2 Tenocyte cell culture 
2.2.1. Two-dimensional culture 
Tenocyte medium composed of DMEM containing 10% FBS, 2 mM L-Q and 1% P/S (all 
Gibco) was used for tenocyte cellular expansion and culture, with conditions being 
maintained at 37°C in 5% CO2. Medium was replaced every 2-3 days with cells being 
passaged using 0.25% trypsin/EDTA (Sigma) once they reached 80% confluency. When 




required cells were cryopreserved in tenocyte medium supplemented with 10% tissue 
culture grade dimethyl-sulfoxide (DMSO) (Sigma). Cells were frozen gradually in 
CoolCellÒ cryogenic freezing containers (Sigma) at -70°C for 24 hours before transferal 
to liquid nitrogen. To thaw, cells were partly thawed in a 37°C water bath before 
transferring to pre-warmed culture medium, centrifuging for 5 minutes at 161 x g and re-
plating in a new culture dish with fresh medium.  
2.2.2. Serial passaging of tenocytes 
Three lines of adult tenocytes were isolated and passaged ten times in 2D culture as 
described in section 2.2.1, with RNA extracted (see section 2.7.1) at every passage to 
measure COL1A1, COL1A2, COL3A1, SCX, THBS4 and TNMD gene expression via 
qPCR as described in section 2.8.  
2.2.3. Three-dimensional culture 
Three-dimensional cell culture was conducted using pairs of 0.2 mm-diameter minutien 
pins (Interfocus fine science tools) embedded at 15 mm distances into silicon-coated six-
well plates (Sylgard 184 Silicone elastomer; Dow Corning) (Figure 2.2). Tenocytes were 
suspended at a concentration of 4 x 105 cells/ml in a mixture of eight parts chilled PureCol 
(Bovine collagen type I; Advanced Biomatrix, Carlsbad, CA, USA) to 2 parts chilled cell 
culture medium (pH adjusted with 1 M sodium hydroxide from a reading of 7.2 to a 
reading of 7.6). Live cell counts were performed using trypan blue (Sigma) exclusion 
staining and a haemocytometer. The chilled cell suspension mix (200 µl) was pipetted 
around each pair of pins and the plate sealed with parafilm, before allowing to set for 60-
90 minutes at 37°C. Once fully set, 3 ml of tenocyte medium was added per well with the 
medium changed every 3-4 days during the 14-day culture period. Images were obtained 
throughout the culture period and contraction analysis was conducted using ImageJ 
software (National Institutes of Health), with results being displayed as a percentage of 
the Day 0 value. For each time point from day 0 to 14, contraction analysis was carried 
out on 3-18 constructs per biological line. Cell survival assays were also performed by 
digesting 3D constructs in 1 mg/ml type 1 collagenase produced by C. histolyticum 
(Sigma) in tenocyte medium for 1-2 hours at 37°C. Survivals were carried out on days 3, 
7 and 14 of culture. Live cell counts using trypan blue exclusion staining (Sigma) were 




performed, with cell counts determined using a haemocytometer. Cell survival was 
calculated as a percentage of the number of cells originally seeded and were carried out 
on three to six constructs per time point for each biological line. 
 
Figure 2.2. Three-dimensional cell culture set-up. A 6-well plate depicting location of 0.2 mm-
diameter minutien pins depicted as grey dots, embedded in silicon coated plate. Pins are placed 
15 mm apart (black arrow), and the collagen/cell suspension is pipetted around and between each 
pair of pins. 
2.3 Embryonic stem cell culture 
2.3.1. Feeder cell production 
Active MF1 mouse embryonic fibroblasts (MEF), which had been tested for both 
bacterial and fungal contamination, were obtained at passage 0 from the Cambridge Stem 
Cell Institute Tissue Culture facility (Cambridge, UK). Cells obtained on dry ice were 
thawed and plated at a density of 8.5-10000 cells per cm2 of tissue culture plastic and 
were maintained in DMEM containing 10% FBS, 2 mM L-Q and 1% P/S (all Gibco). 
Once 60-70% confluency was reached cells were passaged using 0.25% trypsin/EDTA 
(Sigma) and re-plated at the same density to increase the stock. This process was repeated 
up to the fifth passage. Cells were then inactivated using 10 µg/ml of mitomycin C 
(MMC) (Sigma) for 2 hours at 37°C, washed in culture medium and subsequently 
cryopreserved, as described in section 2.2.1, at a concentration of 1.6x106 cells per 
cryovial. Each cryovial was then thawed onto 1 x 6 well plate at least one day before cells 
were used for ESC co-culture. 




2.3.2. Undifferentiated ESC culture 
Three lines of previously characterised ESCs (111,132), isolated from three different 
embryos were used. ESCs were maintained at 37°C in 5% CO2 on a mitotically inactivated 
MEF layer as previously described (111,132). Briefly, cells were cultured in Dulbecco’s 
modified Eagle medium/F12 (DMEM/F12 (Gibco)) containing 15% FBS (Gibco), 2 mM 
of L-Q (Gibco), 1% non-essential amino acids, 1 mM of sodium pyruvate, 0.1 of mM 2-
mercaptoethanol (all from Invitrogen), and 1000 U/ml of human leukaemia inhibitory 
factor (LIF) (Cambridge University, Biochemistry Department, UK). ESCs were 
passaged mechanically (See Figure 2.3) every 5-7 days in the presence of 2 μM 
Thiazovivin (StemGent, Cambridge, MA, USA) with the medium replaced daily. Only 
those colonies which displayed characteristic morphology, i.e. compact, multicellular 
colonies characterised by a distinct border, were passaged. Any areas of spontaneous 
differentiation were removed throughout the culture period using a cell picker (glass 
pipette flamed at the end into a fine point), with the medium containing the removed areas 
of spontaneous differentiation replaced.  
 
 
Figure 2.3 Mechanical passaging of ESCs. Using an EVOS XL Core Cell Imaging System 
(ThermoFisher), once colonies reached approximately 70% confluency mechanical passaging 
was conducted by cutting the colonies into small squares of approximately 50 - 100 µm in size 
(containing approximately 50 - 200 cells) using a scalpel blade. Cut colonies were then lifted 
using a cell picker, collected into a 15 ml falcon tube and allow to settle by gravity. The medium 
above the gravity separated cell pellet was removed to ensure no single cells remained and the 
process repeated with fresh medium. Cell aggregates were then re-plated at a 1:2 splitting ratio 
onto a new plate of inactivate MEFs’ (thawed one day prior to ESC passaging). 




2.3.3. Two-dimensional ESC tenocyte differentiation 
Differentiation of the ESCs in 2D was induced by passaging the cells into feeder-free 
conditions in ESC medium without LIF. Cells were allowed to attach for 24 hours before 
the addition of 20 ng/ml of TGF-b3 (Peprotech, London, UK). Differentiation was 
conducted for 14 days with the medium being replaced every 3 days with fresh TGF-b3 
added.  
2.3.4. Three-dimensional ESC tenocyte differentiation 
Mechanically passaged clumps of ESCs (see section 2.3.2) were isolated, and an aliquot 
dissociated into single cells using TrypLEÔ Select (Invitrogen), by incubating for 8-10 
minutes at 37°C, in order to conduct representative cell counts. Non-dissociated colonies 
of ESCs were then suspended at the same cell density and prepared in the same way as 
tenocyte constructs (see section 2.2.3) but using ESC medium without LIF. Contraction 
analysis and cell survival assays were performed as stated previously (see section 2.2.3).  
2.4 Sexing cell lines 
Genomic DNA from all cell lines used was extracted from 1x106 cells using the QIAamp 
DNA mini kit (Qiagen, Valencia, CA) according to manufacturer’s instruction. Primers 
were designed to amplify the SRY and ZFX-ZFY genes using Primer3 
(http://primer3.ut.ee/) ensuring they had a GC content between 40-80%, were of length 
18-24 bases, with the primers in a pair having a Tm within 5°C of each other, and avoided 
primer secondary structures as determined by the programme mfold (262). Primers are 
found in Table 2.1. 
Table 2.1. PCR primers for sexing cell lines. 
Primer Name Sequence (5’g 3’) PCR Product (bp) Melting Temperatures 
SYR Forward TGCTATGTCCAGAGTATCCAACA Male: 714 58°C 
SYR Reverse TGAGAAAGTCCGGAGGGTAA Female: 0 58°C 
ZFX/Y Forward AAATCAAAACCTTCATGCCAAT Male: 604 + 553 53°C 
ZFX/Y Reverse TTCCGGTTTTCAATTCCATC Female: 604 53°C 




The OneTaq® DNA polymerase (NEB) was used for amplification of the PCR products 
from genomic DNA in accordance with the manufacturer’s instructions. Briefly, for each, 
1.5 µl of genomic DNA (diluted to give approximately 50 ng), 10 µM of each primer, 10 
µl of 5x OneTaq® Standard Buffer, 10 mM of deoxynucleotide triphosphate (dNTPs), 
0.25 µl of OneTaq® Hot Start DNA Polymerase (all NEB) and distilled water were mixed 
to obtain a final volume of 50 µl. For the amplification the BioRad T100™ Thermal 
Cycler was used and set to a program of: 94°C for 30 seconds, 30 cycles of denaturation 
at 94°C for 30 seconds, primer annealing at either 55°C for the SYR primers or 48°C for 
the ZFX/Y primers for 1 minute, extension at 65°C for 1 minute and a final elongation 
step of 65°C for 10 minutes. Amplified PCR products were then run on 1% agarose gel 
and visualised as described in section 2.6.1.  
2.5 Lentiviral infection of cells 
2.5.1. Packaging cell culture 
HEK293T, a human embryonic kidney cell line that expresses a mutant version of the 
SV40 large T antigen was used as a packaging cell. These cells were used due to their 
known ability to produce high lentiviral titers by allowing transfected plasmid DNAs that 
carry the SV40 origin of replication (ORI) to replicate within them (263). HEK293T cells 
were maintained in DMEM containing 10% FBS, 2 mM of L-Q and 1% P/S (all Gibco). 
Once 80% confluency was reached cells were passaged using 0.25% trypsin/EDTA, with 
care being taken to ensure cells did not become overconfluent as this can affect their 
growth rate and the subsequent lentiviral titer produced. Prior to transfection, HEK293T 
lines were passaged 3-4 times after thawing in order to give the cells time to recover from 
the thawing process and return to their normal growth rate.  
2.5.2. Lentiviral production and target cell infection 
TRC2-pLKO.1-puro vector plasmids containing a short hairpin RNA (shRNA) specific 
for human SCX (95.24% identity to the equine SCX sequence) (clone NM_001008271.1-
95s21c1; Sigma) (shSCX), a non-target, scrambled (NT) shRNA sequence (SHC202; 
Sigma) and a Turbo-GFP shRNA (SHC203; Sigma) were utilised for stable cell line 




generation. For visualisation of the Turbo-GFP shRNA (SHC203; Sigma) in ESCs the 
plasmid was modified as described in section 2.6. One microgram of the pLKO.1 plasmid 
alongside 750 ng of psPAX2 (#11260; Addgene, Cambridge, MA) and 250 ng of 
pMD2.G (#12259; Addgene) were transfected into HEK293T packaging cells, using the 
FuGENE® 6 transfection reagent (Promega, Hampshire, UK) as described in Figure 2.4.  
 
Figure 2.4. HEK transfection. To an Eppendorf tube the psPAX2 and pMD2.G packaging 
plasmids, as well as either the shSCX, NT or Turbo-GFP plasmid previously described were 
added, and the volume adjusted with Opti-MEM reduced serum medium (Gibco) to give a 20 µl 
final volume per reaction. In a second Eppendorf tube, 6 µl of FuGENE® 6 transfection reagent 
was added to 74 µl of Opti-MEM per reaction. Both Eppendorf tubes were incubated for 5 minutes 
at room temperature before mixing and incubating for a further 20 minutes. The 100 µl of 
plasmid/FuGENE® mix was then added dropwise per well of HEK293T cells, which were plated 
at 1x105 cells per well one day prior. Cells were returned to the incubator for 12-15 hours, before 
qualitative visualisation of transfection efficiency using the green fluorescent protein (GFP) 
control on the Olympus IMT2-SFR inverted microscope. 
Packaging cell supernatant containing infectious lentiviral material was then collected 
48-, 72- and 96-hours post transfection, filtered through a 0.45 µm filter (Millipore, 
Billerica, MA, USA) to remove cellular debris and frozen at -70°C. Target cells were 
seeded at 1x105 cells per well of a 6-well plate 24-hours before infection with 1x107 IU/ml 
of virus. Puromycin (Sigma) antibiotic selection was then carried out at a concentration 
of 4 µg/ml (determined optimal based on an antibiotic kill curve of non-infected cells). 
The qPCR Lentivirus Titration Kit (LV900) from abm (Applied Biological Materials Inc, 
Richmond, CA) was used to calculate the viral titer of the frozen preparations as described 




in section 2.5.3. Lentiviral infection was optimised using titers varying from 5x105 IU/ml 
to 1x108 IU/ml, with 1x107 IU/ml obtaining the best viral efficiency with limited cytotoxic 
effects and optimal copy number integration (see section 2.5.4). 
All SCX knockdown and paired NT control lines generated were expanded in culture 
with cryopreserved stocks made as described in section 2.2.1. RNA was extracted from 
each line (see section 2.7.1) and similarly coverslips of all SCX knockdown and paired 
NT control lines set up and fixed (as described in section 2.11.1) ready for subsequent 
analysis. Six biological replicates of SCX knockdown and paired NT control lines were 
generated in adult and fetal tenocytes, four of which (i.e. four adult and four fetal tenocyte 
lines) were used in RNA-seq experiments (see section 2.9). All adult and fetal tenocyte 
shSCX and NT lines used in subsequent experiments were between passage (P)5 and P10. 
SCX knockdown in young postnatal foal tenocytes was conducted in three biological 
replicates, with cells being used between P5 and P9 in all subsequent experiments. For 
the undifferentiated ESCs, SCX knockdown was conducted in one biological line, with 
the knockdown being performed in three independent technical replicates. SCX 
knockdown ESCs were used between P19 and P22 in subsequent experiments.  
2.5.3. Lentiviral titer 
The abm qPCR Lentivirus Titration Kit was used to determine the titer of frozen viral 
preparations according to the manufacturer’s instructions. Briefly, viral supernatant was 
centrifuged at 2000 x g for 5 minutes to remove any remaining cellular debris. Viral lysis 
was then conducted by adding 2 µl of viral supernatant to 18 µl of Viral Lysis Buffer 
(abm), which was incubated at room temperature for 3 minutes. A qPCR reaction was 
then set up containing 12.5 µl of SensiMix SYBR No-ROX supermix (Bioline, London, 
UK), 10 µl of reagent-mix (abm) and 2.5 µl of either the viral lysate, standard 1, standard 
2 or distilled water added to give a final reaction volume of 25 µl. Each reaction was set 
up in triplicate and run as described in section 2.8.2. The sample titer was then calculated 
using the abm High Titer Lentivirus Calculator (http://www.abmgood.com/High-Titer-
Lentivirus-Calculation.html).  




2.5.4. Lentiviral copy number integration 
Genomic DNA was extracted from 1x106 lentiviral infected cells using the QIAamp DNA 
mini kit (Qiagen, Valencia, CA) according to manufacturer’s instruction. Transgene copy 
number was quantified using a combination of the protocols described in Joshi et al., 2008 
and Barczak et al., 2014 (264,265). Briefly qPCR was conducted using 100 ng of DNA 
per 25 µl reaction using SensiMix SYBR No-ROX (Bioline). Primers were designed for 
the detection of the Woodchuck Hepatitis Virus Post-Transcriptional Regulatory Element 
(WPRE) sequence, a lentiviral specific fragment, and the 18s rRNA housekeeping gene 
(Table 2.4). All reactions were conducted using the cycling conditions described in 
section 2.8.2. The mass of one copy of the SCX shRNA, NT shRNA and Turbo-GFP 
shRNA plasmids were calculated using the formula below: - 
! = #$!
 
Where m = mass of one copy, M = molecular weight of the plasmid (Dalton) calculated 
based on the length (bp) of the plasmid and the molecular weight of nucleotide (650 
Daltons/base pair) and NA = Avogadro’s number (6.02 x 1023 copies/mole).  
It was calculated that each copy of the SCX shRNA and NT shRNA had a mass of 5.7 ag 
and 1 ng of plasmid therefore had approximately 1.23 x 109 copies of WPRE transgene. 
Each copy of GFP shRNA had a mass of 9.5 ag and 1 ng of plasmid therefore had 
approximately 1.23 x 109 copies of WPRE transgene. Plasmid concentrations were 
quantified using the Quant-iTÔ PicoGreenÔ dsDNA assay kit (Invitrogen) according to 
the manufacturer’s instructions. A standard curve was constructed by carrying out serial 
dilutions of each plasmid, containing the relevant sequence (WPRE), from 1 pg to 10 ag 
allowing quantification of unknown samples. All dilutions were made in the presence of 
10 ng/µl carrier DNA from WT equine tenocytes (not containing the WPRE transgene) 
in order to increase the stability of the dilutions. The number of transgene lentiviral 
integrating events in 100 ng of DNA was calculated from their respective CT (cycle 
threshold) value using a linear equation calculated from each plasmid standard curve. 
WPRE copy number per diploid cell was then calculated based on an average DNA yield 
of 28.33 µg obtained from 1x106 cells as shown in the equation below: -  




%&'()*'	,-!.'(	/0	1'223	4'(	100	,*	7$% = 28.33	µg	100	,* 	= 283.3	,* 
																																								= 	 1>10
"
283.3 = 353	1'223 
Therefore, it was calculated that 100 ng of DNA contains the DNA from approximately 
353 diploid cells.  
2.6 Modification of Turbo-GFP shRNA plasmid 
To facilitate the expression of the green fluorescent protein (GFP) in ESCs the Turbo-
GFP shRNA (SHC203; Sigma) control cytomegalovirus (CMV) promoter, which did not 
have transcriptional activity in equine ESCs, was replaced with either the human 
phosphoglycerate kinase (PGK) or elongation factor 1 alpha (EF1a) ubiquitous promoter 
sequence. To do so, the Turbo-GFP shRNA plasmid (Figure 2.5) was cut using the 
restriction enzymes KpnI and NehI in order to remove the CMV promoter. Restriction 
enzyme digests were typically performed using 10 units of restriction enzyme (NEB) per 
1µg of DNA in the appropriate buffer for 1 hour at 37°C. The cut plasmids were 
dephosphorylated using FastAP Thermosensitive Alkaline Phosphatase (Thermo) 
according to the manufacturer’s instructions, in order to prevent self-ligation. Linearized 
plasmids were run on an agarose gel (see section 2.6.1) and the backbone of the vector, 
minus the CMV insert, excised and purified (see section 2.6.2).  





Figure 2.5. SHC203 Turbo-GFP modification. Scissors highlight the restriction enzyme cut 
sites used during the cloning process to remove the CMV promoter from the Turbo-GFP shRNA 
control plasmid, for replacement with either the PGK or EF1a PCR amplified promoters. Plasmid 
maps visualised in SnapGene® (v.5.1).  
Using modified primers containing recognition sequences for the restriction enzymes that 
were used to remove the CMV promoter, KpnI and NehI at the 5’ and 3’ end respectively 
(Table 2.2), the PGK promoter from the NT shRNA plasmid (SHC202; Sigma) and the 
EF1a promoter from the pLV-EF1a-IRES-Blast (a gift from Tobias Meyer – Addgene) 
were amplified by PCR as described in section 2.6.3. PCR products were then purified 
(see section 2.6.2) and cut using the restriction enzymes KpnI and NehI to create the 
complementary base pair overhangs. Cut PCR products were ligated to the linearized 
plasmid backbone using T4 ligase (NEB) in accordance with the manufacturer’s 
instructions. The ratio of vector to insert was calculated using the NEBioCalculator™ 
(v1.10.1). Ligation products were transformed into competent cells (see section 2.6.4), 
alongside no insert and no T4 ligase internal controls (see section 2.6.4). Eight resistant 
colonies were then picked from each successful ligation and seeded into LB broth 
containing 50 µg/ml ampicillin, and subsequently small-scale plasmid DNA isolations 
performed as described in section 2.6.4. Restriction enzyme test digests were used to 
initially verify correct insertion of the new promoter before sanger sequencing (see 
section 2.6.5). Plasmids with correctly inserted promoters were then isolated using large-
scale DNA isolation as described in section 2.6.4.  




Table 2.2. Primer sequences used for PCR. Capitalised sequence text represents the binding 
region. Green lowercase text indicates additional base pairs added before the restriction enzyme 
digest site. Blue lowercase text indicates the addition of a KpnI restriction digest site. Pink 
lowercase text indicated the addition of a NheI restriction digest site.  
Primer Name Sequence (5’g 3’) PCR Product (bp) 
Melting 
Temperature 
PGK-KpnI Forward tgaggtaccTTGCGCCTTTTCCAAGGCAG 
PGK: 519 
67°C 
PGK-NheI Reverse ttagctagcCTGGGGAGAGAGGTCGGTG 67°C 
EF1a-KpnI Forward tgaggtaccCGATGAGGCCCTTTCGTCT 
EF1a: 1124 
68°C 
EF1a-NheI Reverse cgagctagcGGATCCTCACGACACCTGAAAT 68°C 
 
2.6.1. Agarose gel electrophoresis 
The appropriate percentage agarose gel (1.0% for effective separation of 400–8000 bp, 
1.5% for 200-3000 bp or 2% for 100-2000 bp) was prepared by melting Ultra-Pure 
Agarose (Invitrogen) in 1x TAE (Tris-Acetate-EDTA)(Sigma). GelRedÒ Nucleic Acid 
Gel Stain (Biotium, Fremont, CA) was added to the molten agarose at a 1x final 
concentration. Orange DNA Loading Dye (6X) (ThermoFisher, Loughborough, UK) was 
added to the DNA before loading alongside either the Quick-Load Purple 100bp or 1Kb 
DNA Ladder (NEB). Electrophoresis was performed in 1x TAE at 100 volts for the time 
required for optimal separation (typically 45 minutes). UV light on a transilluminator was 
used to visualise the DNA and gels were photographed using the Alpha Innotech 
Alphalmager 2200 Gel Image Analysis System.  
2.6.2. Plasmid DNA and PCR purification 
Plasmid DNA and products obtained from polymerase chain reactions (PCR) were 
purified using the MonarchÒ PCR & DNA Cleanup Kit (New England BioLabs (NEB), 
UK) according to the manufacturer’s instructions. DNA extraction from agarose gel was 
conducted by excising the appropriately sized band from the gel using a scalpel blade and 
purifying using the MonarchÒ DNA Gel Extraction Kit (NEB, UK) according to the 
manufacturer’s instructions. DNA concentration was calculated from the absorbance at 
260 nm measure using a NanodropÔ One Microvolume UV-vis Spectrophotometer 




(ThermoFisher). A 50 µg/ml solution of double-stranded DNA and a 33 µg/ml solution 
of single stranded DNA have an absorbance of 260nm of 1.0. 
2.6.3. Using PCR to amplify plasmid promoter regions 
Primers were designed using Primer3 (http://primer3.ut.ee/) ensuring they had a GC 
content between 40-80%, were of length 18-24 bases, with the primers in pairs having a 
Tm within 5°C of each other and avoided primer secondary structures as determined by 
the programme mfold (262). 
The Phusion™ High-Fidelity DNA polymerase (ThermoFisher), a Pyrococcus-like 
proofreading polymerase and fused DNA-binding domain, was used to amplify the PGK 
and EF1a promoters (see section 2.6) from plasmid DNA in accordance with the 
manufacturer’s instructions. Briefly, for each, 1 µl of plasmid DNA (diluted to 
approximately 2 ng/µl), 0.5 µM of each primer, 10 µl of HF Buffer, 10 mM of dNTPs, 
0.5 µl of Phusion DNA Polymerase (all ThermoFisher) and distilled water were mixed to 
obtain a final volume of 50 µl. For the amplification the BioRad T100™ Thermal Cycler 
was used and set to a program of: 98°C for 30 seconds, 35 cycles of denaturation at 98°C 
for 10 seconds, primer annealing at 60°C for 30 seconds, extension at 72°C for 30 seconds 
and a final elongation step of 72°C for 10 minutes.  
2.6.4. Bacterial transformation 
All bacterial work was carried out near a Bunsen burner on the blue flame, with the lids 
of glass bottles and L-shaped bent glass pipettes used for spreading transformations 
flamed and treated with 70% ethanol. 
E.coli DH5α competent cells (Invitrogen) were used for transformations, using the heat 
shock method. Briefly, 50 µl of competent cells were thawed on ice and 5 µl of ligation 
reaction or 1 µl of plasmid DNA (approximately 50 ng) added and incubated for 10 
minutes on ice. Following incubation, the reaction was transferred to a 42°C water bath 
for 30 seconds before re-incubating on ice for a further 2 minutes. A volume of 900 µl of 
LB broth, made by adding 5 g of Tryptone, 2.5g of. yeast extract and 2.5 g of NaCl (all 
Sigma) to 500 ml of distilled water which is then autoclaved, was added to the competent 
cells and incubated at 37°C for 30 minutes with gentle shaking. LB agar plates were made 




by adding 5 g of Tryptone, 2.5 g of yeast extract, 2.5 g of NaCl and 7.5g of bactoagar (all 
Sigma), made up to 500 ml with distilled water which is then autoclaved before 50 µg/ml 
ampicillin was added, and the liquid poured into petri dishes. Bacterial transformations 
were then plated onto LB agar plates and incubated upside-down at 37°C overnight.  
Resulting colonies were picked and seeded into 2 ml of LB broth for small scale plasmid 
DNA isolation or 250 ml for large scale plasmid DNA isolation. Small scale plasmid 
DNA isolation were performed using the Monarch® Plasmid Miniprep Kit (NEB) 
according to the manufacturer’s instructions. Large scale plasmid DNA isolation were 
performed using the HiSpeed® Plasmid Maxi Kit (Qiagen) according to the 
manufacturer’s instructions. 
2.6.5. Sanger sequencing of modified plasmids 
Sanger dideoxynucleotide sequencing (266) was carried out in-house. Briefly, sequencing 
reactions were set up containing 5 µl of sequencing buffer (final concentration 80mM 
TRIS-HCl pH 9.0, 2mM MgCl2), 1 µl of Big Dye™ Terminator mix version 3.1 (Applied 
Biosystems), 1.5 µl of sequencing primer (0.08 µM final concentration, primers found in 
Table 2.3), 2.5 µl of purified plasmid (at 50 ng/µl) and water to a final volume of 20 µl. 
Reactions were run on a Biddy Scientific™ Techne™ TC-512 gradient thermo cycler 
(ThermoFisher) using the following program: denaturation at 96°C for 15 seconds, primer 
annealing at 50°C for 10 seconds, and extension at 60°C for 2 minutes, which was 
repeated 25 times. Sequencing products were purified by precipitation by adding 2 µl of 
3M sodium acetate (pH 4.6) and 50 µl of 100% ethanol and incubating for 15 minutes at 
room temperature. Precipitated products were then centrifuged at 3500 x g for 30 minutes 
before removing the liquid and adding 125 µl of 70% ethanol and incubating for a further 
15 minutes. Precipitated products were centrifuged again, and the ethanol removed. For 
the sequencing step, 10 µl of HiDi buffer (Applied Biosystems), was added to each 
precipitated sample and denatured for 1 minute at 96°C, before being placed on ice. 
Sample electrophoresis and analysis was performed on an ABI Prism 3100XL Genetic 
Analyser (Applied Biosystems). Resulting sequencing data was analysed in SnapGene® 
(v.5.1). 




Table 2.3. Primers for sanger sequencing. 
Primer Name Sequence (5’-3’) 
U6 Region Forward GACTATCATATGCTTACCGT 
GFP Region Reverse CATCTTGTTGGTCATGCGGC 
2.7 RNA extraction  
2.7.1. RNA isolation from cells and 3D constructs 
RNA was harvested into 1 ml of Tri-reagent (Sigma) per 10 cm plate for 2D cultured cells 
or per six to nine gel constructs for 3D cultured cells and stored at -70°C until required. 
When ready to use, samples were thawed and incubated at room temperature for 5 
minutes, 300 µl of chloroform (Sigma) added, vortexed for 15 seconds, incubated for a 
further 5 minutes and then centrifuged at 12,000 x g for 15 minutes at 4°C. The aqueous 
layer was then isolated and 700 µl of 70% ethanol added. For 3D cultured cells, the 
aqueous layer of between 9 and 35 gel constructs (harvested from the same biological 
line and experimental set up) were pooled. RNA was then extracted using a RNeasy mini 
kit (Qiagen) according to the manufacturer’s instructions. DNase treatment was then 
conducted using the DNA-free™ kit (Ambion, Texas, USA) as per the manufacturer’s 
instructions. RNA concentrations were calculated using a NanodropÔ One Microvolume 
UV-vis Spectrophotometer, using an absorbance of 260 nm and ensuring the 260:280 
ratio lay within 1.8 and 2.2 indicating high purity RNA. 
2.7.2. RNA isolation from cartilage 
Using a liquid nitrogen cooled pestle and mortar, warmblood cartilage stored in 
RNAlaterÒ (see section 2.1.2) was ground into a powder. The resulting powder was 
collected in PBS (phosphate buffered saline), centrifuged at 161 x g for 5 minutes and 
resuspended in 1 ml of Tri-reagent (Sigma) and stored at -70°C until later use. RNA-
extraction was conducted as described in section 2.7.1.  




2.7.3. cDNA synthesis 
One microgram of total RNA was reverse transcribed using the SensiFAST cDNA 
Synthesis Kit (Bioline, London, UK). Samples were prepared and underwent thermo 
cycling on a BioRad T100™ Thermal Cycler. Briefly, 4 µl of TransAmp Buffer and 1 µl 
of Reverse Transcriptase were added to the RNA and made up to 20 µl with DNase/RNase 
free water before cycling as follows: primer annealing at 25°C for 10 minutes, reverse 
transcription at 42°C for 15 minutes, optional step at 48°C for 15 minutes and inactivation 
at 85°C for 5 minutes. Reactions lacking the reverse transcriptase were also carried out 
to ensure no genomic DNA contamination. Following thermocycling reactions were 
diluted in DNase/RNase free water to a final volume of 50 µl, which assuming 100% 
efficient cDNA synthesis, resulted in a final concentration of 20 ng/µl of cDNA. All 
products were then stored at -20°C until qPCR was carried out.  
2.8 Quantitative PCR (q-PCR) 
2.8.1. Primer design for qPCR 
Equine gene specific primers were designed using NCBI Primer-Blast 
(https://www.ncbi.nlm.nih.gov/tools/primer-blast/) and are found in Table 2.4. The 
programme mfold (262) was used to ensure each amplicon (50-150 bp in size) had a Tm 
of between 58-62°C, a GC content between 40-80% and were devoid of secondary 
structure at Tm 60°C. All primers were ordered from Sigma and were designed to span 
an intron where possible in order to ensure amplicons were devoid of contaminating 
genomic DNA. The efficiency of each primer set was determined by generating a standard 
curve of known quantities of appropriate equine cDNA (40 ng, 20 ng, 10 ng, 5 ng, 2.5 ng 
and 1.25 ng), ensuring the efficiency lay between 85% and 115%, with reactions being 
set up as described in section 2.8.2. The efficiency was calculated using the equation 
Efficiency = 10^(-1/slope) – 1 
Where the slope is derived from the Cycles to Threshold (Ct) values plotted against the 
Log10 of the template amount. The size of all products was also confirmed using agarose 




gel electrophoresis (see section 2.6.1), and the products Tm confirmed via the melt curve 
(see section 2.8.2).   
Table 2.4. qPCR primers. 
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) Product Melting Temp (Tm) 
18s rRNA CCCAGTGAGAATGCCCTCTA TGGCTGAGCAAGGTGTTATG 78°C 
ACAN GCGGTACGAGATCAACTCCC GCGACAAGAAGAGGACACCA 88 C 
ACTB CCAGCACGATGAAGATCAAG GTGGACAATGAGGCCAGAAT 80°C 
CDK1 CTGGGCAGTTCATGGATTCT CAATCCCTTGTAGGATTTGG 74°C 
CNMD GGGAACAACTTGGAGACCTT TTCTCTCCTCCAGCAAAACG 75°C 
COL1A1 TGCGAAGACACCAAGAACTG GACTCCTGTGGTTTGGTCGT 85°C 
COL1A2 GTGCCTAGCAACATGCCAAT GTCCTCTATCTCCGGTTGGG 79°C 
COL2A1 TCCTGGTGTCAAAGGTCACA TCCCTTAGCACCATCCAGAC 78°C 
COL3A1 CTGGTGCTAATGGTGCTCCT TCTCCTTTGGCACCATTCTT 77 C 
COL14A1 CTTCATGTTCTGCCTACGGG CGTCTTGGACAGGGGTGAAT 80°C 
COMP AGAACATCATCTGGGCCAAC CGCTGGATCTCGTAGTCCTC 81°C 
EYA2 GGGCTCCGTGTTTCCTATTG GGCCGAACCTCTGCATTATC 79°C 
GAPDH CGACCACTTTGTCAAGCTCA GTCCACCACCCTATTGCTGT 77°C 
GPRIN3 AGCTTAGACTCTGAACATATGAGG CCAGGGTCTACGTATGCAGG 78°C 
IL1R1 GAAGCGCATAAAGGGCACTA CGTGGGCCTGATTTCATCTA 76°C 
IL1R2 TCTGGCACCTACATCTGCAC CAGGGCAGCTTCTGTCTTCT 81°C 
IL1RN GCCTGTGTCAAGTCTGGTGA CCTCCTTGTTCTTGCTCAGG 78°C 
LHX9 AACAGGGCTGACCAAAAGAG TGAATTTGGCTCGTGCGTTT 72°C 
MKX AAGGCAAAGGAACCATTCGG TTAGCTGTCACCCTTATTGGAT 79°C 
MMP2 CAGGAGGAGAAGGCTGTGTT AGGGTGCTGGCTGAGTAGAC 77°C 
MMP3 TGGACCTGGAAAAGTTTTGG GACCAAGTTCATGAGCAGCA 80°C 
MMP9 GAGATCGGGAATCATCTCCA CCAAGAGTCGCCAGTACCTC 76°C 
MMP13 GCCACTTTGTGCTTCCTGAT CGCATTTGTCTGGTGTTTTG 77°C 
SCX CCCAAACAGATCTGCACCTT ATCCGCCTCTAACTCCGAAT 81°C 
SMAD3 ATCCCCAAATCCGATGTCCC GCGCTGGTTCAGCTCATAGT 83°C 
SOX9 GCTCTGGAGACTTCTGAACGA  GTAATCCGGGTGGTCCTTCT 86°C 
SOX11 GTTCATGGTGTGGTCCAAGA GCTGTCCTTCAGCATTTTCC 82°C 
TENM4 CTGATGGGAAGACATGGAGC GCGGTCATTCTTGTCGAACT 79°C 
THBS4 GGGAAATGGGGTTACCTGTT CGGGTAGCAGGGATGATATT 76°C 
TNC AACCCGTCCAAAGAGACCTT GCGTGGGATGGAAGTATCAT 81°C 
TNMD GTCCCTCAAGTGAAGGTGGA CCTCGACGGCAGTAAATACAA 79°C 
VIM GAGAGCACCCTGCAATCC AAGGTCAAGACGTGCCAAAGA 77°C 
WPRE AGCTGACAGGTGGTGGCAAT TGCTGACGCAACCCCCACTGGT 72°C 
2.8.2. qPCR reaction 
qPCR was carried out using a Biorad CFX96 Touch Real-time PCR detection machine. 
Each qPCR reaction was performed in duplicate and consisted of 10 µl of SensiMix 




SYBR No-ROX supermix (Bioline), 1 µl of forward and reverse primers (final 
concentrations, 0.5 µM), 6 µl of HPLC grade water and 2 µl (40 ng) of relevant cDNA 
(or controls; no reverse transcription RNA and no template control). Cycling was 
conducted using the following program: initial denaturation at 95°C for 10 minutes, 
followed by 45 cycles of denaturation at 95°C for 15 seconds, annealing at 55°C for 15 
seconds and elongation at 72°C for 15 seconds. The temperature was then reduced to 
60°C and gradually increased by 0.5°C every 10 seconds up to 90°C, to produce a melt 
curve. Reactions were quantified relative to the 18s rRNA housekeeping gene, which has 
previously been used as a housekeeping gene in these cell types (121,140,154,267) and 
proved stable upon validation (see section 2.8.3). To calculate the relative gene 
expression the following formula was used: 2-ΔΔCT, where ΔCT = average threshold cycle 
of the gene of interest – average threshold cycle of the housekeeping gene (268).  
2.8.3. Housekeeping gene validation  
cDNA samples from three independent lines of adult, fetal and ESC-derived tenocytes 
(cultured in 3D) used for the RNA-seq experiments were used to validate the most 
suitable housekeeping gene for qPCR. Seven genes were tested and normalised to three 
different equine specific housekeeping genes, 18s rRNA, ACTB and GAPDH (Table 2.4). 
The results were then compared to that obtained from the RNA-seq experiment. The 
stability of the housekeeping genes was also evaluated using RefFinder 
(https://www.heartcure.com.au/reffinder/) which integrates the following computational 
housekeeping validation tools: geNorm, Normfinder, BestKeeper and the comparative 
deltaCT method. As an input for this analysis the triplicate CT values obtained from three 
independent lines of adult, fetal and ESC-derived tenocytes of 18s rRNA, ACTB and 
GAPDH were used and the genes ranked from most to least stable.  
2.9 RNA-sequencing 
2.9.1. Power calculations 
Prior to sequencing power calculations were performed, according to established 
protocols (269), to determine the minimum sample size required per group for RNA-seq 




in order to provide an 80% power to detect a 2-fold change in gene expression at a 
significance level of 5%. Calculations were performed based on the following 
assumptions: A) an estimated co-efficient of variation (CV) in gene expression of 0.25 
between sample of a single cell type. This estimate is based on RNA-seq data in human 
cells and tissues which report CVs’ ranging from 0.2 for peripheral blood mononuclear 
cells (PBMCs) to 0.74 for more complex tissue samples (269). As our experiments are 
based on in vitro cell cultures, comparing tenocytes under different conditions a CV more 
similar to PBMCs was used. B) A mean coverage of 30X, based on obtaining 26 million 
reads per sample which has been shown to be sufficient to detect differential gene 
expression for the majority of genes (246). Based on these assumptions, 3 samples per 
group was calculated to be sufficient to detect a 2-fold change in gene expression at a 
significance level of 5% with 80% power.  
2.9.2. RNA-sequencing sample integrity 
Three lines of adult, fetal and ESC-derived tenocytes cultured in 3D, three lines of adult 
and fetal tenocytes cultured in 2D, four lines of adult shSCX and NT expressing cells and 
four lines of fetal shSCX and NT expressing cells were used in RNA-sequencing 
experiments. Adult and fetal 3D tendon constructs were between P3 and P8. ESC-derived 
3D tendon constructs were between P12 and P22. Adult and fetal tenocytes 2D cultures 
were between P3 and P8. Adult and fetal shSCX and NT lines were between P5 and P8.  
RNA quality was determined for all the aforementioned samples using the Agilent 2200 
Tape station system (outsourced to Cambridge Genomics Service, Cambridge). RNA 
Integrity Number (RINe) values for all samples were between 9.3-10. 
2.9.3. RNA sample library preparation and sequencing 
mRNA library preparation and sequencing were performed by external providers 
(Edinburgh Genomics, Edinburgh, UK and Otogenetics, Atlanta, USA) using a TruSeq 
stranded mRNA kit (Illumina, Cambridge, UK) or Clonetech Smart cDNA kit (Clonetech 
laboratories, CA, USA) and the NovaSeq6000 (Illumina) and Illumina HiSeq2500 
respectively. The generalised workflow of both library prep assays can be found in Figure 
2.6. The size distribution, quality and quantity of the Illumina libraries were determined 




using an Agilent Bioanalyser 2100, before being submitted for sequencing (paired-end 
100-125 nucleotides (nt), designated 26 million reads).  
 
Figure 2.6. RNA-sequencing library preparation steps. (1) Poly(A) selection is used to enrich 
mRNA from the total RNA. This method was used instead of rRNA depletion due to the high 
quality of the RNA samples. mRNA is then fragmented. (2) Random priming is used to synthesise 
the first strand of cDNA, followed by synthesis of the second strand. (3) cDNA is end repaired, 
phosphorylated and A-tailed. (4) Adapters are ligated, and PCR amplification performed before 
the library is then ready for clustering and sequencing. 
2.10 Bioinformatics 
2.10.1. Quality control 
The sequencing data generated in this thesis is available at the National Centre for 
Biotechnology Information Gene Expression Omnibus (NCBI GEO, 
www.ncbi.nlm.nih.gov/geo) under the accession numbers GSE132358, GSE145029 and 
GSE149570. Per sample, on average 32.3 million total read sequences, of approximately 
100 base pairs in length were generated. The raw reads were quality control checked using 
FASTQC and FASTQC Screen (Babraham Institute, Cambridge, UK) to determine if 
trimming of low-quality ends (error rate < 0.05) and adapters was required. 




2.10.2. Genome mapping and downstream analysis 
Mapping via this method was conducted for the 3D adult, fetal and ESC-derived tenocyte 
construct data only. Here the resulting high quality reads were mapped to the Equus 
Caballus reference genome (EquCab 3.0, Ensembl v96) using the HISAT2 (hisat2-align-
s v.2.1.0) spliced aligner (270). Resulting sequence alignment/map (SAM) files were then 
converted into sorted BAM files (binary version of a SAM file) using samtools (271). 
Next featureCounts (v.1.6.2) from the Subread package (272) was used to count how 
many reads were mapped to each single genomic coordinate within the genome. The 
counts table generated from featureCounts was then loaded into R (v.3.5.2), converted 
into a matrix and the R/Bioconductor DSeq2 (v.1.22.2) software used to conduct 
differential expression analysis as described in Love et al., 2014 (273). For analysis of 
differential expression between 3D adult, fetal and ESC-derived tenocyte constructs 
genes with a log 2-fold change (Log2FC) of ±2 and adjusted p-value (p-adj) of < 0.01 
were considered differentially expressed (DE). 
2.10.3. Transcriptome mapping and downstream analysis 
Mapping via this method was conducted for the 3D adult, fetal and ESC-derived tenocyte 
construct data as well as for the 2D cultured adult and fetal tenocyte data and the adult 
and fetal shSCX and NT data. For transcriptome mapping the pseudoaligner Salmon 
(274) in Quasi-mapping based mode was used to align the reads to the Ensembl version 
v96 EquCab 3.0 transcriptome with GC-bias correction (-gcBias) applied. Gene-level 
abundance data was imported into R (v.3.5.2) using Tximport (275) and the 
R/Bioconductor DSeq2 (v.1.22.2) software used to conduct differential expression 
analysis as described in Love et al., 2014 (273). For analysis of differential expression 
between 3D adult, fetal and ESC-derived tenocyte constructs genes with Log2FC of ±2 
and p-adj of < 0.01 were considered DE. For analysis of differential expression between 
2D and 3D adult and fetal tenocytes genes with Log2FC of ±2 and p-adj of < 0.01 were 
considered DE. For analysis of differential expression between adult and fetal NT shRNA 
expressing versus SCX shRNA expressing cells genes with Log2FC of ±1 and p-adj of < 
0.05 were considered DE. Visualisation of differential expression analysis was conducted 
in R (v.3.5.2). Euclidean sample-to-sample distance matrices with hierarchical clustering 
using VST (variance stabilizing transformation) transformed data were generated using 




the R package “pheatmap” (v.1.0.12) (273). Heatmaps were also generated using the R 
package “pheatmap” (v.1.0.12) with dendrograms based on Pearson correlation. 
Euclidean principal component analysis (PCA) plots were generated in ggplot2 (v.3.1.0) 
using VST transformed data. The gene level summaries, including the differential 
expression analysis and normalized counts for all genes and samples can be found at 
NCBI GEO (www.ncbi.nlm.nih.gov/geo) under the accession numbers GSE132358, 
GSE145029 and GSE149570. 
2.10.4. Gene ontology, network and pathway analysis  
Gene Ontology (GO) analysis was performed using Panther (http://www.pantherdb.org/), 
with a false discovery rate (FDR) of < 0.05 being defined as significantly enriched. 
Pathway analysis was performed using GeneAnalytics from the LifeMap’s GeneCards 
Suite (http://www.geneanalytics.genecards.org), with an entity score of > 5 being 
equivalent to a corrected p-value of < 0.05 and therefore defined as significantly enriched. 
Entity scores of > 13 were considered highly significantly enriched being equivalent to a 
corrected p-value of < 0.01. Network analysis was conducted using the STRING Protein 
network analyser plug-in of Cytoscape (v.3.7.2) 
(http://apps.cytoscape.org/apps/stringapp) using the human reference set. Networks were 
generated using a less stringent cut off of Log2FC ± 0.6 p.adj < 0.05 to encompass a 
larger number of DE genes.  
2.11 Histology 
2.11.1. Preparation of tissues and cells  
Three lines of adult, fetal and ESC-tenocyte 3D constructs (P6 to P9 for adult and fetal 
tenocytes and P18 – 20 for ESC-tenocytes) were embedded in OCT compound (VWR) 
and snap frozen in liquid nitrogen cooled isopentane (Sigma). Longitudinal sections at 11 
µm thick, were cut using a cryostat, fixed on glass slides for 10 minutes in 100% acetone 
and stored at -20°C. Four biological lines of adult and fetal NT shRNA and SCX shRNA 
infected (shSCX) tenocytes were cultured on gelatin-coated (Sigma) coverslips (P8 to 




P10). Coverslips were fixed for 20 minutes in 3% paraformaldehyde, washed 3x in PBS 
and stored in PBS at 4°C.  
2.11.2. Haematoxylin and eosin (H&E) staining 
Previously fixed slides were placed in slide holders and transferred into Mayers 
haematoxylin (Sigma) for 5 minutes. “Blueing” was then carried out by placing the slides 
in running water for 10 minutes, before placing in eosin (Sigma) for 5 minutes. Slides 
were briefly rinsed in tap water before passing through an alcohol gradient of 70% 
ethanol, 95% ethanol, absolute ethanol twice and histoclear (National Diagnostics, 
Atlanta, USA) twice, shaking 5-10 times in each solution. Coverslips were then mounted 
on glass slides using Dpx mountant (Sigma).  
2.11.3. Picro Sirius red staining 
Picro Sirius red staining was conducted using the Abcam Picro Sirius Red Stain Kit 
according to the manufacturer’s instructions. Briefly, slides were rinsed in distilled water 
before submerging in Picro Sirius Red Solution (Abcam) for 60 minutes. Slides were then 
rinsed in Acetic Acid Solution (Abcam), followed by dehydration in two changes of 
absolute alcohol before mounting using Dpx mountant (Sigma).  
2.11.4. Immunofluorescence  
For immunofluorescence, paraformaldehyde fixed 2D coverslips were permeabilized in 
0.1% triton-X-100 (Sigma) for 1 hour before blocking. 3D slides or 2D coverslips were 
then blocked in 2.5% normal horse serum (Vector Laboratories, Peterborough, UK) for 
20 minutes at room temperature. Following the blocking step, the serum was removed 
before incubating with primary antibodies overnight at 4°C. Following primary antibody 
incubation, the slides or coverslips were washed in PBS (3x 5 minutes) and subsequently 
incubated with fluorescently labelled secondary antibodies for 3 hours at room 
temperature. All primary and secondary antibodies were used at optimized concentrations 
in 2.5% normal horse serum (Table 2.5). Finally, all slides and coverslips were washed 
in PBS (3x 5 minutes), rinsed in water and mounted in VECTASHIELD® HardSet™ 
mounting media containing DAPI (Vector Laboratories).  





Table 2.5. Primary and secondary antibodies used for immunofluorescence. 
Primary Antibodies 
 
Antibody Target Species Dilution Company 
Actin, muscle mouse 1:200 Dako (M0635) 
BMP7 rabbit 1:100 Abcam (ab56023) 
CADM1 rabbit 1:100 Abcam (ab3910) 
Collagen type 1 mouse 1:100 Abcam (90395) 
COMP rabbit 1:500 Kindly provided by Professor Roger 
Smith, Royal Veterinary College, UK 
IGF1 goat 1:50 Abcam (ab106836) 
LOXL4 rabbit 1:100 Biorbyt (orb100094) 
PDGFB rabbit 1:50 Abcam (ab181341) 
RUNX2 rabbit 1:50 Santa Cruz (sc10758) 
SCX rabbit 1:100 Abcam (ab58655) 
SPP1 mouse 1:50 Santa Cruz (sc21742) 
THBS4 rabbit 1:100 Santa Cruz (sc7657-R) 




Antibody Target Fluorescence Dilution Company 
Anti-mouse IgG Alexafluor 594 1:200 Thermo Fisher (A11005) 
Anti-rabbit IgG Alexafluor 594  1:200 Thermo Fisher (A11012) 
Anti-mouse IgG  FITC 1:200 Abcam (ab7064) 
Anti-goat IgG  FITC 1:200 Abcam (ab7121) 
 
2.11.5. Image acquisition 
All brightfield and immunofluorescence images were acquired using the Zeiss Axioplan 
2 imaging suite (Zeiss, Oberkochen, Germany). An Olympus IMT2-SFR inverted 
microscope, with polarizing filters was used for visualising Picro Sirius Red staining 
(Abcam). An EVOS XL Core Cell Imaging System (ThermoFisher) was used for 
visualising colorimetric images such as H&E staining. All images were processed and 
arranged using Microsoft PowerPoint.  




2.12 Enzyme-linked immunosorbent assay (ELISA) 
The Equine IL-10 ELISA Kit (ab155466; Abcam) was used to measure IL-10 levels in 
the supernatant from 3D cell cultures, according to the manufacturer’s instructions. Cell 
culture supernatant from 3D constructs was collected at days 7, 9 and 14 of culture and 
frozen in 2 ml volumes at -20°C until required. Supernatant was either used as collected 
or concentrated using Amicon® Ultra-2 Centrifugal filter units (2 ml sample volume) 
(Millipore, Massachusetts, USA) according to the manufacturer’s instructions.  
To conduct the ELISA, IL-10 Equine Standard was serially diluted 8 times in 1x Assay 
Diluent B (Abcam) to produce a standard curve. Standards and samples, carried out in 
duplicate, were incubated in the equine IL-10 coated 96-well plate for 2.5 hours at room 
temperature to allow any IL-10 present in the sample to bind to the immobilized antibody. 
The wells were then washed, and a biotinylated anti-equine IL-10 antibody (Abcam) 
added to each well and incubated for 1 hour at room temperature with gentle shaking. 
The wells were then washed again to remove any unbound biotinylated antibody, and 
HRP-conjugated streptavidin (Abcam) added and incubated for a further 1 hour at room 
temperature with gentle shaking. The wells were washed to remove any unbound HRP-
conjugated streptavidin and a TMB substrate solution (Abcam) added and incubated with 
gentle shaking in the dark for 30 minutes, with colour developing in relation to the level 
of bound IL-10. The reaction was then stopped using the Stop Solution (Abcam) and read 
immediately on a microplate absorbance reader (ThermoMax Technologies, Columbia, 
MD, USA) at 450 nm. Results were exported as a txt file and the data input into 
ElisaAnalysis.com (Leading Technology Group, Australia) in order to determine the 
mean sample concentration.  
2.13 Chromatin immunoprecipitation (ChIP) 
2.13.1. DNA-protein cross-linking 
Three lines of non-transduced adult and fetal tenocytes (between P4 - P8) and one line of 
2D ESC-derived tenocytes (P19) (approximately 25x106 cells) were washed in PBS and 
fixed in 11% formaldehyde for 10 minutes at room temperature with gentle shaking. 




Fixation was quenched by adding glycine at a final concentration of 125 mM. Samples 
were washed twice in PBS, pelleted and stored at -80°C until required.  
2.13.2. Cell lysis and chromatin shearing 
All subsequent steps were performed on ice. The iDeal ChIP-qPCR Kit (# C01010180; 
Diagenode, Seraing, Belgium) was used to prepare chromatin, conducted according to 
the manufacturer’s instructions. Briefly, samples were thawed on ice and 1 ml cold lysis 
buffer iL1b (Diagenode) per million cells added and incubated for 20 minutes at 4°C 
under constant rotation. Samples were then pelleted at 500 x g for 5 minutes at 4°C, the 
supernatant removed and 600 µl of cold lysis buffer iL2 (Diagenode) added per million 
cells. Samples were incubated this time for 10 minutes at 4°C under constant rotation, 
before again pelleting and removing the supernatant. Pellets were then resuspended in 
100 µl shearing buffer containing protease inhibitor cocktail (Diagenode) per 1.5 million 
cells and incubated for 10 minutes. Chromatin shearing was performed using the Misonix 
Sonicator XL2020 Ultrasonic Liquid Processor (Misonix, NT, USA) using the cup horn 
water bath probe. Shearing optimisation determined that a programme of 7 minutes and 
40 seconds, with pulse parameters of 20 seconds on and 20 seconds off provided the most 
efficient shearing. Sheared chromatin was then centrifuged at 16,000 x g for 10 minutes 
at 4°C and stored at -80°C until required, except for a 50 µl aliquot which was taken 
forward for shearing analysis. For shearing analysis 2 µl of diluted RNase cocktail 
(Ambion) (1 µl diluted in 150 µl of ChIP grade water) was added to the sheared sample 
and incubated at 37°C for 1 hour. Cross-linking was then reversed by adding elution 
buffers (Diagenode) and incubating overnight at 65°C. DNA was then purified as 
described in section 2.6.2 and run on a 1.5% agarose gel as described in section 2.6.1.  
2.13.3. Magnetic immunoprecipitation 
Sheared chromatin was immunoprecipitated using antibody bound DiaMag Protein A-
coated magnetic beads (Diagenode). Briefly beads were washed three times with 1x ice-
cold 1x ChIP Buffer iC1b (Diagenode) before incubating at 4°C for 4 hours with gentle 
rotation with either 4 µg of anti-SCX antibody (#PA5-23943; ThermoFisher), 2 µg anti-
Histone H3 antibody (#ab1791; Abcam) and either 2 µg or 4 µg of rabbit non-immune 
IgG (#C15410206; Diagenode), according to the iDeal ChIP-qPCR Kit instructions. Once 




antibodies were bound to the beads 250 µl of sheared chromatin was added to each 
reaction, keeping aside 2.5 µl at 4°C to be used as an input sample, and incubated 
overnight at 4°C under constant rotation. Following overnight incubation samples were 
washed 4 times in wash buffers iW1, iW2, iW3 and iW34 (Diagenode). Input samples 
and immunoprecipitation (IP) samples were then treated in parallel, incubating in DIB 
buffer containing Proteinase K (Diagenode) at 55°C for 15 minutes, followed by 15 
minutes at 100°C in order to isolate the DNA from the beads and de-cross-link. Samples 
were placed on a magnetic rack and the supernatant containing the DNA transferred to a 
freshly labelled tube and stored at -20°C for subsequent analysis. 
2.13.4. ChIP-qPCR 
Immunoprecipitated DNA was subjected to qPCR as previously described (see section 
2.8.2). Primer generation was conducted using the sequences of equine proximal 
promoter regions of 11 genes in order to identify putative E-box regions (consensus 
sequence CANNTG (N = any nucleotide)) in which SCX may bind (Table 2.6). As 
promoter regions in the horse are currently not well annotated, the sequence 2 Kb 
upstream of the transcription start sites were used to define the “promoter” region. Some 
genes contained multiple E-boxes within their predicted promoter regions, therefore 
where necessary multiple primers were designed in order to capture these. Negative 
control regions included genes which had no expression in equine tenocytes, were not 
within a predicted promoter region and had no E-box binding sites within 250 bp either 
side of the primers (TEX33 and RNASE9) and intronic regions which contained no E-
box binding sites within 1.5 Kb of the primers (Intronic #1 and Intronic #2). The relative 
amount of immunoprecipitated DNA compared to the input DNA (% recovery) was 
calculated using the following formula as described in the iDeal ChIP-qPCR Kit protocol 
(Diagenode):  
% recovery = 2^((Ctinput – 6.64) – Ctsample) * 100% 
Where the Ctinput and Ctsample are the threshold cycles obtained from the exponential phase 
of the qPCR for the input sample and the immunoprecipitated DNA sample respectively. 
The amplification efficiency is 2, based on the assumption that the PCR is 100% efficient 
and the compensatory factor is 6.64 in order to correct the input dilution (where 1% input 
was used, i.e. 2.5 µl of input to 250 µl sheared chromatin per IP). Fold enrichment was 




then calculated by dividing the ratio of IP-bound DNA to the average of the negative 
controls (TEX33, RNASE9, Intronic #1 and Intronic #2) normalised for input DNA.  
Table 2.6. Primers for ChIP-qPCR.  
Gene Forward Primer (5’-3’) Reverse Primer (5’-3’) 
Reason for 
Selection 
Intro #1 TTTGGGGGAGGTTTTGCTTC AACCGAAGTCCTGATACTGC Negative Control 
Intro #2 AGAGGAGATTCAACATTCTGC CCTTTGCAGTATTCAGTGTACC Negative Control 
RNASE9 CCAGCCCTTGAAAGATCCATT GCTTCCAACCCTATCTTTGCT Negative Control 
TEX33 CTCACAACGATGGAGAAAGGG CTCCTCTCAGCTCCACAACT Negative Control 
ACTA #1 CATTCCCCTTCAAAAGGTCCA GGGAATTGCTTACATTTTGGC RNA-seq Result 
ACTA #2 TCCTCTGACCCCCATTCTG CCTGCTGAAGCGGTTCTATTT RNA-seq Result 
CLDN16 CGTTCAGCATGAGTGACAGA  AAAGCATGGCAAAGTTGGAA RNA-seq Result 
COL1A2  CCAACAGTAGGCGTCCTC GGTTCTGTCTGTGGAGGGTT Positive Control 
FGF9 CAATACAGCTTGCGCTTGTG CATGTTGCATTGCGCTAGGA RNA-seq Result 
FGF19 AGCGGTTGGAGGAATAATGAG AGGGGACTTTGGCTCAACAC RNA-seq Result 
IGF2BP1 #1 GTGAACGGCATGAAATCGTCT TTCCTTGTGATTTTGTGTGCAG RNA-seq Result 
IGF2BP1 #2 GCTTCTCTTTGTCTCTCTCGG GAGTTTGCCCACCCTACCTC RNA-seq Result 
KLF15 CCTCCACGCATGCTTACTTC GATTCTGGGAAAGCTCACGA RNA-seq Result 
MMP3 #1 CAAACGAGCTCCAACCTACC ACAACTACGCAGAGTCAAGA RNA-seq Result 
MMP3 #2 GGTAAGTAGGTGAGGTTGGTG AGACCCTAAACATTCCCAGA RNA-seq Result 
MMP3 #3 CCTGAACTAACTGCCACCTT AGGGTCAGATAATGGCTGGT RNA-seq Result 
NOV CCCAAACTTCAGGCATCCTTC CAAGCAGGGCTGCGAATGTA RNA-seq Result 
PDGFB TTTAGCCGGCGAGTGAAGAC CAAGAGGAAAAAGAACACGGC RNA-seq Result 
TNMD GGTGGGGATGAAAAGTTGCC ACAGGTTCTTTGCTCTCCTCT Positive Control 
2.14 Statistical analysis 
Statistical analysis of qPCR and gel contraction data was performed using XLSTAT 
(version 22.1.3). Histograms were plotted to visualise the distribution of the datasets and 
all were confirmed to have a Gaussian distribution using the Shapiro Wilks normality test 
and subsequent visualisation of Q-Q plots. For comparisons of two groups the Student's t-
test (unpaired, two-tailed) was used. For comparisons of more than two groups with equal 
variance ANOVA was used, followed by the Tukey’s post hoc test. When unequal 
variance was observed (as determined by the k-sample comparison of variance test, 
Levene’s Test) Welch’s ANOVA was used, followed by the Games-Howell post hoc test. 
For comparisons of two groups in which two continuous variables were compared, such 
as in the serial passaging experiment (see section 2.2.2), linear regression analysis was 




conducted, which was deemed appropriate following visualisation of diagnostic plots 
including Residuals vs Fitted, Normal Q-Q, Scale-Location and Residuals vs Leverage to 
ensure the test/model was suitable (all conducted in R (v.3.5.2)). In all cases the 
significance threshold was set at P < 0.05 and is marked with an asterisk (*). The number 




Chapter 3 - Comparison of Adult, Fetal 
and ESC-Derived Tenocytes  
3.1 Introduction 
As previously described, tendon injuries occur frequently in equine athletes. Treatment 
options are limited, and the prognosis is often poor with functionally deficient scar tissue 
resulting. Fetal tendon injuries in contrast are capable of healing without forming scar 
tissue. ESCs may provide a potential cellular therapeutic to improve adult tendon 
regeneration however, whether they can mimic the properties of fetal tenocytes is 
unknown. To this end, this chapter will focus on trying to better understand the unique 
expression profile of normal adult and fetal tenocytes, which is crucial to allow validation 
of ESC-derived tenocytes as a cellular therapeutic.  
3.1.1. Regenerative healing in the animal kingdom 
Examples of regenerative healing are abundant in the animal kingdom, the capacity of 
which varies considerably from species to species. Whereas more primitive vertebrates 
such as fish and amphibians are able to regenerate entire limbs, by contrast high level 
mammals have a much more limited regenerative capacity (276). Furthermore, this 
regenerative ability also typically declines throughout development and ageing, the most 
classic example of this being the shift from fetal regenerative healing to adult reparative 
healing in mammals, which was first explored in early human fetuses in the 1970s (277). 
Regeneration appears not only to be age specific, but also tissue specific, with neonatal 
hearts being able to undergo complete regeneration within the first week after birth, 
whereas other wounds such as early fetal wounds of the gut being found to still heal with 
scar formation (278–280).  




Where at first it was believed that the amniotic fluid-rich sterile uterine environment was 
the reason for this fetal regenerative capability, this was later opposed with studies in 
marsupials showing scar-less healing up to pouch day 9 (281). Further to this it was found 
that regeneration is intrinsic to the fetal cells themselves, with fetal skin transplanted into 
an adult environment continuing to heal without scarring (43,282). In contrast, when adult 
skin is transplanted into a fetal environment it continues to heal in a reparative manner 
(43,282). Whilst the precise mechanisms which account for this regenerative fetal healing 
are still largely unknown, a summary of those factors identified in fetal versus adult skin 
wounds can be found in Table 3.1.  
Table 3.1. Summary of differences found in fetal wounds as compared to adult wounds. 
Adapted from information provided in the following reviews:- Larson et al., 2010, Rolfe et al., 
2012 and Wilgus et al., 2020 (41,278,283). 
 Fetal Wound Healing Reference 
Collagen 
Content  
Less dense, finer structure with basket-weave orientation (43,282,284–287) 
Less crosslinking (288) 
Higher levels of collagen III to collagen I in healthy fetal skin, 




Tenascin C earlier deposition (287,295) 
Increased expression of some integrins (296) 
Decreased lysyl oxidase expression (297) 
Reduced decorin (298–300) 
Increased MMPs, reduced TIMPs (301) 
Increased fibromodulin levels, inhibiting fibromodulin leads 
to scar formation, fibromodulin addition reduces scar 
formation 
(302,303) 
Growth Factors  
Lower levels of VEGF and less vascular, scar-forming 
phenotype induced by endogenous VEGF addition 
(304) 
Lower levels of TGF-b1 and 2 in fetal wounds and no 
upregulation of TGF-b3 in response to injury, no TGF-b 
receptor expression 
(305–309) 
Increased PDGF but more rapid clearance from wound, 
exogenous addition causes fibrosis 
(310,311) 




FGF2 increased in expression, FGF7 and FGF10 
downregulated 
(312,313) 
Fetal dermal fibroblasts have lower proliferation and collagen 




High levels of HA and HA-stimulating activity (HASA) (315–319) 
Lower levels of hyaluronidase (degrades HA), exposing to 
hyaluronidase leads to fibrotic response 
(320–322) 
Inflammation  
Fewer resident inflammatory macrophages and mast cells (323–325) 
Fewer and less activated cells of the acute immune system (324,326–329) 
Fewer circulating inflammatory cells recruited to injury site (284,330–333) 
Neutrophils less adherent to fetal cells (334) 
Interleukins  
Diminished IL-6 production, IL-6 addition leads to scar 
formation 
(335) 
Diminished IL-8 production (336) 
Increased IL-10 production, IL-10 knockout fetal mice heal 
with scars, enhancing IL-10 reduces inflammation and scar 
formation 
(337–340) 







Microarray analysis between scar free E15 murine fibroblasts 
and E18 fibrotic fibroblasts have differences in genes 
involved in cell proliferation, cell signalling, inflammatory 
pathways and cell-cell interactions 
(342) 
Microarray analysis between scar free E16 murine fibroblasts 
and E18 fibrotic fibroblasts have differences in genes related 
to PDGF signalling and degradative enzymes for superoxide 
radicals 
(343) 
Microarray analysis of wound healing shows rapid 
upregulation of groups of genes involved in cell growth and 
proliferation, proposed to contribute to rapid wound healing 
(344) 
Wound Closure  
Absence of fibroblast to myofibroblast transition (345,346) 
Basal differences in proliferation rates, migration rates and 
contractile ability 
(347–351) 
Wounds close by actin cable (352,353) 
Rapid upregulation of adhesion proteins stimulates cell 
attachment and migration 
(295,296,354,355) 
 




3.1.2. Fetal wound healing in the tendon 
Models of fetal tendon wound healing have similarly demonstrated that they undergo 
regenerative healing. Here partial tenotomy of the lateral extensor tendon was performed 
in fetal sheep at 60-70% of the way through gestation and compared to those created in 
maternal limbs (254). Fetal tendons healed regeneratively, with no abnormalities found 
and complete reconstitution of the collagen architecture (254). In contrast adult wound 
tissue appeared granulated, with increased inflammatory cells and disorganised fibre 
orientation at the site of injury (254). Furthermore, it was later demonstrated that injured 
fetal tendon transplanted into an adult environment retained its regenerative properties, 
suggesting that the adult environment does not impede scar less repair, with this repair 
mechanism being intrinsic to the fetal tissue itself (255). Similarly studies have 
demonstrated that intrinsic differences exist between adult and fetal tendon cells (259). 
When fetal tendon fibroblast scaffolds were sutured into adult mouse Achilles tendon 
injuries it resulted in higher levels of collagen deposition and improved microstructure 
repair compared to that of adult tendon fibroblast seeded scaffolds (259). Moreover, the 
fetal fibroblast seeded wounds had less inflammatory cells present and increased 
recruitment of native fibroblast-like cells (259). The mechanisms behind this are not 
understood, nor is the timepoint in which fetal tendon regeneration switches to fibrotic 
repair. However, taken together this remarkable healing capacity of fetal cells has driven 
investigations into their use as a cellular therapy. 
3.1.3. Understanding the fetal cell phenotype to aid therapeutics 
Fetal skin progenitor cells are currently being tested in clinical trials for burns victims 
and show a remarkable ability to rapidly close wounds with little hypertrophy (356,357), 
with similar investigations also being conducted with fetal tendon progenitor cells (260). 
However, access to fetal tissue presents as an issue. Sources of fetal tissue are often 
limited, being typically obtained from aborted fetuses as a result of viral infections, 
bacterial infections, mycotoxins or gene mutations which may be of concern if they are 
to be utilised as a cellular therapy. Furthermore, in order to obtain enough cells for 
transplantation, cells must be serially passaged on tissue culture plastic, which can lead 
to an altered cellular phenotype due to in vitro selective pressures (358–362). 




Regenerative medicine methodologies which mimic fetal-like regeneration are therefore 
required. 
Embryonic stem cells (ESCs) may provide a potential cellular therapeutic to improve 
adult tendon regeneration, however whether they can mimic the properties of fetal 
tenocytes in unknown. Equine ESCs differentiate into tenocytes in vitro in response to 
transforming growth factor-β3 (TGF-β3) and three-dimensional (3D) culture 
(60,140,154). Similarly, human ESCs have been differentiated into tenocytes in vitro 
(213,230). Transplantation of differentiated human ESC derived 3D fibrin tendon gels 
into rat patella tendon injury models has indicated that ESC-tenocytes secrete a number 
of fetal tendon matrix and differentiation factors (230), highlighting the potential role 
ESC-tenocytes may play in tissue regeneration. However, to date a full transcriptional 
characterisation of ESC differentiated tenocyte progeny has not been performed. 
3.1.4. Chapter aims 
Understanding the unique expression profile of normal adult and fetal tenocytes is crucial 
to allow validation of ESC-derived tenocytes as a cellular therapeutic. Therefore, the aim 
of this chapter is to:-  
1)  Determine the transcriptional differences between equine adult, fetal and ESC-
tenocytes cultured in 3D by comparing their global gene expression profiles. 
 
2) Identify the global transcriptional effects of culturing adult and fetal tenocytes in 
conventional monolayer systems compared to that of a 3D culture system.





3.2.1. Determining sex of cell lines 
The sex of the horses from which tendon samples were obtained was not recorded at the 
time of collection, therefore PCR was used to determine this by amplifying sex specific 
sequences (Figure 3.1). Of the eight adult tenocyte cell lines used seven were determined 
to be male. This was demonstrated by amplification of a 714 bp region of the SYR (sex-
determining region Y) gene which is located on the short branch of the Y chromosome, 
as well as amplification of the zinc finger protein Y-linked and X-linked genes (ZFY and 
ZFX) resulting in a double band at 604 bp and 553 bp. One adult tenocyte line was 
determined to be female, having no amplification of the SYR gene and only amplification 
of the ZFX gene (604 bp). Of the eight fetal tenocytes lines, two were determined to be 
male and six were female. Finally, of the ESC lines, one was determined to be male and 
the remaining two were female.  
 
 
Figure 3.1. Sexing cell lines. PCR followed by agarose gel electrophoresis to amplify the SYR 
gene and the ZFX/Y genes in equine tenocytes and ESCs. Adult tenocyte lines are numbered from 
A1-A8. Fetal tenocyte lines are numbered from F1-F8 and ESC lines are numbered from E1-E3. 
Control known female sample (C1) and control known male samples (C2) were included as 
positive controls. Male samples should amplify a 714 bp fragment when SYR primers are used 
and both a 604bp and 714 bp fragment when ZFX/Y primers are used. Female samples should 
have no amplification when the SYR primers are used and a single 604 bp fragment when ZFX/Y 
primers are used.  
 




3.2.2. Serial passaging alters gene expression 
Due to the difficulty in obtaining large numbers of cells from primary tissue for research 
purposes, serial monolayer passaging is utilized to increase cell numbers. Typically, 
primary cells are recommended to be used in experimental studies before the tenth 
passage (P10) as many primary tissues have been shown to exhibit changes in cell 
morphology and gene expression (359–361). The effect of serial passaging on the 
expression of six tendon associated genes COL1A1, COL1A2, COL3A1, SCX, THBS4 and 
TNMD, in adult equine tenocytes was therefore measured (Figure 3.2). COL1A1 had 
significantly higher expression at P0 than at P3 through to P10. However, COL1A1 levels 
did not significantly change beyond P3 with the further passage. COL1A2 expression was 
variable with passaging, with a significant difference from P0 only being observed at P6 
and P7 (p-value = 0.0256 and 0.0027 respectively). COL3A1 was expressed at high levels 
at all passages, although the results showed variability between donors. No significant 
differences in COL3A1 expression were observed at any passage between P0 and P10. 
SCX expression at P0 was significantly higher than from P4 through to P10 (p-values all 
< 0.05). However, SCX levels did not change beyond P4 with further passaging. THBS4 
at P0 was significantly higher than from P1 through to P10 (p-values all < 0.05). However, 
THBS4 levels did not change beyond P4 with further passaging. TNMD at P0 was 
significantly higher than at P1 through to P10 (p-value = 0.009). However, TNMD 

















Figure 3.2. Box and whisker plots of tendon gene expression over serial passaging in adult 
equine tenocytes. Changes in COL1A1, COL1A2, COL3A1, SCX, THBS4 and TNMD expression 
from freshly isolated adult tenocytes (passage 0) through 10 subsequent passages. Error bars 
represent the maximum and minimum relative gene expression values of three tenocyte lines 
derived from different donors. Statistical significance was tested using linear regression analysis 
in R (v.3.5.2), with an asterisk (*) denoting statistical significance using P0 as the intercept. 
 




3.2.3. Histological characterisation of 3D constructs 
Our group have previously demonstrated that equine ESCs can differentiate into 
tenocytes in both 2D and 3D culture, showing increased differentiation in 3D (154). To 
further characterise equine ESC derived tenocytes, 3D constructs cultured for 14 days 
were compared to that of adult and fetal seeded constructs. No significant differences in 
the degree of contraction was observed between the cell types during the 14 days of 
culture (Figure 3.3.A). Histological analysis was then performed on the 3D cultured 
constructs as described in (Figure 3.3.B). There were no qualitative differences in either 
collagen fibre alignment or cell distribution as determined by H&E staining (Figure 
3.3.C). Picro Sirius Red staining similarly indicated that the relative staining of type I 












Figure 3.3. Histological characterisation of 3D constructs. A) Adult, fetal and ESC-tenocytes 
are capable of contracting a collagen gel to the same degree. Contraction shown as the percentage 
of the day 0 value. p = > 0.05 using ANOVA. Error bars represent the SEM of 3-7 biological 
replicates per condition. B) Overview of histology procedure for 3D constructs. C) H&E and 
Picro Sirius Red staining of three biological lines of adult, fetal and ESC-derived 3D constructs. 
All cell types show similar collagen fibre alignment and collagen content within the constructs 
after 14 days of culture. Scale bar for H&E = 0.5 mm. Scale bar for Picro Sirius Red = 250 µm. 
Under light microscopy all collagen fibres are red following Picro Sirius Red staining, under 
polarized microscopy collagen type I fibres have yellow-orange birefringence and collagen type 
III fibres have green birefringence. 
 




3.2.4. Quality control and technical validation of 2D and 3D RNA-
sequencing data 
RNA was extracted from day 14 adult, fetal and ESC-tenocytes seeded constructs and 2D 
monolayer cultures of adult and fetal tenocytes for subsequent RNA-seq analysis. All 12 
RNA samples passed quality control checking, using an Agilent 2200 TapeStation 
performed by Cambridge Genomics Services (CGS) (Figure 3.4).  
 
 
Figure 3.4. RNA Integrity Scores. RNA integrity results obtained for all the samples used in 
RNA-sequencing experiments in this chapter were between 9.3-10, indicating high quality RNA. 
Lane A0 shows the electronic ladder and D6 the no sample control. RINe values are obtained 
based on computational analysis, by generating sample electropherograms and determining 
degradation based upon decreasing signal intensity for the ribosomal bands 18S (1.9 Kb) and 28S 
(4.7 Kb) rRNAs, as well as other features, resulting from increased short fragments.  
 
Following the RNA-seq run a total of 29.4 billion reads were generated across all the 3D 
cultured cell lines, with an average of 94.8 million reads per sample group (s.d. 1.17 
million read pairs). For the 2D data a total of 19.3 billion reads were generated across all 
the 2D cultured cell lines, with an average of 96.3 million reads per sample group (s.d. 
3.04 million read pairs). The average read number was 3.1 billion (1.55 billion read pairs) 




for the 3D cultured adult tenocytes, 3.2 billion (1.6 billion read pairs) for the 3D cultured 
fetal tenocytes and 3.2 billion (1.6 billion read pairs) for the 3D cultured ESC-derived 
tenocytes. The average read number was 3.1 billion (1.55 billion read pairs) for the 2D 
cultured adult tenocytes and 3.3 billion (1.65 billion read pairs) for the 2D cultured fetal 
tenocytes. Detailed analysis of the 3D cultured RNA-seq data set quantity and size 
distribution of the Illumina sequencing run can be found in Table 3.2.  
All RNA samples passed quality control (QC) carried out using FastQC and FastQC 
Screen. Trimming of reads was not required due to the high sequence quality and minimal 
adapter content. A GC content of 50-52% was obtained, with no sequences being flagged 
as poor quality. The RNA-seq dataset generated for this chapter is freely available in the 
National Centre for Biotechnology Information Gene Expression Omnibus repository 
(NCBI GEO, www.ncbi.nlm.nih.gov/geo) under the accession numbers GSE132358 and 
GSE145029. 




Table 3.2. Overview of 3D and 2D cultured RNA-seq metrics. The total size and number of read pairs refers to the total read sizes and counts per group. The 
same applies for the median and mean values, both of which include three biological replicates. Phred score is a measurement of the quality of the nucleotide 
base calling. Encoding has been carried out using the Sanger format (Phred+33) where scores range from 0-41, with increasing scores corresponding to higher 
quality base scoring. (363,364). 










Total size of all reads per group (bp) 9,558,774,440 9,728,203,108 10,143,681,660 9,410,000,000 9,840,000,000 
Median size of reads per sample (bp) 3,090,000,000 3,190,000,000 3,310,402,472 3,140,000,000 3,230,000,000 
Mean size of reads per sample (bp) 3,186,258,147 3,242,734,369 3,381,227,220 3,136,666,667 3,280,000,000 
Total number of all reads per group 93,516,740 95,330,218 95,695,110 94,100,000 98,400,000 
Median number of reads per sample 30,900,000 31,900,000 31,230,212 31,400,000 32,300,000 
Mean number of reads per sample 31,172,247 31,776,739 31,898,370 31,366,667 32,800,000 
Mean Phred score per sample 36.06 36.16 36.03 36.12 36.08 




3.2.5. Genome and transcriptome mapping comparison of the 3D 
cultured tenocytes  
Following quality control checking of the generated RNA-seq reads, mapping was 
performed using two different pipelines on the data produced from the 3D cultured 
tenocytes (Figure 3.5.A). Figure 3.5.B shows the mapping statistics for both the 
alignment-based (HISAT2) and alignment-free (Salmon) methods. For the adult 
tenocytes the average mapping rate for HISAT2 and Salmon was 65.3% and 65.5% 
respectively. For the fetal tenocytes the average mapping rate for HISAT2 and Salmon 
was 64.3% and 64.7% respectively. For the ESC-tenocytes the average mapping rate for 
HISAT2 and Salmon was 61.5% and 60.9% respectively.  
Gene expression profiles obtained by RNA sequencing of the entire equine transcriptome 
yielded 7,557 DE (DE) genes in total across the three 3-D cultured cell type comparisons 
(Log2FC of ±2 and p-adj of < 0.01) when using the alignment-based HISAT2 pipeline, 
this is in comparison to the 6,190 detected DE genes (Log2FC of ±2 and p-adj of < 0.01) 
when using the alignment-free Salmon pipeline. Of the 21,689 mapped genes deemed to 
be expressed across the three sample types as determined by both alignment methods, 
554 genes were DE between the adult and fetal tenocytes, 3,562 genes were DE between 
the adult and ESC-tenocytes and 3,441 genes were DE between the fetal and the ESC-
tenocytes when using alignment-based HISAT2 pipeline (Figure 3.5.C). In comparison, 
542 genes were DE between the adult and fetal tenocytes, 2,940 genes were DE between 
the adult and ESC-tenocytes and 2,708 genes were DE between the fetal and the ESC-
tenocytes when using the alignment-free Salmon pipeline (Figure 3.5.D). Of those genes 
determined as DE between adult and fetal tenocytes, 441 genes were identified using both 
pipelines, an additional 113 genes were identified when using HISAT2 only and an 
additional 101 genes were identified using Salmon only (Figure 3.5.E). The gene lists 
corresponding to Figure 3.5.E can be found in appendix A. The RNA sequencing data is 
freely available in the National Centre for Biotechnology Information Gene Expression 
Omnibus repository (NCBI GEO, www.ncbi.nlm.nih.gov/geo) [accession number 
GSE145029]. The lists of differentially expressed genes are available in full in (Paterson 
et al., 2020, additional file 3).  





Figure 3.5. Mapping comparison overview. A) Overview of the genome alignment›‹ method, 
mapping using HISAT2 versus the transcriptome alignment method using Salmon. B) Overview 
of mapping statistics for HISAT2 and Salmon mapped data showing the percentage of reads 
mapped to exons and number aligned. C) Venn diagram of those genes which are significantly 
DE based on a p-adj of < 0.01 and ±2 Log2FC using the alignment-based HISAT2 pipeline. 179 
genes are DE between all three groups. 59 are uniquely DE between adult and fetal tenocytes, 
521 are uniquely DE between ESC-derived tenocytes and fetal tenocytes and 636 are uniquely 
DE between ESC-derived tenocytes and adult tenocytes. D) Venn diagram of those genes which 
are significantly DE based on a p-adj of < 0.01 and ±2 Log2FC using the alignment-free Salmon 
pipeline. 191 genes are DE between all three groups. 99 are uniquely DE between adult and fetal 
tenocytes, 367 are uniquely DE between ESC-derived tenocytes and fetal tenocytes and 571 are 
uniquely DE between ESC-derived tenocytes and adult tenocytes. E) Venn diagram of those 
genes which are significantly DE based on a p-adj of < 0.01 and ±2 Log2FC in adult and fetal 
tenocytes using the alignment based versus the alignment-free pipelines. 441 genes are identified 
as being DE in adult and fetal tenocytes using both HISAT2 and Salmon. 113 genes are identified 
as being DE in adult and fetal tenocytes using HISAT2 only. 101 genes are identified as being 
DE in adult and fetal tenocytes using Salmon only. 
 




3.2.6. Validation of 3D RNA-sequencing results by qPCR and 
correlation with protein-level expression  
To validate the biological significance of the RNA-seq data, several DE genes were 
investigated at either the RNA level, protein level or both. For qPCR validation the 
original samples sequenced were used alongside an additional cohort of adult (total n = 
8) and fetal tenocytes (total n = 7), with the expression relative to three different 
housekeeping genes determined (18s rRNA, GAPDH and ACTB).Of the seven genes 
tested there was a 90.5% corroboration to that of the RNA-seq data when the 18s rRNA 
housekeeping gene was used, an 85.7% corroboration when GAPDH was used and an 
80.9% corroboration when ACTB was used (Figure 3.6.A-C). Using RefFinder as 
described in section 2.8.3 the stability of the three different housekeeping genes was then 
determined, with 18s rRNA being the most stable overall across the four different stability 
tests (Figure 3.6.D). A further four genes (SCX, SOX11, CDK1 and THBS4) were 
therefore assessed, with expression calculated relative to the 18s rRNA housekeeping 
gene only, which resulted in an overall 79% corroboration to that of the RNA-seq data 
across the eleven genes tested (Figure 3.6.E-G). Corroboration of differential expression 
was achieved when both the required fold-change (Log2 FC ±2) as well as the required p-
value (RNAseq adj.-p <0.01; RT-qPCR p <0.05) was achieved.   
 





Figure 3.6. qPCR validation of RNA-sequencing results. A-C) Comparison of DE genes in 
three biological replicates of adult, fetal and ESC-tenocytes using RNA-seq and qPCR results 
using a Log2FC cut-off ± 2 for both datasets. Significance threshold for RNA-seq p-adj values < 
0.01 as routinely used. Significance threshold for qPCR p-value < 0.05 as routinely used. Red 
shaded boxes indicate no significant difference. Yellow shaded boxes represent a significant p-
adj value; but do not meet the Log2FC cut-off. Green shaded boxes indicate there is a significant 
difference based on both p-adj/p-value and Log2FC. NA values arise due to count outliers as 
detected by Cook’s distance, and are therefore not significant. D) Housekeeping gene validation 
scores obtained using RefFinder for the housekeeping genes 18s rRNA, GAPDH and ACTB. For 
all four tools (Delta CT, BestKeeper, NormFinder and Genorm) the lower the value the greater 
the stability. Green highlighted boxes represent the most stable gene, yellow boxes the 
intermediate and red the least stable. E-G) RNA-seq validation using qPCR on larger cohort of 
adult and fetal tenocytes (n = 8 and n = 7 respectively). For the ESC-tenocytes a larger cohort 
could not be assessed due to only three biological lines being available. Expression shown relative 
to the 18s rRNA housekeeping gene on a log 10 scale. A single asterisk (*) denotes significance 
detected in the RNA-seq results only (p-adj values < 0.01 & Log2FC cut-off ± 2). A double 
asterisk (**) denotes significance detected both in the RNA-seq results and following qPCR (p-
value < 0.05 using two-tailed Student’s t-test ). A triple asterisk (***) denotes significance 
detected following qPCR only. Error bars represent the SEM. 




Validation via immunocytochemistry, although not quantitative, showed a high 
consensus to that of the sequencing data, with ACTA1, IGF1, LOXL4, SCX and THBS4 
having visibly higher protein expression in the adult tenocytes compared to the fetal and 
ESC-tenocytes as predicted from the RNA-seq data (Figure 3.7). Protein expression of 
PDGFB and RUNX2 did not corroborate with sequencing data, and no visible differences 
were observed between the three groups (Figure 3.7). BMP7 expression was expected to 
be absent from adult and ESC-tenocytes based on the RNA-seq data, however, protein 
was detectable in the ESC-tenocytes and adult tenocytes, although at a lower level than 
in fetal tenocytes (Figure 3.7). Note the antibodies BMP7, IGF1, LOXL4 and PDGFB 
were due to be tested in western blots to confirm their specificity in the horse, however 
as a result of the COVID19 pandemic this could not be completed (see preface). However, 
all antibodies were predicted to cross-react with the horse, having over 80% homology to 
the intended target species.  





Figure 3.7. Correlation of protein level expression with RNA-sequencing results. 
Comparison of the corresponding proteins for 12 significantly DE genes. Images represent 
longitudinal sections of 3D adult, fetal and ESC seeded constructs following 14 days of culture 
(n = 3 for each cell type). RNA-sequencing Log2FC are listed in the adjoining tables with green 
text indicating significance based on p.adj value of < 0.01 and red text indicating no significant 
difference. Scale bar = 40 μm. DAPI staining of the nuclei is shown in blue. Anti-ACT1, COL1A1 
and IGF1 are detected using the FITC secondary antibody shown in green. Anti-BMP7, COMP, 
LOXL4, PDGFB, RUNX2, SCX, SPP1, THBS4 and TNC are detected using the Alexa Fluor 594 
secondary antibody shown in red.  




The cytokine Interleukin 10 (IL-10) was notably decreased in adult tenocyte in 
comparison to both fetal and ESC-tenocytes, having over 7-fold decreased expression 
(p.adj 0.001 and 0.004 respectively) (Figure 3.8.A). IL-10 is a key anti-inflammatory 
cytokine which has been implicated in tendon wound healing, enhancing cell proliferation 
and migration at the wound site (365,366). In order to confirm whether adult tenocytes 
secrete less IL-10 protein in comparison to both fetal and ESC-tenocytes an IL-10 
sandwich ELISA was conducted on both fresh and concentrated 3D culture supernatant 
(Figure 3.8.B). Fresh medium collected following 7, 9 and 14 days of culture had barely 
detectable IL-10 protein levels in adult, fetal or ESC-tenocytes. Control culture medium 
in which 10 ng/ml of IL-10 was added on days 3, 7 and 11 had detectable IL-10 protein 
as expected, however at a much lower concentration than that added (0.4 pg/ml) (Figure 
3.8.C). To determine if this was due to the sample being too dilute, the proteins present 
in the culture medium were concentrated by ultra-centrifugation and the ELISA repeated. 
Again, medium collected following 7, 9 and 14 days of culture, even following 
concentration, had barely detectable levels of IL-10 protein in adult, fetal and ESC-
tenocytes (Figure 3.8.D). Control culture medium in which IL-10 was added, following 
medium concentration had higher detectable levels of IL-10 (4.5 pg/ml). Again the 
detectable IL-10 within the day 14 culture supernatant was less that that added on day 11, 
this may be due to the half-life of IL-10 being 2.7 to 4.5 hours (367) resulting in a drop 
in concentration by day 14. The ELISA assay therefore did not corroborate the decreased 
IL-10 expression in adult tenocyte in comparison to both fetal and ESC-tenocytes 
identified by RNA-sequencing.  





Figure 3.8. Investigating IL-10 protein expression. A) IL-10 gene expression in adult, fetal and 
ESC-tenocytes. Y-axis shows the gene expression in terms of the log normalised RNA-seq counts. 
Asterisk (*) represents a significant difference between the adult tenocytes and both fetal and 
ESC-tenocytes (p-adj values < 0.01 & Log2FC cut-off ± 2). B) Outline of ELISA experiment, 
where 3D cultured adult, fetal and ESC-tenocyte medium was used in an IL-10 sandwich ELISA. 
Sample is incubated onto an ELISA plate which is coated with primary capture antibody, to which 
present IL-10 will bind. A primary detector antibody (biotin), followed by a streptavidin label is 
then added and following addition of development solution a coloured product is detected using 
a microplate reader and the absorbance compared to known standards. C) ELISA results from 
fresh 3D culture supernatant. Values shown as the mean concentration of IL-10 (pg/ml) in each 
sample based on duplicate microplate wells. D) ELISA results from concentrated 3D culture 
supernatant. Values shown as the mean concentration of IL-10 (pg/ml) in each sample based on 
duplicate microplate wells. 




3.2.7. ESC-derived tenocytes are transcriptomically more similar to 
fetal than adult tenocytes when cultured in 3D 
Further analysis of the RNA-seq data was conducted using the alignment-free Salmon 
pipeline only. Hierarchical clustering and principal component analysis (PCA) on adult, 
fetal and ESC-tenocytes cultured in 3D showed clear segregation of the three cell types, 
with the greatest variance separating the ESC-tenocytes from the adult and fetal tenocytes 
(Figure 3.9.A&B). To further identify the cells as being tenocytes, a panel of 28 
musculoskeletal associated genes identified from the current literature (240,368–371) 
were specifically examined (Figure 3.9.C). ESC-tenocytes expressed all tendon 
associated genes, however at lower levels compared to adult and fetal tenocytes (Figure 
3.9.C). Of the eight cartilage genes, only COMP and THBS3 showed significant 
differences between the cell types, with both markers having the lowest expression in 
ESC-tenocytes. Of the bone genes CD36, SNCG and SPP1 were expressed significantly 
more in the ESC-tenocytes, but RUNX2 was expressed at a significantly lower level in 
the ESC-tenocytes.  
To better understand the differences between fetal and adult tenocytes, heatmaps were 
constructed of the top 30 DE gene, ranked based on both the p-adj value and FDR. This 
resulted in dendrogram clustering of the fetal tenocytes with the ESC-tenocytes, with 21 
out of the 30 genes showing a more similar expression pattern than with adult tenocytes 
(Figure 3.10.A). Cluster 1 highlights six genes which are highly upregulated in adult 
tenocytes, whereas clusters 4 and 5 show 15 genes which are highly downregulated in 
adult tenocytes. Two clusters, 2 and 3, consisting of 9 genes in total, show a more closely 
related expression pattern between ESC-tenocytes and adult tenocytes. Heatmaps of the 
top 100, 200 and 500 genes were also constructed and resulted in similar dendrogram 
clustering of the fetal tenocytes with the ESC-tenocytes, again being ranked based on 
both their p-adj value and FDR (Figure 3.10.B). 





Figure 3.9. Transcriptomic comparison of adult, fetal and ESC-tenocytes. A) Euclidean 
sample-to-sample distance matrix with hierarchical clustering using VST transformed data across 
all mapped genes of three biological lines of 3D cultured adult, fetal and ESC-tenocytes. B) 
Principal component analysis of gene expression data profiling three biological lines of 3D 
cultured adult, fetal and ESC-tenocytes across all mapped genes. C) Boxplots of gene expression 
of cartilage, tendon and bone markers in adult (teal), fetal (orange) and ESC-tenocytes (yellow). 
Y-axis shows the gene expression in terms of the log normalized counts. Significant differences 
are depicted by an asterisk (*) with black asterisks representing a significant difference between 
the ESC-tenocytes and both the adult and fetal tenocytes, blue asterisks representing a significant 
difference between the ESC-tenocytes and adult tenocytes only, green asterisks representing a 
significant difference between the adult tenocytes and both the ESC and fetal tenocytes and purple 
asterisks representing a significant difference between all three groups.  





Figure 3.10. Heatmap of top DE genes comparing adult, fetal and ESC-tenocytes. A) 
Differential gene expression analysis for top 30 genes DE in adult and fetal tenocytes. 
Dendrograms are based on Pearson correlation, with red and blue colours representing up and 
down regulated genes respectively. Samples with intermediate expression are represented in 
yellow. Groups are visualized in columns, with the coloured bar above the heatmap indicating the 
grouping variable. Genes are represented in individual rows, with patterns of up and down 
regulated genes being classified into 5 clusters. B) Differential gene expression analysis for top 
100, 200 and 500 genes DE in adult and fetal tenocytes. Dendrograms are based on Pearson 
correlation, with red and blue colours representing up and down regulated genes respectively. 
Samples with intermediate expression are represented in yellow. Groups are visualized in 
columns, with the coloured bar above the heatmap indicating the grouping variable. Genes are 
represented in individual rows, with patterns of up and down regulated genes being classified into 
clusters. 




3.2.8. Comparison of over-represented gene ontologies and pathways in 
adult, fetal and ESC-derived tenocytes cultured in 3D 
Gene ontology (GO) analysis was performed on the genes identified as being DE between 
the three different groups based on pairwise analysis. The top 10 over-enriched terms are 
listed in Table 3.3. Next to the more common terms (e.g. regulation of cell 
communication, signal transduction, cellular processes etc.), DE genes between adult and 
fetal tenocytes were assigned to processes involving the inflammatory response, cellular 
migration and motility. Chemokines, growth factors and growth factor binding proteins, 
all of which have been shown to play a role in cellular migration during wound healing 
(372–375), were amongst the genes associated with these enriched GO terms (Figure 
3.11). Comparing ESC-tenocytes to adult and fetal tenocytes revealed pathways involved 
in organism processes, development and biological and cellular adhesions as being 
significantly overrepresented (Table 3.3).  
Table 3.3. Gene ontology analysis. Summary of the top 10 significantly enriched GO biological 
process terms for each pairwise comparison of DE genes in adult, fetal and ESC-derived 
tenocytes. GO terms are arranged alphabetically to allow easier comparison between each group. 
REFLIST COUNT = number of genes in the reference list that map to the particular annotation 
category, INPUT COUNT = number of genes in DE gene list that map to the particular annotation, 
INPUT (expected) = number of genes that would be expected in the DE gene list for this category 
based on the reference list, INPUT (Fold Enrichment) = fold enrichment of the genes observed in 
the DE gene list over the expected, INPUT (FDR) = the FDR showing the probability that the 









INPUT   
(expected) 
INPUT                  
(Fold 
Enrichment) 
INPUT        
(FDR) 
Adult vs Fetal 
Cell migration (GO:0016477) 131 20 4.27 4.69 3.45E-05 
Cell motility (GO:0048870) 155 20 5.05 3.96 1.32E-04 
Cellular process (GO:0009987) 4616 200 150.34 1.33 5.65E-04 
Cellular response to stimulus 
(GO:0051716) 
1506 88 49.05 1.79 4.61E-05 
Defence response (GO:0006952) 98 19 3.19 5.95 3.71E-06 






60 14 1.95 7.16 2.84E-05 
Localization of cell (GO:0051674) 155 20 5.05 3.96 1.48E-04 
Regulation of cell communication 
(GO:0010646) 
258 27 8.4 3.21 1.10E-04 
Regulation of signal transduction 
(GO:0009966) 
258 27 8.4 3.21 9.40E-05 
Signal transduction (GO:0007165) 1267 84 41.27 2.04 2.36E-06 
Adult vs ESC-tenocytes 
Biological adhesion (GO:0022610) 265 86 46.61 1.84 2.83E-04 
Cell adhesion (GO:0007155) 265 86 46.61 1.84 3.05E-04 
Cell surface receptor signalling 
pathway (GO:0007166) 501 154 88.13 1.75 1.59E-06 
Cellular process (GO:0009987) 4616 945 811.97 1.16 6.14E-05 
Enzyme linked receptor protein 
signalling pathway (GO:0007167) 
200 73 35.18 2.08 8.61E-05 
Multicellular organism 
development (GO:0007275) 
464 146 81.62 1.79 1.67E-06 
Multicellular organismal process 
(GO:0032501) 
897 255 157.78 1.62 3.52E-08 
Signal transduction (GO:0007165) 1267 304 222.87 1.36 1.23E-04 
System development 
(GO:0048731) 
364 109 64.03 1.7 3.27E-04 
Transmembrane receptor protein 
tyrosine kinase signalling 
pathway (GO:0007169) 
164 60 28.85 2.08 4.86E-04 
Fetal vs ESC-tenocytes 
Biological adhesion (GO:0022610) 265 85 42.61 1.99 2.13E-05 
Cell adhesion (GO:0007155) 265 85 42.61 1.99 2.37E-05 
Cell surface receptor signalling 
pathway (GO:0007166) 
501 152 80.56 1.89 7.52E-08 
Cellular process (GO:0009987) 4616 876 742.29 1.18 1.39E-05 




Cellular response to stimulus 
(GO:0051716) 
1506 321 242.18 1.33 1.92E-04 
Enzyme linked receptor protein 
signalling pathway (GO:0007167) 
200 68 32.16 2.11 5.28E-05 
Multicellular organism 
development (GO:0007275) 
464 134 74.61 1.8 2.32E-06 
Multicellular organismal process 
(GO:0032501) 
897 231 144.24 1.6 9.16E-08 
Signal transduction (GO:0007165) 1267 306 203.74 1.5 4.64E-08 
Transmembrane receptor protein 
tyrosine kinase signalling 
pathway (GO:0007169) 
164 58 26.37 2.2 1.03E-04 
 
 
Figure 3.11. Heatmap of genes within the enriched inflammatory response, cellular 
migration and motility GO terms between adult and fetal tenocytes. Chemokine, cytokine 
and GF receptors which were expressed are also depicted. Dendrograms are based on Pearson 
correlation, with red and blue colours representing up and down regulated genes respectively. 
Samples with intermediate expression are represented in yellow. Groups are visualized in 
columns, with the coloured bar above the heatmap indicating the grouping variable. Genes are 
represented in individual rows, with patterns of up and down regulated genes being classified into 
clusters. Additional chemokine, cytokine and GF receptors, not belonging to an enriched category 














DE genes were then overlaid into GeneAnalytics Pathway Analysis. ERK, PAK, Akt and 
PI3K-Akt signalling were differentially regulated among all three groups, as was 
extracellular matrix (ECM) degradation (Table 3.4). In corroboration with the GO 
analysis cytokine signalling in the immune system was found to be differentially 
regulated in adult and fetal tenocytes (Table 3.4). 
Table 3.4. GeneAnalytics pathway analysis. The Gene Analytics pathway analysis tool was 
used to determine the top 10 pathways which are upregulated for each pairwise comparison of 
DE genes in adult, fetal and ESC-tenocytes based on entity score. Entity Score = a SuperPath is 
a cluster of pathways with similarities in their associated genes, based on various data sources 
including KEGG, Reactome and BioSystems. The binomial distribution is used to test the null 
hypothesis that the input gene list is not over-represented within any SuperPath, with the higher 
the score the smaller the p-value. Entity scores above 13 represent a p-value smaller or equal to 
0.0001. Number of Genes in SuperPath = The total number of genes listed per SuperPath. Number 
of Gene Matched = the number of genes in the input list that appear in the SuperPath.  







Adult vs Fetal 
ERK Signalling 39.55 1180 60 
Akt Signalling 23.78 682 35 
Signalling by GPCR 22.52 2599 84 
PAK Pathway 22.14 683 34 
TGF-Beta Pathway 22.02 653 33 
RET Signalling 21.48 972 42 
PI3K-Akt Signalling Pathway 20.48 524 28 
Degradation of the Extracellular Matrix 20 297 20 
Microglia Activation During Neuroinflammation 19.82 71 10 
Cytokine Signalling in Immune System 18.74 760 34 
Adult vs ESC-Derived 
ERK Signalling 166.1 1180 257 
Degradation of the Extracellular Matrix 67.19 297 103 
Phospholipase-C Pathway 48.42 500 128 
Akt Signalling 43.21 682 154 
Integrin Pathway 41.08 568 133 
Cell Junction Organization 39.2 134 51 
PAK Pathway 39.18 683 150 
Apoptotic Pathways in Synovial Fibroblasts 36.38 727 154 
PI3K-Akt Signalling Pathway 32.34 524 117 
Activation of CAMP-Dependent PKA 32.26 630 134 




Fetal vs ESC-Derived 
ERK Signalling 166.1 1180 239 
Degradation of the Extracellular Matrix 64.66 97 97 
Phospholipase-C Pathway 53 500 125 
Akt Signalling 46.29 682 149 
PAK Pathway 46.12 683 149 
Integrin Pathway 39.78 568 125 
CREB Pathway 35.7 529 115 
Activation of CAMP-Dependent PKA 34.25 630 129 
PI3K-Akt Signalling Pathway 33.43 524 112 
Angiogenesis (CST) 31.53 89 89 
 
3.2.9. 2D Monolayer culture results in convergence in the expression 
profiles of adult and fetal tenocytes  
To investigate the effect on gene expression of culturing adult and fetal tenocytes in either 
2D and 3D culture RNA-seq was performed (Figure 3.12.A). Hierarchical clustering and 
PCA was conducted on adult and fetal tenocytes cultured in either 2D or 3D (Figure 
3.12.B&C). Analysis revealed a convergence of expression profiles in 2D, with only 10 
genes being DE. This is in comparison to 542 DE genes in 3D (Figure 3.5.D). When 
comparing adult tenocytes cultured in either 2D or 3D culture, 502 genes were DE, 
whereas in fetal tenocytes cultured in either 2D or 3D culture, 851 genes were DE. Of 
these only 183 genes were common between adult 2D versus 3D culture and fetal 2D 
versus 3D culture (Figure 3.12.D).  





Figure 3.12. Comparison of gene expression changes upon 2D and 3D culturing of equine 
tenocytes. A) Comparison of RNA transcriptome profile between three biological lines of fetal 
and adult tenocytes cultured in either 2D or 3D. B) Euclidean sample-to-sample distance matrix 
with hierarchical clustering using VST transformed data. C) Principal component analysis of gene 
expression data profiling three biological lines of 3D versus 2D cultured adult and fetal tenocytes. 
D) Quantitative VENN diagram showing overlap of DE genes in the adult 3D versus 2D culture 
comparison (blue) and fetal 3D versus 2D culture comparison (orange). Top 4 upregulated genes 
based on their p-adj value are shown in both groups next to the green arrow and the top 4 
downregulated genes value are shown in both groups next to the red arrows.  
 
GO analysis of these 183 genes revealed cell adhesion (GO:0007155) and cell surface 
receptor signalling (GO:0007166) as key overrepresented biological processes (Table 
3.5).  




Table 3.5. GO analysis of DE genes between adult and fetal tenocytes cultured in 2D versus 
3D. Summary of the significantly enriched GO biological process terms. The panther GO-slim 
statistical overrepresentation test tool was used to determine over representation of defined GO 
classification for the 183 genes that were commonly DE between adult and fetal cells in 2D versus 
3D culture.  









INPUT                  
(Fold 
Enrichment) 
INPUT      
(FDR) 
Cell Adhesion (GO:0007155) 191 13 2.55 5.09 2.57E-03 
Cell Surface Receptor Signalling 
(GO:0007166) 
350 16 4.68 3.42 1.54E-02 
 
Degradation of the ECM was a common pathway which was differentially regulated in 
both adult and fetal tenocytes as a result of 2D or 3D culture, with differences in 
collagens, matrix metalloproteinases, and integrins (Table 3.6). Muscle contraction was 
a predominant pathway which was found to be enriched in monolayer cultures, whereas 















Table 3.6. GeneAnalytics pathway analysis of DE genes in 2D versus 3D cultured tenocytes. 
A) The GeneAnalytics pathway analysis tool used to determine the top pathways which are 
upregulated in monolayer cultures of fetal and adult tenocytes compared to 3D fetal and adult 
cultures respectively and the top pathways which are upregulated in 3D cultures of fetal and adult 
tenocytes compared to monolayer fetal and adult cultures respectively.  










































Diseases of Glycosylation 22.04 
Vascular Smooth Muscle 
Contraction 
18.99 Phospholipase-C Pathway 20.44 
Smooth Muscle Contraction 15.84 
Degradation of the 
Extracellular Matrix 
18.94 
Muscular Dystrophies and 
Dystrophin Glycoprotein 
Complex 
15.3 ERK Signalling 17.99 
Peptide Ligand Binding Receptors 13.63 Integrin Pathway 17.51 
Myometrial Relaxation and 
Contraction Pathways 
12.95 Dilated Cardiomyopathy 16.95 
Cytoskeleton Remodelling 11.93 
Vascular Smooth Muscle 
Contraction 
16.95 
Degradation of the Extracellular 
Matrix 
11.83 Striated Muscle Contraction 15.79 
G Alpha Signalling Events 11.73 Cardiac Conduction 14.18 
EPHA Forward Signalling 11.67 






































Cytokine Immune System 
47.14 
 
Degradation of the Extracellular 
Matrix  
20.22 PAK Pathway 39.74 
Integrin Pathway 19.09 NF-kappaB Signalling 38.68 
Akt Signalling 18.31 Akt Signalling 36.16 
PAK Pathway 18.27 ERK Signalling 34.8 
Phospholipase-C Pathway 18.19 Innate Immune System 32.83 
Apoptotic Pathways in Synovial 
Fibroblasts 
16.78 TGF-Beta Pathway 31.09 
ECM-Receptor Interactions 16.16 Pathways in Cancer 27.11 





The results in this chapter outline the transcriptional profiling of adult, fetal and ESC-
tenocytes cultured in a 3D environment and show that ESC-tenocytes are 
transcriptomically closer to fetal as opposed to adult tenocytes. It demonstrates that 
culturing adult and fetal cells in 3D results in a large divergence of their gene expression 
profiles in comparison to 2D static monolayer culture. This result indicates that 3D culture 
is a more robust method to assess differences in the same cell types from different 
developmental stages, which would otherwise be lost in conventional culture systems. 
Collectively, these results indicate that 3D differentiated ESC-tenocytes may be a useful 
cell source for the treatment of tendon injuries in the future. The results in this chapter 
have been published (376). 
3.3.1. RNA-sequencing pipelines for differential expression analysis  
Current knowledge regarding the entire transcriptome of equine tendon cells or ESC-
derived tenocytes is limited, with information only being available from a few studies in 
adult equine tendon cells (240,377) or via quantitative PCR of small numbers of genes in 
both adult (368) and fetal tenocytes (267). Here, I report for the first time the use of RNA 
sequencing to carry out deep transcriptional profiling of adult and fetal tenocytes and 
compare them to tenocytes which have been differentiated from ESCs. By using this 
approach, we can start to look at the molecular signatures which define adult and fetal 
tenocytes, which may help reveal why early gestation fetal tendon wounds repair rapidly 
without any scar tissue production (255,259). This in turn will allow us to start to 
determine if ESC-derived tenocytes are a viable source of cells for regenerative cellular 
therapies.  
This sequencing methodology was chosen based on its ability to investigate all present 
RNAs in a sample with extremely high resolution, allowing for both characterisation of 
their sequence and quantification of their abundances. Although RNA-seq is fast 
becoming standard practice in biological research, in order to obtain reliable results good 
study design is crucial, and all efforts have been made within this thesis to achieve this. I 
have ensured that our RNA is of high quality with minimal degradation (indicated by the 
RIN numbers), that the size of the final fragments are long enough to provide accurate 




sequencing (longer paired-end reads used), that we have a good sequencing depth 
(designated 20 million reads) and have adequate replicates as determined by power 
calculations (3 biological replicates) (246). Quality control checking has also been carried 
out throughout (FastQC, FastQC Screen, DESeq2).  
The analysis pipeline chosen to both map the generated reads to the transcript and 
subsequently normalise and determine differential gene expression can also have a large 
effect on the overall study results (378). Whilst many comparative studies on different 
RNA-seq analysis tools have been performed (378–385), each study needs to be tailored 
to determine the most suitable workflow. This includes the sequencing technology used, 
sample size, availability of genomic resources for the species being studied, desired 
analysis type and computation resources available (379). As such I decided to compare 
both an alignment-based and alignment-free tool (HISAT2 and Salmon respectively), 
choosing those which had proven most consistent and efficient across multiple studies 
and were computationally less demanding to perform (379,384,385).  
Overall both mappers provided comparable percentage mapping results of between 60-
70% for all three groups. Unfortunately, even though transcriptomics is constantly 
evolving, providing fine-tuned annotated gene details in well studied organisms such as 
mouse and human, less well characterised species such as the horse still lack sufficient 
annotation of basic structures such as untranslated regions, protein-coding regions, non-
protein coding regions and splice variants, all of which can affect downstream differential 
expression analysis (386). Given that in human RNA-seq runs, 70-90% of reads are 
predicted to map to the human genome, with a significant number of reads being predicted 
to map to multiple loci (246), a 60-70% alignment is an indicator of fairly good quality 
mapping when considering the limitations associated with the less well annotated horse 
genome.  
The differential expression analysis in this thesis has been conducted using DESeq2, 
however many other statistical methods are available which rely on different 
normalisation strategies to correct for sequencing depth and count bias. Using different 
normalisation strategies can result in quite different lists of differentiated genes being 
produced. DESeq2 was chosen due to its proven consistency in comparative studies, 
being one of the more conservative tools when determining DE genes (95% true positive 
rate) (253,387). Using this approach, I obtained a 79% corroboration between the RNA-




sequencing data obtained using the Salmon alignment-free pipeline, and qPCR data from 
a larger cohort highlighting the suitability of this approach for our data set.  
3.3.2. Determining if ESC-derived tenocytes more closely resemble 
adult or fetal tenocytes 
The data presented in this thesis suggests that the differentiation protocol used, like others 
(140,154,159,187,388,389), mimics normal tenocyte development. As previously 
described, the contraction rates and survival of 3D adult, fetal and ESC-tenocyte 
constructs showed no significant differences, with histological analysis showing similar 
cellular morphology and alignment of the collagen fibres (154). Quantitative methods to 
analyse the H&E stained 3D construct alignment could have included the analysis of 
nuclear angular deviations, where the angles between the longitudinal axis of the 3D 
construct and the long axis of the tenocyte nuclei are determined, with the smaller the 
angular deviation showing higher quality alignment similar to the healthy tendon. 
Collagen type I and type III, which are the major components in tendon tissue, did not 
significantly differ in gene expression and no qualitative differences were determined 
histologically. Additional quantification of the precise collagen content and fibre 
alignments would be needed to confirm this. Although there are many differences in gene 
expression between ESC-derived, fetal and adult tenocytes (suggesting all three groups 
represent unique populations), this study shows that of the 26,991 genes mapped ESC-
tenocytes have fewer DE genes when compared to fetal tenocytes (2,708 genes) as 
opposed to adult tenocytes (2,940 genes), using the Salmon pipeline analysis. Results 
similar to this have been described in ESC-derived human neural stem cells, where 2,041 
genes were DE compared to fetal neural stem cells (390), and ESC-derived human 
pancreatic β-cells, where 755 genes were DE compared to adult pancreatic β-cells (391).   
One of the main challenges in assessing tendon differentiation is the lack of definitive 
markers to identify tendon populations (183) and a panel of tendon related genes is 
usually used. Yet, many of these tendon-related genes are widely expressed in various 
tissues (183,259,392). Similarly, Zhang et al., 2018 highlighted the lack of available 
microarray and RNA-seq datasets documenting the transition from fetal to adult tendon, 
with most datasets only comprising of the initial stages of embryonic limb development 
(183), therefore what stage of tendon development differentiated progeny represent is not 




always apparent. This study further highlights the issues in this form of assessment. Of 
the 12 tendon related genes commonly investigated, four were found to be DE between 
adult and fetal tenocytes. Three of these genes THBS4, SCX and MKX (168,218) are some 
of the most commonly cited “tendon” genes and interestingly all show a clear gradient of 
expression, with adult tenocytes having the highest expression, followed by the fetal and 
then ESC-tenocytes. SCX and THBS4 are also found to be rapidly downregulated in 2D 
culture and the response of all three of these putative marker genes to 2D and 3D culture 
differs between adult and fetal cells. They may therefore not be the most suitable markers 
of a regenerative cell type. 
This work does not however address the heterogeneity of our sample populations. 
Although it is believed that 3D culture is a potent driver of ESC differentiation into 
tenocytes, quantification of the percentage of desired cell fate achieved has not been 
conducted (154). Yet even in very optimised differentiation protocols in human ESCs 
significant variation in differentiation efficiencies are found, with certain lines more 
readily differentiating down certain lineages than others due to epigenetic, cell cycle 
patterns and genetic differences between lines (393–395). To try and counteract this 
problem cell sorting is typically performed (396), however this relies on a suitable marker 
being available. Similarly, I have not measured the heterogeneity within the tendon 
population itself. Studies using single-cell RNA-seq suggest that different sub-
populations of tenocytes exist (397), with multiple progenitor populations having been 
derived (398). Therefore, further study to identify sub-populations of cultured tenocytes 
is required. The heterogeneous nature of the ESC-tenocyte population is therefore likely, 
in part, to explain why the musculoskeletal gene expression profile is less robust in ESC-
tenocytes compared to both adult and fetal tenocytes. 
3.3.3. Investigating differences in gene expression in adult reparative 
and fetal regenerative tenocyte 
Wound healing occurs firstly via an acute and local inflammatory response, this leads to 
cellular proliferation and ECM deposition to remodel the injured tissue (36). In adults, 
there is rapid cellular proliferation and a delayed but excessive accumulation of 
unorganised ECM resulting in scar tissue. In contrast, fetal wounds regenerate with non-
disrupted collagen ECM through simultaneous proliferation and synthesis of organised 




collagen (41). Although the exact mechanisms of fetal scar-less healing are unknown, 
various studies suggest this regenerative ability is partly explained by intrinsic differences 
between adult and fetal fibroblasts themselves. Comparative studies have indicated that 
differences in the migratory activity, inflammatory responses, cellular mediated 
expression of chemokine, cytokines and growth factors, and deposition of components of 
the ECM may play a vital role (41–44).  
One of the top DE genes between adult and fetal tenocytes was LOXL4, a member of the 
lysyl oxidase gene family which are responsible for initiating collagen and elastin 
crosslinking in the ECM via signalling through the TGF-β pathway (399). LOXL4 has 
been heavily implicated in fibrosis in skin and vascular tissue (400) and is downregulated 
in Murphy Roth Large (MRL) mice which heal without scarring (401). Interestingly, this 
gene is significantly downregulated in both fetal, and ESC-tenocytes (-5.03 and -9.68 
Log2FC respectively) compared to adult tenocytes, a result which was confirmed at the 
protein level using immunofluorescence assays. Other genes within this top cluster 
(Figure 3.10.A) that are downregulated in both fetal and ESC-tenocytes, compared to 
adult tenocytes include the Integrin Subunit Beta Like 1 (ITGBL1) gene which can 
promote chondrogenesis (402) and ANKH, an inorganic pyrophosphate transport 
regulator, which has been linked to calcification in articular cartilage. The relevance of 
other genes within this cluster, WSCD2, FRMD7 and PYCR1 are not yet clear. Heatmap 
clusters 2 and 3 (Figure 3.10.A)  contain genes that are significantly higher in fetal 
tenocytes compared to both adult and ESC-tenocytes and include ADGRL3, which play a 
role in cell adhesion, and LURAP1L which is involved in cell migration. FNDC3A, is 
involved in extremity development and fin regeneration (403), but its role in mammalian 
limb development is still to be determined. Other genes in these clusters have no clear 
role in tendon development.  
Interestingly, the expression patterns of many chemokines, cytokines and growth factors, 
involved in cell migration were also found to differ between adult and fetal tenocytes, all 
of which have been shown to play a role in cellular migration during wound healing (372–
375). Several of these genes are upregulated in the injured tendon at both the gene and 
protein level, including IGF-1 (insulin-like growth factor 1), bFGF (basic fibroblast 
growth factor), PDGF (platelet derived growth factor) and SDF-1 (stromal cell derived 
factor 1) (404–407), which can influence cell migration (407–411). To confirm this 




immunofluorescence and ELISA analysis was performed. IGF-1 showed similar results 
at the protein level to the sequencing results, whereas regardless of the over 7-fold change 
in IL-10 expression, secretion was not found to differ between adult, fetal and ESC-
tenocytes. IL-10 ELISAs were however performed on 3D cell culture supernatant only 
and it is unknown if this lack of difference is due to the IL-10 being retained within the 
3D constructs themselves which would not have been detectable using this method. 
Further ELISA’s to test digested and extracted medium held within the constructs should 
be performed to determine this. Further ELISA’s on other chemokines, namely IL-8 and 
RANTES, as well as further replicates were due to be performed however could not be 
completed due to the COVID19 pandemic as described in the preface section of this 
thesis. 
Research performed by several students in our group was also conducted to investigate 
the differences in adult and fetal cells’ migratory response to growth factors. Of those 
tested TGF-β3, which is heavily involved in the wound repair process (306,412,413), 
significantly inhibited fetal tenocyte migration, yet had no effect on adult tenocytes (376). 
This observation confirms previous reports in skin and oral mucosa fibroblasts 
(44,374,375). Interestingly, TGF-β3 has been implicated as a “critical traffic controller” 
which can selectively halt the migration of certain cell types during skin wound repair to 
ensure proper wound closure (414). Further investigations to underpin the potential 
mechanism behind this differing response to TGF-β3, and the effect of TGF-β3 on ESC-
tenocytes are warranted. 
3.3.4. The effect of culture conditions on tenocyte gene expression 
profiles 
One limitation of the migration studies performed is that investigations were conducted 
on conventional plastic substratum. It has previously been reported that cytokine and 
growth factor actions are substratum-dependant (374,415,416) which highlights the need 
to develop assay systems which more closely resemble the in vivo environment. Our 
results highlight this point, with only ten genes being found to be significantly different 
between the 2D cultured adult and fetal tenocytes, compared to the 542 genes which were 
DE in 3D culture. This supports previous studies showing that distinct gene expression 
profiles between cell types isolated from different stages (417), and different tissues 




(362), are better preserved in 3D culture. What was more surprising was that adult and 
fetal tenocytes appeared to modulate gene expression differently when exposed to a 3D 
culture environment, with very few DE genes overlapping when comparing the two. 
Unfortunately, I was unable to compare these results to the native tissue, therefore further 
research is necessary to confirm whether this change in expression under 3D culture 
mimics that of their true in vivo counterpart.  
Similar studies investigating the effect of 2D versus 3D culture have been conducted on 
adult cells alone, with one report highlighting that when human foreskin fibroblasts are 
cultured in 3D versus monolayer culture there is upregulation of a subset of skin-specific 
genes that resemble that of the native tissue (417). Evidence of convergence of gene 
expression profiles as a result of monolayer culturing has also been described. Mueller, 
et al., 2016 showed that when chondrocytes, tenocytes and dermal fibroblasts are cultured 
in 2D and compared to their respective native tissues, all three cultured cell types 
clustered together showing very few DE genes, whereas significantly more genes are DE 
between the native tissues (362). They also compared this to 3D alginate and fibrin 
models, which although did not completely recapitulate the native gene expression 
profiles, did have significantly less DE genes compared to the monolayer cultures.  
Another factor which must be considered is how long-term passaging may affect gene 
expression. Over-subculturing on conventional plastic substratum has been documented 
to place selective pressure on many cell types leading to morphological, developmental 
and gene expression changes which ultimately alter the original functional characteristics 
of the cells (418–421). This phenotypic drift has been demonstrated in tendon cell 
cultures, with studies showing rapid changes in gene expression of several tendon 
associated genes from native tissue through to the 10th passage (240,422,423). Similarly, 
in this study TNMD and THBS4 were found to dramatically decrease following the first 
passage in vitro. COL1A1 and SCX also showed a decrease in expression, although this 
was more gradual with significance only determined from passage 3 and 4 respectively. 
However, this decreased expression was not observed for all genes with some remaining 
variable from the first passage through to the tenth passage (COL1A2 and COL3A1). 
Although all efforts were made to use low passage cells it is not typically possible to 
obtain enough cells for experimental use below passage 3, the stage in which many of 




these gene expression changes have already occurred. Methods to improve the efficiency 
of cell isolation from tissue should be examined.  
3.3.5. Summary  
In summary, this chapter demonstrates that there are significant differences in tenocyte 
populations cultured in 3D at different developmental stages. ESC-tenocytes were 
transcriptomically closer to fetal as opposed to adult tenocytes. I was also able to add 
further evidence to the benefits of 3D culture compared to conventional monolayer 
passaging. Future studies to optimise this 3D model to allow study of the wound healing 
environment in adult and fetal cells is likely to prove fruitful, and our transcriptomic data 
may help to identify key modulators involved in the scarring process as well as highlight 
if ESC-tenocytes will indeed prove a useful therapeutic.   
 
 
Chapter 4 – Investigating 
Transcriptional Changes Resulting 
from Scleraxis Knockdown  
4.1 Introduction 
Transcription factors ability to regulate the expression of multiple target genes allows 
them to play a powerful role in the pathophysiology of many cells, tissues and organs. 
Identifying how transcription factors act to alter target gene expression may unlock 
crucial information on disease progression and potential therapeutics. This chapter will 
focus on scleraxis (SCX), a bHLH transcription factor which, as previously described, is 
essential for the formation of force transmitting tendons and is believed to play a role in 
tissue fibrosis.  
4.1.1. SCX function in injury repair 
The SCX protein is highly conserved between species, with the equine SCX protein 
having over 90% identity to that of humans, mice and rats (Figure 4.1). This high level 
of conservation indicates the critical developmental role it plays, with it being shown to 
be essential not only for normal tendon development in mice, as indicated in SCX 
knockout studies, but also in a number of other species including chicken and zebrafish 
(163,424–426). SCX expression is thought to be regulated primarily through TGF-b 
signalling, with SCX being upregulated in response to TGF-b addition, the effects of 
which are mediated through the canonical TGF-b-Smad pathway (163,175,182,242). 
Mechanotransduction has also been shown to be a key regulator of SCX expression, with 
mechanical loading causing upregulation of SCX expression and proliferation of SCX 
expressing cells (388,427).  





Figure 4.1. SCX protein sequence alignment. NCBI protein sequences from equine 
(NP_001098620.1), human (NP_001073983.1), mouse (NP_942588.1) and rat 
(NP_001123980.1) were aligned using COBALT (https://www.ncbi.nlm.nih.gov/tools/cobalt). 
Red text shows conserved amino acid residues and grey where there are alignment mismatches 
or gaps. Insert shows the BLAST sequence alignment identity between the equine SCX protein 
and human, mouse and rat SCX protein sequences. Figure design adapted from Bagchi et al., 
2011 (428).  
SCX is expressed in a wide variety of tissues, however its mechanisms of action in each 
tissue type are still not thoroughly defined. SCX has however been implicated in several 
disease and pathological processes, playing a central role in tendon healing in adult 
(140,162,429) and neonatal animals (430). One study in an adult mouse wound healing 
model showed that, using a SCX-GFP tracking system, SCX positive cells were the first 
to migrate to the injury site, increasing production of ECM in order to bridge the wound 
gap (429). In comparison SCX-null wounds had impaired ECM assembly, with tendon 
progenitors displaying increased chondrogenic potential resulting in the formation of 
cartilage-like tissue at the wound site (429). This was further validated in another SCX 
lineage tracing model of murine flexor tendon repair which similarly showed SCX 
positive cells localising to the injury site leading to organisation of the wound bridging 
scar tissue (431).  
SCX has also been implicated in the induction of cardiac fibrosis, being found to 
significantly increase in expression in surgically induced myocardium infarct scar tissue, 
an increase which was not detected in non-infarcted or sham-operated myocardium 
(428,432). Similarly, SCX was also shown to be upregulated in a transgenic mouse model 
of acute heart failure (433). This upregulation occurred several days prior to the increase 
in fibrillar collagen expression which gives rise to the fibrotic scar tissue, suggesting a 
role of SCX in fibrotic induction (428,433). In accordance with this, SCX expression is 




also strongly upregulated in dermal keloids, which are enlarged fibrotic scars of the skin 
characterised by the excessive accumulation of fibrillar collagens (434). Taken together 
SCX therefore seems to be heavily involved in tissue injury repair and fibrosis, 
highlighting it as an important candidate for the development of novel anti-fibrotic 
therapies.  
Although SCX appears to have a key role in both early embryonic development as well 
as in adult injury repair, less is known about the role of SCX in fetal development and in 
young, postnatal tendons. Tendon tissue continues to grow and develop, with 
fibrillogenesis and remodelling continuing after birth (11,435). As described in chapter 
3, fetal tissues including tendons have also been shown to exhibit regenerative capacities 
following injury (254,255,279,436–438) and young animals generally undergo better 
tissue regeneration than mature animals (439–441). However, it has not yet been 
demonstrated if SCX has alternative roles in different stages of tendon development and 
ageing.  
4.1.2. SCX transcriptional regulation 
How exactly SCX functions to enable tenocyte differentiation and ECM remodelling 
during tendon healing remains unclear, and there is limited information on its downstream 
regulatory effects. Currently COLIA1 and TNMD are the most well documented genes 
which have been shown to be directly regulated by SCX in adult tenocytes (442,443). 
However, emerging evidence suggests that SCX has a key role in driving ECM 
production during development and remodelling in others tissue types including the heart 
and periodontal ligaments (444,445). In cardiac fibroblasts, genes including COL1A2, 
Snai1, Twist1, MMP2 and FN1 have been identified as direct targets of SCX (242,446–
448) but the large-scale identification of SCX regulated genes is still lacking. Table 4.1 
shows a number of genes which have, at the time of writing this thesis, been suggested to 
be under SCX regulatory control, however direct causal relationships have not in many 
cases been properly demonstrated. A more detailed description of those genes which have 
been identified as under the direct control of SCX will be described in chapter 5. 




Table 4.1. Genes effected by altering SCX expression. Asterisk (*) represents those which have been demonstrated to be under direct control of SCX.  
Gene Effected by altering 
SCX expression 
(Gene Names or Protein 
Names) 
Study Design Effect Tissue/Cells Reference 
ACAN*, COL II, OP, COL I, 
AP SCX overexpression  
Enhanced expression of ACAN via binding of SCX to E-box within its 
promoter, increased mRNA levels of type II collagen and osteopontin 
while suppressing expression of osteoblast phenotype-related genes 






determined using ChIP and 
luciferase assays 





determined using ChIP and 
luciferase assays 





determined using ChIP and 
EMSA 





determined using ChIP, 
luciferase assay and EMSA 
SCX-mediated regulation of Twist1 and Snai1  Mouse and Rat 
Cardiac Fibroblasts 
(450) 
COL1A2* SCX overexpression and 
luciferase assay 
SCX-mediated regulation of COL1A2 
Mouse and Rat 
Cardiac Fibroblasts 
(451) 
COL I, F-actin, Vinculin SCX overexpression and 
knockdown 
SCX overexpression increased COL I gene expression and F-actin, 
ITGb1 and Vinculin protein expression (adhesion genes), and 
decreased cell migration. SCX knockdown increased cell migration 
Mouse and Rat 
Cardiac Fibroblasts 
(452) 
COL1A1, COL1A2, COL3A1, 
COL5A1, Fmod, LUM, 
DNC, MMP2, MMP3, 
MMP9, MMP11 
SCX overexpression and SCX 
knockdown 
SCX upregulation significantly increases COL1A1, COL1A2, COL3A1, 
COL5A1, Fmod, LUM, DNC, MMP2, MMP3 and decreases MMP9 and 
MMP11 expression. SCX knockdown significantly decreases COL1A1, 
COL1A2, COL3A1, COL5A1, Fmod, LUM, DNC, BGN, MMP2, MMP3 and 








COL2A1* SCX knockdown, luciferase 
reporter, EMSA and ChIP 





SMA*, BMP4 SCX overexpression, EMSA, 
ChIP, luciferase assay, Co-IP 
SCX physically associated with E12 and bound the E-box in the 
promoter of SMA and negatively regulated the advanced glycation 
end product (AGE)-induced SMA expression. SCX induced expression 




COL1, TNC SCX overexpression  Increased COL I and TNC protein and gene expression Human ESC-derived 
MSCs 
(177) 
COL1A1, COLXIV SCX overexpression qPCR analysis of SCX-overexpression clones showing higher expression 




DNC, Fmod, LUM, SMA, 
SOX9, COL I, TNMD SCX overexpression  
Increased DNC, Fmod, LUM and ACTA1 gene expression and 
decreased SOX9 gene expression, increased collagen I secretion and 
TNMD protein expression. 
Human MSCs (176) 
TNMD, SOX9 Inactivation of endogenous 
SCX using SCXcre mouse 
TNMD absent in tendon and ligament, SOX9 decreased expression in 
developing cartilage, patella and deltoid tuberosity 
Mouse Model (456) 
LUM, Fmod, Brevican, 
Neuroncam, DNC, BGN 
Investigation of 
Atrioventricular canal 
regions SCX-null mice 
Decreased LUM, Fmod, Brevican, Neuroncam, DNC, BGN in postnatal 
atrioventricular canal regions SCX-null mice 
Mouse Model (457) 
BMP4* 
SCX null mice, SCX 
overexpression, luciferase 
assay and ChIP 
BMP4 decreased in SCX null mice, BMP4 increased in C3H10T1/2 cell 
overexpressing SCX, SCX directly binds to E-box in BMP4 promoter 
Mouse Model and 
C3H10T1/2 Cells 
(458) 
Osteocalcin SCX overexpression and 
knockdown 
osteocalcin, a marker for bone formation was downregulated and 
upregulated by SCX overexpression and knockdown of 
endogenous SCX in PDL cells, respectively 




1,247 DE genes 
RNA-seq of remodelling 
heart valves isolated from 
E15.5 SCX null mice and 
overexpression mice 
Immuno-validation of decreased levels of COL4A1, COL4A2, Fmod, 





Transferrin*, ABP* SCX overexpression and 
luciferase assay 
SCX regulated the transferrin promoter and androgen binding protein 
(ABP) promoter activity 
Rat Sertoli Cells (461) 




COL1A1* SCX overexpression studies 
and EMSA 
SCX-mediated regulation of COL1A1 Mouse Tendon 
Fibroblasts 
(442) 
SOX9, COL II SCX-null murine tendon 
progenitor cell lines 





COL I, TNMD SCX overexpression and 
knockdown 
COL I and TNMD were downregulated and upregulated by SCX 
overexpression and knockdown of endogenous SCX in TSCs 
Rat Tendon Stem 
Progenitor Cells 
(462) 
COL XIV, TNMD, Col I SCX null mice Complete loss of expression of COL XIV and TNMD and slight decrease 
of COL I 
Mouse Tendons (163) 
TNMD* SCX knockdown TNMD gene expression significantly decreased, SCX directly 
transactivates TNMD via two E-boxes in TNMD promoter Rat Tenocytes (422) 
COL1A1, COMP, SOX9 SCX knockdown and 
overexpression  
Reduced COL1A1, COMP, SOX9 gene expression in fetal tenocytes 
only, no change noted in tendon genes in adult tenocytes 
Equine Adult and 
Fetal Tenocytes 
(267) 





TNMD, ACAN, ChM-I SCX overexpression TNMD significantly upregulated in SCX overexpressing tenocytes, 




COL I SCX knockdown siRNA-mediated knockdown of scleraxis completely eliminated 





2,136 DE Genes RNA-seq of SCX null 
zebrafish dorsal tissue 
TNMD, MKX, TNC, FGF4, FGF8b, COL1A1, COL1A2, SP7, ENTP5, BMP2, 
BMP4, BMP9, Smad1, Smad5/8, Smad4 SCX null compared to control - 











4.1.3. Chapter aims  
Previous work from our group has shown that knocking down SCX expression in adult 
equine tenocytes has no effect on their ability to re-organise a 3D matrix to generate 
artificial tendons whereas SCX knockdown in fetal tenocytes completely prevents their 
ability to form 3D tendons (267). SCX knockdown also caused considerably different 
effects on tendon related gene expression in fetal and adult tenocytes further suggesting 
that SCX regulates gene expression differently during different developmental stages. 
Therefore, the aim of this chapter is to expand on this work by:- 
1)  Using a global RNA-sequencing approach to analyse the transcriptome of equine 
adult and fetal tenocytes following SCX knockdown.  
 
2) Compare DE genes in adult and fetal tenocytes as a result of SCX depletion to 
tenocytes from young postnatal foals and ESCs in which SCX expression has also 
















4.2.1. Optimisation of SCX knockdown using a lentiviral system 
In order to identify downstream target genes of SCX, a retroviral delivery system to 
express a short hairpin RNA (shRNA) was used to generate stable SCX knockdown lines 
(shSCX) or non-target controls (NT) in four biological replicates of fetal and adult 
tenocytes. Alongside, GFP-Turbo lines were also generated as a positive control allowing 
visualisation of transduction efficiency and puromycin selection. In doing so it was 
important to ensure that the process was optimised to ensure all lines had as similar a 
level of knockdown as possible. To do so batches of lentivirus were made and the titer 
tested before optimisation commenced. A drop in titer was detected when comparing 
freshly harvested virus to that stored at -70oC. Batch-to-batch variation was also observed, 
with it being apparent that each lentiviral plasmid (NT, GFP, shSCX) yielded different 
viral titers (Figure 4.2). Although in the previous chapter (chapter 3) it was demonstrated 
that 3D culture was a superior method for analysing transcriptional changes between adult 
and fetal tenocytes, it is important to note that this work was conducted in conventional 
2D culture due to the poor survival of fetal tenocytes in 3D gels following SCX 
knockdown. 
 





Figure 4.2. Lentiviral infection methods comparing freshly isolated versus frozen virus. A) 
Lentiviral titer testing using the three plasmids Turbo-GFP shRNA (GFP), non-target, scrambled 
shRNA (NT) and scleraxis shRNA (shSCX). Fresh lentiviral supernatant was harvested (Fresh) 
with some being frozen at -70oC (Frozen) before titer testing via qPCR. B) The titer of fresh viral 
supernatant was compared to two different batches of frozen viral preparation (Batch 1 & Batch 
2) for each of the three plasmids. 
 
Subsequently frozen lentiviral titers ranging from 5x105 IU/ml to 3x107 IU/ml, as well as 
fresh virus (> 1x108 IU/ml), were tested on one line of fetal tenocytes and the percentage 
knockdown of scleraxis gene expression (Figure 4.3.A) and copy number integrations 
(Figure 4.3.B) recorded in order to determine the most effective titer for subsequent cell 
line generation. A titer of 1x107 IU/ml was found to provide a good percentage 
knockdown (84.12%) and cells proliferated well during puromycin selection. Viral titers 
below 5x106 IU/ml did not produce enough infected cells to successfully expand 
following puromycin selection. Viral titers above 1x108 IU/ml led to toxic effects where 
cell death occurred prior to any puromycin selection (Figure 4.3.C).  





Figure 4.3. Lentiviral optimisation. A) Scleraxis gene expression in one line of fetal tenocytes 
stably transfected with shRNA to scleraxis. No data (N.D) could be collected for titers of 5x105 
or 1x106 as cells did not survive puromycin selection following infection. Similarly, no data could 
be collected from cells infected with fresh virus (> 1x108) as cells died prior to puromycin 
infection. SCX knockdown was detected in those cells infected with 5x106 to 3x107. Error bars 
show the standard deviation of two technical replicates. B) DNA was collected from tenocytes 
infected with varying titers of NT shRNA or SCX shRNA, following puromycin antibiotic 
selection. No data (N.D) could be collected for titers of 5x105 or 1x106 as cells did not survive 
puromycin selection following infection. Similarly, no data could be collected from cells infected 
with fresh virus (> 1x108) as cells died prior to puromycin infection. Cell lines with titers ranging 
from 5x106 to 3x107 in either NT shRNA infected or SCX shRNA infected cells, had 
approximately 0.5-1 copy of plasmid per diploid cell. Water (H20) and wild type (WT) non 
infected DNA were used as negative controls. C) GFP control infection of one line of fetal 
tenocytes with fresh HEK293T viral supernatant (Left) vs frozen viral supernatant (Right) prior 
to selection with puromycin antibiotic. Cells infected with fresh virus show very high levels of 
GFP expression with cells showing morphological signs of cellular stress, compared to frozen 
virus where GFP levels were much lower, and no cellular stress was observed. Scale bar = 40 µm.  
 




4.2.2. SCX knockdown cell line generation for RNA-sequencing analysis 
The optimised protocol was used to generate four biological replicates of fetal and adult 
tenocyte SCX knockdown and NT control lines for subsequent RNA-seq analysis. The 
average percentage of SCX mRNA knockdown was 72.6% in adult tenocytes and 80% in 
fetal tenocytes, which did not significantly differ (p-value = 0.336) (Figure 4.4.A). Viral 
copy number integration was measured in each line of shSCX and NT expressing 
tenocytes and approximately one copy number event was detected per diploid cell across 
all cell lines (Figure 4.4.B). RNA extracted from each line passed quality control checking 
using an Agilent 2200 TapeStation performed by Cambridge Genomics Services (CGS) 
(Figure 4.4.C).  





Figure 4.4. SCX knockdown in each biological line of adult and fetal tenocytes. A) Four 
biological replicates of adult and fetal tenocytes exhibit consistent and comparable reduction in 
SCX mRNA expression following viral transduction with a specific shRNA against SCX (shSCX) 
when compared to cells transduced with a control non-target scrambled shRNA (NT). Arrows 
highlight the percentage decrease between the NT control and shSCX expressing cells. Using a 
two-tailed Student’s t-test no significant difference between percentage knockdown is detected 
between the adult and fetal lines (p = 0.336). Error bars represent the SD of two qPCR replicates. 
B) Adult and fetal shSCX or NT copies per diploid cell determined by copy number assays in 
each biological line. Water (H20) and wild type (WT) non infected DNA were used as negative 
controls. Using a two-tailed Student’s t-test no significant difference in copy number was detected 
between fetal NT and shSCX lines (p = 0.462), between adult NT and shSCX lines (p = 0.101) or 
between the adult and fetal infected lines (p = 0.548). C) RNA integrity for all lines was between 
9.9-10, indicating high quality RNA. Lane A0 shows the electronic ladder and D6 the no sample 
control.  




A reduction in SCX protein expression was also confirmed using immunocytochemistry 
(Figure 4.5). In some shSCX lines, SCX protein was reduced but still detectable, in other 
lines SCX protein was no longer detectable. 
 
Figure 4.5. Comparing SCX protein expression following SCX knockdown. 
Immunocytochemistry confirms a reduction in SCX protein (red) in both adult and fetal tenocytes 
following shSCX expression. Scale bar = 40 μm. DAPI staining of the nuclei is shown in blue. 
 




4.2.3. Technical validation of SCX knockdown and NT control line 
RNA-sequencing data 
Following the RNA-seq run a total of 50.8 billion reads were generated across all the 
adult and fetal NT and shSCX cell lines, with an average of 134 million reads per sample 
group (s.d. 0.35 million read pairs). The average read number was 3.4 billion (1.7 billion 
read pairs) for the adult NT tenocytes, 3.4 billion (1.7 billion read pairs) for the shSCX 
adult tenocytes, 3 billion (1.5 billion read pairs) for the NT fetal tenocytes and 2.9 billion 
(1.45 billion read pairs) for the shSCX fetal tenocytes. Detailed analysis of the 
knockdown RNA-seq data set quantity and size distribution of the Illumina sequencing 
run can be found in Table 4.2. 
Table 4.2. Overview of knockdown RNA-seq metrics. The total size and number of read pairs 
refers to the total read sizes and counts per group (adult NT, adult shSCX, fetal NT and fetal 
shSCX tenocytes). The same applies for the median and mean values, both of which include four 
biological replicates. 
 
Adult NT Adult shSCX 
Total size of all reads per group (bp) 13,460,000,000 13,410,000,000 
Median size of reads per sample (bp) 3,430,000,000 3,355,000,000 
Mean size of reads per sample (bp) 3,365,000,000 3,352,500,000 
Total number of all reads per group 134,600,000 134,100,000 
Median number of reads per sample 34,300,000 33,550,000 
Mean number of reads per sample 33,650,000 33,525,000 
Mean phred score per sample 36.05 36.18 
 
Fetal NT Fetal shSCX 
Total size of all reads per group (bp) 12,000,000,000 11,940,000,000 
Median size of reads per sample (bp) 3,045,000,000 2,925,000,000 
Mean size of reads per sample (bp) 3,000,000,000 2,985,000,000 
Total number of all reads per group 120,000,000 119,400,000 
Median number of reads per sample 30,450,000 29,250,000 
Mean number of reads per sample 30,000,000 29,850,000 
Mean phred score per sample 36.02 36.11 
 
 




All RNA samples passed quality control (QC) carried out using FastQC and FastQC 
Screen. Trimming of reads was not required due to the high sequence quality and minimal 
adapter content. A GC content of 50-52% was obtained, with no sequences being flagged 
as poor quality. 
4.2.4. Scleraxis knockdown leads to differential changes in gene 
expression in adult and fetal tenocytes 
RNA-sequencing was performed to measure transcriptional changes in four lines of adult 
and four lines of fetal tenocytes following SCX knockdown. A total of 13,159 and 13,142 
genes were detectable (out of 21,689) in the adult and fetal tenocytes respectively. Of 
these, 183 genes were DE using a Log2FC±1 p.adj< 0.05 cut off between adult shSCX 
and NT controls, with 120 genes being upregulated and 63 genes being downregulated 
(Figure 4.6.A). In comparison, 477 genes were DE between fetal shSCX and NT controls, 
with 358 genes being upregulated and 119 genes being downregulated (Figure 4.6.A). Of 
these DE genes only 117 were commonly differentially regulated as a result of SCX 
knockdown in both adult and fetal tenocytes lines, with 87 genes being upregulated and 
30 genes being downregulated. MMP3 was found to be the most significantly upregulated 
gene common to both groups. IGF2BP1 was the most significantly downregulated gene 
common to both adult and fetal groups following SCX knockdown, however CLDN16 
was the most significantly downregulated gene when looking at the effects of shSCX in 
adult tenocytes alone. The results of the differential gene expression analysis can be 
visualized in the volcano plots in Figure 4.6.B. The RNA sequencing data is freely 
available in the National Centre for Biotechnology Information Gene Expression 
Omnibus repository (NCBI GEO, www.ncbi.nlm.nih.gov/geo) [accession number 
GSE149570]. The lists of differentially expressed genes are available in full in (Paterson 
et al., 2020, Supplementary File 1). 







Figure 4.6. Differential expression in adult and fetal tenocytes following SCX knockdown. 
A) VENN diagram showing overlap of DE genes in the adult (teal) and fetal (orange) tenocytes 
following SCX knockdown. The top 4 upregulated genes with the greatest Log2FC are shown in 
both groups next to the green arrow and the top 4 downregulated genes are shown in both groups 
next to the red arrows. B) Volcano plot displaying the DE genes between the shSCX and NT 
control in adult and fetal tenocytes. The x-axis corresponds to the Log2FC and the y-axis the 
mean expression value of log 10 (p.adj). The red dots represent those genes which are considered 
DE based a Log2FC±1 p.adj< 0.05 cut off. Positive values on the x-axis represent upregulated 
genes and negative values represent downregulated genes. 
 
 




To validate some of the potential direct or indirect targets of SCX, qPCR analysis was 
conducted using both the original shSCX and NT sequenced lines alongside an additional 
cohort of two adult and two fetal shSCX and NT tenocyte biological replicates (Figure 
4.7). Of the eight genes tested SCX, MMP2 and MMP3 were significantly DE as a result 
of SCX knockdown in both adult and fetal tenocytes, corroborating the RNA-sequencing 
results (Figure 4.7). In the fetal tenocytes, MMP9, COL14A1 and COL1A2 had significant 
adjusted p-values following RNA-seq. However, upon analysis of further biological 
replicates these genes were no longer significant, whereas VIM reached significance with 
further biological replicates (Figure 4.7). All of the RNA-sequencing data for the adult 
tenocytes was corroborated by the qPCR analysis. Overall, for all genes in both adult and 
fetal tenocytes, there was a 75% corroboration between the RNA-sequencing data and the 
qPCR analysis of the larger cohort. 
 








Figure 4.7. Validation of RNA-seq with an additional biological cohort. A) Validation of 8 
DE genes detected from RNA-seq using qPCR on a larger cohort (6x biological replicates) of 
SCX knockdown lines. Expression shown relative to the NT control on a log 2 scale. * p < 0.05 
using a two-tailed Student’s t-test. Error bars represent the SEM of 6 biological replicates. B) 
Comparison of significance in expression following SCX knockdown in RNA-seq and qPCR 
results from adult and fetal tenocytes. A significance threshold of < 0.05 was used for both RNA-
seq p.adj and q-PCR p-values. Red shaded boxes indicate no-significant difference. Yellow 
shaded boxes with a double asterisk (**) represent a significant p.adj value, but do not meet the 
fold cut-off (±1). Green shaded boxes indicate there is a significant difference based on both 
p.adj/p-value and Log2FC±1.  
 
 




It has previously been demonstrated that SCX either directly or indirectly regulates the 
expression of several collagens, proteoglycans, matrix metalloproteinases and other 
transcription factors in both tendon and heart tissue (242,377,442,444,446–
448,450,464,465). Using the aforementioned literature available on SCX regulation, a 
panel of 16 genes previously demonstrated to be affected by SCX knockdown in either 
tendon or cardiac fibroblasts was collated from the RNA-seq data (Figure 4.8), excluding 
those already investigated in the qPCR validation (Figure 4.7). In fetal tenocytes 10 of 
the 16 genes were found to significantly differ as a result of SCX knockdown (p.adj< 
0.05). In adult tenocytes only one gene, MMP1, was found to significantly differ 
following SCX knockdown.  
 
 
Figure 4.8. RNA-seq data on literature panel of genes thought to be under SCX regulatory 
control. Bar chart of gene expression of collagens, proteoglycans, matrix metalloproteinases and 
other transcription factors previously demonstrated to be affected by SCX knockdown in tendon 
and cardiac fibroblasts in adult (teal) and fetal (orange) shSCX expressing tenocytes. Y-axis 
shows the normalised Log2FC relative to the NT controlf. Significant differences based on both 
Log2FC±1 p.adj<0.05 are depicted by a double asterisk (**). Those genes which are significant 
based on p.adj but not Log2FC are depicted by a single asterisk (*). Error bars represent the SEM 
of 4 biological replicates. 
 
 




Validation via immunocytochemistry, although not quantitative, was also performed with 
ACTA1 and CADM1 antibodies. ACTA1 gene expression was significantly decreased in 
fetal shSCX tenocytes compared to the NT control (Log2FC = -2.65, p.adj = 0.0001), but 
had no difference as a result of SCX knockdown in adult tenocytes. CADM1 gene 
expression was significantly decreased in adult and fetal shSCX tenocytes compared to 
the NT control (Log2FC = -1.89 and –1.85, p.adj = 2.19E-05 and 2.77E-12 respectively). 
Protein expression of ACTA1 and CADM1 did not corroborate with the sequencing data, 
and no visible differences were observed between NT and shSCX lines in adult or fetal 
tenocytes (Figure 4.9). Antibodies for other DE genes including IGF2BP1, TNMD, 
MMP1, MMP3, Collagen 1, Collagen XIV and RANKL were also due to be tested, 
however this was not completed due to the COVID19 pandemic (see preface). Similarly, 
the antibody CADM1 was due to be tested in western blots to confirm its specificity in 
the horse, however as a result of the COVID19 pandemic this could not be completed 
(see preface). However, all antibodies were predicted to cross-react with the horse, having 
over 80% homology to the intended target species.  
 
Figure 4.9. Immunocytochemistry validation of SCX knockdown RNA-seq results. 
Comparison of the corresponding proteins for two significantly DE genes. Images representative 
of 4 biological lines of 2D cell cultures of adult NT, adult shSCX, fetal NT and fetal shSCX 
tenocytes. Scale bar = 40 μm. DAPI staining of the nuclei is shown in blue. Anti-ACTA1 is 
detected using the FITC secondary antibody shown in green. Anti-CADM1 is detected using the 
Alexa Fluor 594 shown in red.  




4.2.5. Gene ontology and pathway analysis of SCX knockdown adult 
and fetal tenocytes 
To determine the biological processes altered as a result of SCX knockdown, gene 
ontology (GO) analysis was performed. The top ten significantly enriched terms are listed 
in Table 4.3. In adult tenocytes SCX knockdown resulted in over-representation of genes 
involved in the regulation of responses to endogenous stimulus, stress, signal transduction 
and organic substrates. These included several mRNAs from the growth factor protein 
class as well as g-protein coupled receptors, and membrane traffic proteins. In fetal 
tenocytes SCX knockdown resulted in over-representation of genes involved in cellular 
migration and motility as well as tissue development and structure morphogenesis. These 
included several mRNAs from the growth factor protein class as well as ECM structural 
proteins, metalloproteases and membrane bound signalling molecules.  
Table 4.3. Gene ontology analysis of SCX knockdown RNA-seq data. Summary of the top 10 
significantly enriched GO biological process terms for each pairwise comparison of DE genes in 
adult and fetal tenocytes following SCX knockdown. GO terms have been arranged alphabetically 









INPUT   
(Expected) 
INPUT                  
(Fold 
Enrichment) 
INPUT        
(FDR) 
Adult Knockdown 
Cellular response to endogenous 
stimulus (GO:0071495) 
638 21 5.32 3.95 6.22E-04 
Cellular response to organic 
substance (GO:0071310) 
1503 34 12.53 2.71 8.05E-04 
Cellular response to organic 
substance (GO:0071310) 
1178 27 9.82 2.75 6.18E-03 
Regulation of response to 
stimulus (GO:0048583) 
2435 42 20.3 2.07 9.41E-03 
Regulation of signal transduction 
(GO:0009966) 
1845 35 15.38 2.28 8.59E-03 
Regulation of signalling 
(GO:0023051) 
2095 38 17.46 2.18 8.09E-03 
Regulation of system process 
(GO:0044057) 
275 12 2.29 5.24 8.79E-03 
Response to endogenous 
stimulus (GO:0009719) 
697 23 5.81 3.96 4.29E-04 




Response to organic substance 
(GO:0010033) 
1488 32 12.4 2.58 3.02E-03 




1382 67 30.48 2.2 4.86E-06 
Cellular response to chemical 
stimulus (GO:0070887) 
1503 67 33.15 2.02 7.52E-05 
Positive regulation of response to 
stimulus (GO:0048584) 
1334 62 29.42 2.11 4.80E-05 
Positive regulation of signal 
transduction (GO:0009967) 
990 52 21.84 2.38 1.92E-05 
Regulation of cell migration 
(GO:0030334) 
558 39 12.31 3.17 2.17E-06 
Regulation of cell motility 
(GO:2000145) 
595 39 13.12 2.97 6.39E-06 
Regulation of cellular component 
movement (GO:0051270) 
642 41 14.16 2.9 5.64E-06 
Regulation of locomotion 
(GO:0040012) 
647 39 14.27 2.73 3.71E-05 
Tissue development 
(GO:0009888) 
1072 59 23.64 2.5 9.20E-07 
Tube development (GO:0035295) 586 37 12.92 2.86 2.94E-05 
 
In addition to GO analysis, DE genes were also overlaid into the GeneAnalytics Pathway 
Analysis tool (Table 4.4). Genes DE following SCX knockdown in adult tenocytes 
resulted in significant enrichment of pathways including metabolism and ECM 
remodelling. Genes DE following SCX knockdown in fetal tenocytes resulted in 
significant enrichment of pathways including the TGF-Beta and differentiation pathways.  
 




Table 4.4. GeneAnalytics pathway analysis of SCX knockdown RNA-seq data.Summary of 
the top 10 Pathways based on entity score for each pairwise comparison of DE genes in adult and 
fetal tenocytes following SCX knockdown. 








Carbon Metabolism 9.64 143 6 
Cell Adhesion_ECM Remodelling 9.2 61 4 
GnRH Secretion 8.95 64 4 
Metabolism 10.64 2621 37 
Nitrogen Metabolism 11.29 17 3 
PAK Pathway 9.28 683 14 
PPAR Signalling Pathway 11.13 76 5 
Statin Pathway 9.03 63 4 
Transcription Role of VDR in Regulation of Genes 
Involved in Osteoporosis 
10.81 45 4 
Type II Diabetes Mellitus 9.37 59 4 
Fetal Knockdown 
Activation of CAMP-Dependant PKA 20.03 630 34 
Akt Signalling 21.83 682 37 
CREB Pathway 24.1 529 33 
Embryonic and Induced Pluripotent Stem Cell 
Differentiation Pathways and Lineage-specific 
Markers 17.03 
133 13 
ERK Signalling 35.5 1179 63 
MAPK Signalling Pathway 17.04 321 21 
Oxytocin Signalling Pathway 17.49 216 17 
PAK Pathway 23.27 683 38 
RhoGDI Pathway 18.65 181 16 
TGF-Beta Pathway 20.34 653 35 
The STRING plugin from Cytoscape was then used to predict interactions between the 
top DE genes resulting from SCX knockdown, using a less stringent cut off of Log2FC 
±0.6 p.adj < 0.05. This approach allowed us to encompass a larger number of DE genes 
and prevented bias in the network by imposing too high a fold change cut-off (466). This 
cut-off resulted in a total of 465 DE genes as a result of shSCX expression in the adult 
tenocytes (305 upregulated and 160 downregulated) and 1149 genes in the fetal tenocytes 
(803 upregulated and 346 downregulated).  




In the adult network 423 genes were recognised by the STRING software which resulted 
in a network of 332 connected genes and 91 singletons. Within this network the first to 
third direct neighbouring interactors of SCX can be found in Figure 4.10, with the 
cytokine CCL26 representing the first direct neighbouring interaction. The top five 
functional annotations which are common throughout the network are depicted by the 
coloured bars surrounding each node and include responses to stimulus and cell migration 
(Figure 4.10).  
 
Figure 4.10. Adult STRING interaction network. Interaction network showing first to third 
direct neighbouring interactors for SCX within the DE genes in adult tenocytes following SCX 
knockdown. The top five functional annotations linking connecting nodes are colour coded and 
can be visualized around each note in the network. Networks as predicted by STRING and 
visualized in Cytoscape.  




In the fetal network 1060 genes were recognised by the STRING software which resulted 
in a network of 1001 connected genes and 59 singletons. Within this network the first and 
second direct neighbouring interactors of SCX can be found in Figure 4.11. In this case 
only the first and second neighbours were considered in order to reduce the overall size 
of the network and allow for easier visualisation. This resulted in SOX9, BGN, DCN, 
GDF6 and CCL26 (the only direct neighbour found in the adult network) representing the 
first direct neighbouring interactions. The top five functional annotations which are 
common throughout the fetal network do not overlap with the adult network and include 
extracellular matrix organisation and skeletal system development (Figure 4.11). 
 
Figure 4.11. Fetal STRING interaction network. Interaction network showing first and second 
direct neighbouring interactors for SCX within the DE genes in fetal tenocytes following SCX 
knockdown. The top five functional annotations linking connecting nodes are colour coded and 
can be visualized around each note in the network. Networks as predicted by STRING and 
visualized in Cytoscape. 




4.2.6. Foal tenocytes are differentially affected by scleraxis knockdown 
compared to both adult and fetal tenocytes 
Young postnatal foal tenocytes (aged 54 days – 84 day postpartum) were examined to 
determine if target genes of SCX are differentially regulated at this developmental stage. 
Foal tenocytes were capable of remodelling an artificial 3D collagen gel with no 
significant difference in contraction rate or cell survival observed compared to adult or 
fetal tenocytes (Figure 4.12.A). Foal tenocytes also express a panel of tendon associated 
markers with no significant differences compared to adult or fetal cells (Figure 4.12.B).  
  
Figure 4.12. Comparison of foal, adult and fetal tenocyte contraction rates and expression 
of tendon associated markers. A) Adult, fetal and foal tenocytes are capable of contracting a 
collagen gel to the same degree. Contraction is shown as the percentage of the day 0 value. 
Similarly, no significant difference in percentage cell survival was detected between the adult, 
fetal and foal tenocytes. p > 0.05 using Welch’s ANOVA. Error bars represent the SEM of 3 
biological replicates per cell type. B) qPCR showed no significant differences in tendon gene 
expression between adult, fetal and foal tenocytes using Welch’s ANOVA. Expression shown 
relative to the 18s rRNA housekeeping gene. N.D. = expression not detected. Error bars represent 
the SEM of 3 biological replicates.  




SCX expression was knocked down by an average of 79.3% in the foal tenocytes (Figure 
4.13.A). SCX knockdown in foal tenocytes did not affect their ability to contract a 
collagen gel or their cell survival within the collagen gels (Figure 4.13.B). 
 
Figure 4.13. SCX knockdown in foal tenocytes does not affect their ability to contract a 3D 
gel. A) Foal tenocytes exhibit a significant reduction in SCX mRNA expression following viral 
transduction with a specific shRNA against SCX (shSCX) when compared to cells transduced 
with a control non-target scrambled shRNA (NT). * p <0.001 using a two-tailed Student’s t-test. 
Expression shown relative to the 18s rRNA housekeeping gene. Error bars represent the SEM of 
3 biological replicates. B) Foal tenocytes expressing shSCX can contract a collagen matrix to the 
same degree as the NT control cells, ~16% of their starting size. Similarly, no significant 
difference in percentage cell survival was detected. Significance tested between the two 
conditions (NT vs. shSCX) using a two-tailed Student’s t-test. Error bars represent the SEM of 3 
biological replicates.  
 
 




Expression of 11 genes were measured by qPCR in shSCX and NT foal tenocytes. Gene 
selection was based on the results obtained in the adult and fetal knockdown results.  Only 
COMP was shown to be significantly DE in the foal tenocytes (Figure 4.14.A). TNC and 
MMP3 were consistently upregulated to a high degree in all foal replicates (4.76 and 
14.66 average fold change relative to NT control), however no significant changes were 
detected due to the large variation in fold change increase between the biological 
replicates. Interestingly, of the genes examined COMP and TNC were not DE in either 
fetal or adult tenocytes (Figure 4.14.B). 
 
Figure 4.14. Effect of knocking down SCX in young postnatal foal tenocytes. A) Gene 
expression in foal tenocytes following SCX knockdown produces a significant reduction in 
COMP. Error bars represent the SEM of 3 biological replicates. Relative expression is plotted on 
a log10 scale. * p < 0.001 using a two-tailed Student’s t-test. B) Comparison of DE genes in adult, 
fetal and foal tenocytes using qPCR. Table shows the p-values obtained following Student’s t-
testing of the fold change in gene expression of adult, fetal and foal shSCX expressing tenocytes 
relative to the NT control. Red shaded boxes indicate no-significant difference and green shaded 
boxes indicate there is a significant difference p< 0.05. Data obtained from 3-6 biological 
replicates per condition. 




4.2.7. Preliminary results on SCX knockdown in ESCs  
As described in section 4.2.1, in parallel with the NT and shSCX lentiviral vectors, a 
GFP-Turbo lentiviral plasmid under the control of the CMV promoter was used to 
visualize transduction efficiency and the success of puromycin selection in adult and fetal 
tenocytes. Using this lentiviral vector in ESCs however resulted in no GFP expression. 
The lack of transcriptional activity of CMV in ESCs has been previously described in 
mouse ESCs. However why it is inactive is not fully understood, with it being suggested 
that ESCs might lack all the cofactors necessary for full transcriptional activity (467). As 
such, using standard cloning techniques, the CMV promoter was removed and replaced 
with either the EF1a or PGK promoter, both of which have proven superior for stable 
transgene expression in mouse and human ESCs (467–470). Lentiviral infection of ESCs 
with GFP-Turbo plasmid under the control of the EF1a promoter resulted in strong GFP 
expression, whereas no GFP was expressed using the PGK driven plasmid (Figure 
4.15.B). The EF1a-GFP-Turbo plasmid was therefore used for subsequent experiments.  
The same delivery system as used in the adult, fetal and foal tenocytes, i.e. lentiviral 
vectors containing shSCX or NT shRNA under the control of the U6 promoter, was then 
used to generate stable SCX knockdown lines (shSCX) or non-target controls (NT) in one 
biological line of undifferentiated ESCs, conducted in independent technical triplicates 
(Figure 4.15.A). Following this, ESC lines underwent 2D tenogenic differentiation and 
qPCR was subsequently performed. SCX is not expressed in undifferentiated ESCs, but 
this approach resulted in an average percentage knockdown of SCX mRNA of 43.9% 
following tenogenic differentiation (Figure 4.15.C). Viral copy number integration was 
measured in each replicate of shSCX and NT expressing tenocyte differentiated ESCs 
and approximately one copy number event was detected per diploid cell across all 
technical repeats (Figure 4.15.D).  






Figure 4.15. Knocking down SCX expression in undifferentiated ESCs. A) Undifferentiated 
ESCs were transduced with lentivirus before undergoing puromycin section and expansion. Once 
expanded undifferentiated ESCs were then differentiated into tenocytes in 2D for two weeks 
before RNA and DNA sample collection and subsequent analysis. This was conducted in one 
biological line of ESCs in independent technical triplicates. SCX knockdown was also due to be 
conducted in ESC-derived tenocytes however this could not be completed due to the COVID-19 
pandemic (see preface). B) GFP control infection of one line of ESCs with GFP-Turbo plasmid 
driven by the EF1a promoter versus the PGK promoter. Strong GFP expression was found with 
the EF1a-GFP-Turbo plasmid whereas no GFP was visible with the PGK-GFP-Turbo plasmid. 
Scale bars = 40µm. C) Transduced ESCs following tenogenic differentiation exhibit a significant 
reduction in SCX mRNA expression following viral transduction with a specific shRNA against 
SCX (shSCX) when compared to cells transduced with a control non-target scrambled shRNA 
(NT). * p < 0.001 using a two-tailed Student’s t-test. Expression shown relative to the 18s rRNA 
housekeeping gene. Error bars represent the SEM of 3 independent technical replicates. D) ESC 
shSCX or NT copies per diploid cell determined by copy number assays in each independent 
technical replicate. Water (H20) and wild type (WT) non-infected DNA were used as negative 
controls. Using a two-tailed Student’s t-test no significant difference in copy number was detected 
between ESC NT and shSCX lines (p = 0.81). 
 




Several genes which were affected by SCX knockdown in adult and fetal tenocytes 
(MMP2, MMP3, MMP9, LHX9 and COL1A2), several tendon associated genes (MKX, 
GPRIN3, EYA2, THBS4, TENM4 and TNC) and several cartilage associated genes 
(COMP, SOX9, CNMD, ACAN and COL2A1) were also investigated using qPCR in the 
ESC shSCX and NT control lines following tenocyte differentiation (Figure 4.16). SOX9 
and TENM4 were significantly upregulated following SCX knockdown (p-value = 0.0057 
and 0.009 respectively), whereas GPRIN3 was significantly downregulated (p-value = 
9.79E-0.5). MMP3 and COMP also appeared to be upregulated, however they were just 
above significance (p-values 0.08 and 0.07 respectively). ACAN had an over 27-fold 
increase following SCX knockdown compared to the NT control, and although all 
replicates showed upregulation the variability between the replicates meant this was not 
significant. COL2A1 expression was also induced in shSCX expressing ESC following 
tenogenic differentiation, whereas it was not expressed in the NT control.  
Infection with shSCX was also due to be conducted in ESCs that had been pre-
differentiated into tenocytes prior to infection (Figure 4.15.A), however as a result of the 
COVID19 pandemic further technical and/or biological replicates could not be conducted 
for either the undifferentiated ESCs or the ESC-tenocytes (see preface).  







Figure 4.16. SCX knockdown alters ESC-tenocyte gene expression. shSCX ESCs following 
tenogenic differentiation show significant reduction in GPRIN3 expression and significant 
increase in SOX9 and TENM4 compared to the NT control. Error bars represent the SEM of 3 
independent technical replicates. Relative expression to the NT control is plotted on a log10 scale. 
* p < 0.05 using a two-tailed Student’s t-test.  
 
 





The transcription factor SCX is expressed throughout tendon development and plays a 
key role in directing tendon wound healing. However, little is known regarding its role in 
fetal or young postnatal tendons, stages in development that are known for their enhanced 
regenerative capabilities. In this chapter RNA-seq was used to compare the 
transcriptomes of adult and fetal tenocytes following SCX knockdown. SCX knockdown 
had a larger effect on gene expression in fetal tenocytes, with gene ontology, network and 
pathway analysis revealing an overrepresentation of extracellular matrix (ECM) 
remodelling processes. These included several matrix metalloproteinases, proteoglycans 
and collagens, some of which were also investigated in SCX knockdown ESCs and 
tenocytes from young postnatal foals. The results presented indicate a role for SCX in 
modulating ECM synthesis and breakdown and provides a useful dataset for further study 
into SCX gene regulation. This results in this chapter have been published (471). 
4.3.1. Optimising SCX knockdown via lentiviral infection to improve 
consistency for RNA-sequencing 
To allow identification of downstream target genes of SCX a short-hairpin RNA against 
the human SCX gene was used, which was introduced using a lentiviral system. This 
method has previously been used in our lab, producing a significant reduction in 
endogenous SCX expression with no effect on 2D cellular proliferation or morphology 
(267). In this study however, care needed to be taken to produce multiple SCX 
knockdown cell lines from different biological donors for RNA-seq, with the protocol 
refined to ensure as little technical variability occurred as possible. Poor tissue culture 
practices have been shown to lead to poor viral titers and low transduction efficiencies 
(472), therefore producer cells were carefully monitored. Daily medium exchanges were 
performed to prevent large pH changes which have been linked with cellular stress and 
destabilisation of the viral envelope (473). Similarly, as factors such as vector inoculum 
volume, target cell number and vector exposure time to target cells have all been found 
to influence the transduction results, some varying the final titer by as much as 50-fold 
difference from the same stock of vector (472), a protocol was generated and rigidly 
adhered to. A range of lentiviral titers were therefore tested, the percentage of SCX 
knockdown determined as well as the viral copy number integration recorded so as to 




ensure that all lines had a similar level of SCX knockdown and copy number integrations. 
Although SCX knockdown was confirmed both using qPCR and immunocytochemistry, 
it should be noted that quantitative western blotting would be required to give a more 
accurate reflection of the degree of SCX knockdown at the protein level.  
Infection of tenocytes with fresh high titer viral supernatant (> 1x108 IU/ml) resulted in 
high infection rate with intense GFP signal found in the control cells. These cells 
underwent apoptosis prior to addition of any antibiotic selection agent. This could suggest 
that due to high plasmid DNA incorporation, toxic effects may have occurred leading to 
cell death (474,475). When titers lower than 5x106 IU/ml were used cells did not survive 
following puromycin selection, suggesting a lack of sufficient virally infected cells to 
generate stable lines. Optimisation of the viral titer ensured that each line received the 
same dose of virus and thus minimised the risk of each line having differing copy number 
integrations which could affect the results. This approach allowed us to study the effects 
of SCX knockdown on the transcriptome of four biological replicates per group allowing 
more reliable biological conclusions to be drawn. Limitations in using a single biological 
replicate for RNA-seq experiments have been extensively documented (476–478) and are 
highlighted in Nichols et al., 2018. In this study a SCX knockdown of 57% was achieved 
via siRNA in a single adult equine tenocyte line which resulted in significant 
downregulation of genes involved in focal adhesions (377). Upon validation of these 
genes with an additional biological cohort (n = 7), the focal-adhesion genes identified 
were no longer significant (377). In comparison, in our study a 75% corroboration 
between the RNA-seq data (n=4) and cohort qPCR (n=6) was found, a result which is 
similar to that observed in chapter 3 (79% corroboration).  
Validation of candidate genes at the protein level was also initiated. Of the two genes 
tested at the protein level (ACTA1 and CADM1), no corroboration to the sequencing 
results was determined. Due to the COVID pandemic (see preface) further genes could 
not be tested, however the data from chapter 3 on protein validation demonstrated that 7 
out of the 12 proteins investigated corroborated with the RNA-seq results so it is likely 
that more genes would need to be tested to get an accurate picture of the true 
corroboration. TNMD and COL1A1, which were due to be tested, have been robustly 
demonstrated to be directly under SCX regulatory control in tenocytes, directly 
transactivating their expression (422,442,446,451). Interestingly in this study, neither 




appeared to be augmented at the mRNA level, with TNMD being absent. TNMD is 
regularly reported as a marker of tendon cells in humans and rats, however its expression 
in equine tenocytes is less well documented. Regardless of this lack of TNMD mRNA, 
protein expression is still detectable in equine tenocytes suggesting the rate of TNMD 
protein degradation is different to its mRNA (140). Similarly, collagen I expression has 
been shown to vary at the mRNA and protein level in SCX overexpression studies (176). 
It would therefore be of particular interest to examine these two genes at the protein level 
using qualitative immunocytochemistry and quantitative immunoblotting.  
4.3.2.  Effect of SCX knockdown in adult and fetal tenocytes  
SCX is postulated as being a key mediator in ECM and collagen production in response 
to matrix building cues in a number of tissue types (242,444). Through gain- or loss-of-
function studies several collagens, proteoglycans and matrix metalloproteinases have 
been shown to be regulated, either directly or indirectly by SCX (242,377,442,444,446–
448,450,464,465). In particular, in cardiac fibroblasts SCX has been demonstrated to 
directly transactivate MMP2, COL1A2 and FN1 expression, following its recruitment to 
the gene promoter regions via the pro-fibrotic cytokine TGFβ (242,446–448). SCX has 
therefore been suggested to be a key regulator in maintaining the balance of ECM 
synthesis and breakdown during injury repair, highlighting its potential as a theraputic 
target for controlling these processes (447). Our results similarly indicate a significant 
involvement of SCX in regulating MMPs 1, 2, 3, 12 and 13, collagens 4A1 and 18A1 as 
well as ECM proteoglycans VIM and LUM, with pathway analysis also highlighting ECM 
remodelling and TGFβ pathway signalling as being significantly overrepresented. It 
would therefore be of interest to investigate whether SCX is directly regulating these 
ECM components in equine tenocytes, and as such altering the equilibrium between 
MMPs and their inhibitors’ (tissue inhibitors of metalloproteinases (TIMPs)) activities. 
This could be assayed firstly using mutagenesis of E-boxes, chromatin 
immunoprecipitation (ChIP) and electrophoretic mobility shift assay (EMSA) techniques 
followed by zymography to determine changes in MMP and TIMP activity. Such changes 
may highlight a role of SCX in the regulation of tendon ECM synthesis and breakdown.  
The exact role of scleraxis through fetal to adult development has not been defined. In 
this study SCX knockdown had a much larger effect on fetal tenocyte gene expression 




than adult tenocytes, resulting in 477 DE genes in fetal tenocytes and only 183 DE genes 
in adult tenocytes. Only 25-35% of the DE genes in both groups were downregulated, 
with the majority being upregulated as a result of the knockdown. As SCX has only been 
reported as being a transcriptional activator (453,479), this would suggest that the high 
proportion of upregulated genes reported are not direct targets of SCX and are instead 
being affected by some downstream intermediate. However, this traditional view of 
classifying transcription factors as “activators” or “repressors” is being questioned, and 
in many cases “activators” often have an indirect repression effect by blocking the 
binding of other transcriptional activators (480,481). Similarly, this high percentage of 
upregulated genes may be due to SCX activation of transcriptional repressors, such that 
when SCX is knocked down this reduced activation of transcriptional repressors may 
result in de-repression of other genes leading to their upregulation. As SCX has been 
reported to work with other co-factors (453,479,482), the observed differences in 
downstream genes in fetal and adult stages, may indicate that there is a difference in the 
availability of such co-factors at the different stages of development. SCX gene regulation 
will be explored further in chapter 5.  
The fetal tenocytes used in this study were from around 85-90% of the way through 
gestation, which our group have previously proposed represent a period in which the 
tendons are still actively developing (267). The large effect on gene expression that was 
observed following SCX knockdown in fetal tenocytes may indicate that SCX still has a 
critical role in tendons at this developmental stage. This is supported by previous work 
from our group which demonstrated that SCX knockdown in fetal tenocytes prevented 
them from contracting a 3D collagen gel, whereas adult SCX knockdown tenocytes 
contracted the collagen gels as normal (267). Our data demonstrates that SCX is 
regulating fewer genes in adult tenocytes. Although SCX is also implicated in adult 
tendon injury and repair, its expression is thought to be mainly altered through pro-
fibrotic TGFβ signalling and via mechanical loading in response to injury (175,388,427), 
it would therefore be of interest to look at the transcriptome of SCX knockdown adult 
tenocytes following such stimulus. Similarly, performing SCX overexpression studies on 
both non-transduced and shSCX expressing adult and fetal tenocytes would be of great 
benefit to validate the DE genes found as a result of SCX knockdown.  




In order to identify potential interactions between the DE genes resulting from SCX 
knockdown, network analysis was performed in STRING. This form of analysis uses text-
mining as well as computational predictions in order to determine protein-protein 
interactions (483). In the adult network response to stimuli and cellular migration were 
overrepresented, with only one direct interacting partner of SCX being detected, namely 
CCL26. CCL26 is a cytokine that displays chemotactic activity to eosinophils and 
basophils. Why a direct connection between CCL26 and SCX is predicted is unclear. 
Other genes within this network include MMP 1 and 2, as well as the transcription factor 
Snai1, a key regulator in the epithelial-to-mesenchymal transition (450). MMP2 and 
Snai1 have been shown to be directly regulated via SCX in cardiac fibroblasts (447,450). 
Why no direct connection is made is surprising and highlights the limitations in this form 
of analysis when investigating less well studied proteins where reference sources are 
limited. In the fetal tenocyte network a clear overrepresentation of ECM and skeletal 
system development processes were found with direct connections to SOX9, BGN, DCN, 
GDF6 and CCL26 being detected. Knockout of BGN and DCN in mouse embryos results 
in tendon defects and SOX9 and GDF6 are heavily implicated in cartilage development 
(426,484) suggesting that SCX regulation, or perhaps coordinated expression of these 
genes, is critical to ensure normal tendon development.  
4.3.3. Effect of SCX knockdown in young postnatal tendon 
Using a candidate gene approach, it was further demonstrated that SCX-dependent 
processes differ in young postnatal tenocytes compared to both adult and fetal tenocytes. 
These tenocytes were isolated from foals of around 3 months of age which represents a 
period of rapid tendon growth and development (485). Cartilage oligomeric matrix 
protein (COMP), a non-collagenous ECM protein which is primarily present in cartilage 
but also found in tendons and ligaments, was the only tested gene which significantly 
differed following SCX knockdown in foal tenocytes. In adult and fetal tenocytes no 
change in COMP expression was observed in shSCX expressing tenocytes. Although 
COMP is not currently a known target of SCX, it does have two E-box binding sites for 
SCX in its promoter, therefore further investigation into COMP regulation by SCX in 
foal tenocytes is warranted.  




SCX has been implicated as an important factor for adaptive changes in postnatal tendons, 
with it being induced upon mechanical loading (486). This increased SCX expression as 
a result of mechanical load, leads to an increased proliferation of SCX expressing cells, 
as well as upregulation of collagen type I and TNMD gene expression (486). Whereas in 
contrast, immobilization results in a decrease in SCX expression and collagen turnover 
(487). This change in SCX regulation through fetal-to-foal-to-adult development may 
therefore correlate with this transition from lack of mechanical loading through to weight-
bearing and then to increased physical demand and body weight at adulthood. Follow-up 
studies looking at the transcriptome and direct target genes of SCX in foal tenocytes 
would be required to make more detailed comparisons, with the integration of 
mechanotransduction likely to provide further insight into how SCX is regulated during 
different stages of tendon maturation.  
4.3.4. Effect of SCX knockdown in ESCs 
The effect of SCX knockdown on ESCs and ESC-tenocytes was also starting to be 
investigated, however as a result of the COVID-19 pandemic (see preface), it could not 
be completed. The preliminary data obtained did however indicate a role of SCX in 
altering the expression of several cartilage genes. These included SOX9, an SRY-Box 
transcription factor which is essential during multiple steps of chondrogenic 
differentiation (488), as well as ACAN, a member of the aggrecan/versican proteoglycan 
family and COL2A1 which are integral parts of the ECM of cartilaginous tissue.  
Following tenogenic differentiation of shSCX expressing ESCs, SOX9 expression was 
found to significantly increased in the resulting population. During embryonic 
development SCX and SOX9 have been shown to work in a coordinated manner, with 
this concerted interaction being required for divergence of precursor cells into either 
tendon or cartilage progenitors (484). Furthermore, SCX and E47 have been shown to 
cooperatively bind with SOX9 and p300 to regulate the SOX9-dependent transcription of 
COL2A1 (453). However, this SOX9-dependent transcription of COL2A1 can also be 
initiated through SOX9 and p300 alone (453). COL2A1 expression was induced in 
tenogenic differentiated shSCX expressing ESCs, which may be the result of increased 
SOX9 rather than as a direct result of decreased SCX expression. Taken together this 
suggests that, once SCX expression is repressed in ESCs the SOX9 transcriptional 




cascade is activated, thus hampering the switch to a tenogenic phenotype in promotion of 
a more cartilage-like phenotype. It would therefore be of interest to further investigate 
the differentiation potential of shSCX expressing ESCs, particularly down the 
chondrogenic lineage to see if SCX knockdown improves their chondrogenic potential.  
In accordance with this hypothesis of impaired tenogenic potential, GPRIN3 a member 
of the GPRIN protein family recently identified as an equine specific marker for tendon 
(240) was significantly decreased in tenogenic differentiated shSCX expressing ESCs. 
TENM4, another gene suggested to be equine tendon specific was also significantly 
affected, being upregulated in tenogenic differentiated shSCX expressing ESCs which 
does not fit this hypothesis. TENM4 has however also been implicated as a novel 
regulator in chondrogenic differentiation, increasing in expression in early differentiation 
of human BMSCs to chondrocytes (489). This peak in TENM4 and subsequent decline is 
coupled with an upregulation of ACAN, COL2A1 and COL10A1, which are common 
chondrogenic differentiation markers (489). The observed increased TENM4 may 
therefore be indicative of early chondrogenic differentiation. Finally, ACAN although not 
significant, had a very high fold increase (27-fold change) in tenogenic differentiated 
shSCX expressing ESCs. ACAN is a major glycoprotein component in cartilage which 
has already been shown to be directly regulated by SCX in osteosarcoma cells (449) as 
well by SOX9 in TC6 chondrocytes (490). Upregulation of ACAN therefore fits with this 
hypothesis of decreased tenogenic potential in favour of a more cartilage like phenotype. 
Caution however must be taken with the results presented on the ESCs as, as mentioned 
previously, this is only based on three technical repeats using one biological line. Given 
the interesting results obtained it would be worth repeating this on further lines to see if 
the hypothesis holds true. Further characterisation of the DE genes at the protein level, as 
well as looking if they are under direct SCX regulatory control would also be required. 
In doing so this may shed more light on the complex role SCX plays in embryonic 
specification of tendon and cartilage lineages.  
4.3.5. Summary  
In summary, this chapter , as previously reported in cardiac fibroblasts, identifies SCX as 
a key regulator of ECM gene expression in tendon cells. It is also the first study to confirm 
that SCX regulation differs during adult and fetal development. Creation of this dataset 




provides a crucial resource for directing further studies into SCX regulation which, given 
the significant role SCX plays in tissue repair, may prove useful for the development of 
therapeutics for tendon injury and disease. Chapter 5 will start to explore whether some 




















Chapter 5 – Identification of Scleraxis 
Target Genes  
5.1 Introduction 
Transcription factors fundamentally work through their ability to scan the genome, 
binding to specific transcription factor binding sites in order to form complexes which 
guide and control gene expression. In chapter 4, using scleraxis (SCX) knockdown 
coupled with RNA-seq techniques many potential genes downstream of SCX signalling 
were identified. However, using these techniques alone doesn’t allow for direct causal 
regulatory mechanisms to be determined. Here I will explore the mechanisms by which 
transcription factors act to regulate gene expression, and more specifically what is known 
in regard to SCX gene regulation.  
5.1.1. Gene regulation by transcription factors 
There are numerous types of regulatory factors which function to control gene expression 
however, the main regulators are transcription factors. Not only can transcription factors 
function as “master regulators” to control developmental patterning and cell specification, 
but they can also act dynamically, with the same transcription factor being able to control 
distinct regulatory networks across different cell types within the same organism 
(481,491,492). By binding to short sequence-specific DNA base pair patterns, termed 
motifs or cis-regulator elements, individual transcription factors can control tens, if not 
hundreds of target genes (480,493). However, more often than not they do not act alone, 
binding cooperatively with other transcriptional cofactors in order to exert their desired 
effect.  
Transcription factors are typically classified into families based on the specific structural 
domains which allows them to bind to DNA. These families include, but are not restricted 




to, basic helix loop helix (bHLH), basic leucine zipper (bZIP), homeodomain (HD), 
C2H2-zinc finger (ZF) and nuclear hormone receptor (NHR) DNA binding domains, 
many of which were first described in the 1980s (494). The mechanisms by which 
transcription factors can impact transcription are vast, some of which are outlined in 
Figure 5.1.  
 
Figure 5.1. Mechanisms of transcription factor actions. Transcription factors can act through 
a number of mechanisms. They can bind as a monomer, homo- or heterodimer, directly recruiting 
RNA-polymerase to activate transcription (Gene A). Alternatively, transcription factors can bind 
as a monomer, homo- or heterodimer and act as repressors, blocking recruitment of RNA-
polymerase (Gene B). Transcription factors can also act by simply blocking other proteins from 
binding to the same sites preventing their ability to activate transcription (Gene C). Most 
transcription factors however act by recruiting accessory factors. These can be coactivators (Gene 
D) or corepressors (Gene E), which are frequently large protein complexes which contain domains 
involved in nucleosome remodelling, chromatin binding or covalent modifications of histones 
such as p300. Similarly, many transcription factors work cooperatively, with other transcription 
factors needing to be present in order to allow transcription (Gene F). Equally, transcription 
factors can recruit multiple cofactors, including transcriptional activators and repressors which 
can act together to prevent gene transcription (Gene G). Figure inspired from the text in Lambert 
et al., 2018 (481).  




5.1.2. Identification of SCX as a basic helix-loop-helix (bHLH) protein 
As described in chapter 4, SCX belongs to the bHLH family of transcriptional regulatory 
proteins (Figure 5.2), a superfamily which plays important roles in various cellular 
differentiation and developmental processes (495). Over 240 bHLH transcription factors 
have been identified thus far and, as such, features including their different protein 
structure and molecular phylogenetic relationships are used to categorise them into 
different subfamilies from Class A to F (495,496). All bHLH proteins bind to a specific 
hexanucleotide DNA motif (CANNTG, where N represents any nucleotide), known as E-




Figure 5.2. Structure of bHLH transcription factors. These proteins contain two highly 
conserved domains; the basic domain (yellow) located at the amino-terminal end which contains 
the interface region for DNA interactions and the HLH domain (red) located at the carboxy-
terminal end which enables interactions with other protein subunits to occur (498). The HLH 
domain is composed of two amphipathic alpha-helices separated by a loop, which facilitate 
folding and packing against other protein subunits to form homo- and heterodimeric complexes 
(428,479,498). Image represents the SCX protein binding to E-box domain as a homodimer.  
SCX was first identified in a yeast two-hybrid screen, developed to uncover potential 
interacting partners of the E2A (also known as TCF3) gene product E12 (479). This newly 
identified 22 kDa protein, SCX, had high homology to other bHLH proteins, having a 
proline rich region near the carboxyl-terminus like that of several other bHLH activators 
and was demonstrated to bind specifically to E-boxes as a heterodimer with E12 (479). 
Similarly, E47, an alternative splice variant of the E2A gene, has also been shown to bind 




as a heterodimer with SCX, synergistically enhancing transcription of an E-box 
containing promoter (482). SCX was also revealed to be capable of transactivating 
aggrecan gene expression without heterodimerization with either E12 or E47 (449). 
Likewise, when the HLH domain is removed from SCX, which is the region which 
facilitates protein-protein interactions, it is found to still be capable of transactivating the 
COL1A2 promoter, although with approximately 50% reduced activity, demonstrating 
that heterodimerization is not specifically required for SCX function (428,451). In 
comparison, when the basic domain, the region required for binding to E-box DNA 
regions, was removed SCX was no longer capable of transactivating the COL1A2 
promoter highlighting its need to interact with the promoter via direct DNA binding in 
order to regulate gene expression (428,451). Other SCX binding partners have been 
identified, for example activating transcription factor 4 (ATF4, part of the cAMP-
response element binding protein family) has been demonstrated to repress SCX function 
in Sertoli cells of the testes (499). However, further work to identify additional binding 
partners and their effect on SCX function is necessary.  
5.1.3. SCX direct gene regulation 
Although several studies have identified potential candidate genes which are under SCX 
regulatory control (Table 4.1), few have demonstrated whether this is via direct or indirect 
means. In tendon cells, only two genes COL1A1 and TNMD have been demonstrated to 
be under direct SCX-mediated control (422,442). Using a combination of electrophoretic 
mobility shift assays (ESMA) and promoter assays, SCX was found to bind as a SCX/E47 
heterodimer with the short cis-acing element TSE2 (tendon-specific element 2) to 
promote COL1A1 transcription via binding to the E-box site CACGTG (442). Similar 
techniques were used to demonstrate SCX’s ability to bind preferentially to two of the 
five E-boxes (E2:CATCTG and E5:CAGATG) found around the mouse TNMD gene 
promoter, with luciferase promoter assays confirming activation via these two E-boxes 
(422). In other tissue, SCX has been demonstrated to directly regulate aggrecan (ACAN), 
a major proteoglycan found in cartilage, in osteoblastic ROS17/2.8, as well as transferrin 
and androgen binding protein (ABP) in Sertoli cells (449,461). Much work on SCX-
mediated regulation has been conducted in cardiac fibroblasts, Table 4.1 in the previous 
chapter highlights several of the genes which have been demonstrated as under direct 
SCX control in this cell type, as marked by the asterisk.  




5.1.4. Determining and validating transcription factor binding  
As discussed in chapter 4, knockdown and overexpression studies are useful tools to allow 
determination of potential candidate genes which may be downstream of a transcription 
factor of interest, however a direct causal relationship cannot be determined from this 
alone. In order to confirm transcription factor binding a number of techniques are 
available which are broadly categorized as either in vitro or in vivo based, with the most 
commonly used being outlined in Table 5.1. In vitro approaches generally provide 
information on intrinsic TF binding sequence preferences and the biophysical parameters 
controlling these binding events, whereas in vivo methods are performed in living cells 
and can recover information on transcription factor binding events sequence specificity 
as well as the biological context of those interactions (e.g. cell type, time point, 
treatment), a concept which is further demonstrated in Figure 5.3 (500,501).  
 





Figure 5.3. Different approaches for determining transcription factor binding. A) Example 
of in vitro methods, which can be low or high throughput, which provide information on the 
sequence specificities of particular transcription factors. B) In silico methods use known DNA-
protein binding sites to generate computational ‘DNA motif models’ to predict the specificity of 
binding to another potential site based on the predicted sequence information and shape models. 
C) In vivo methods, which can be low or high throughput, provide information on transcription 
factor binding within a tissue or cell type at that particular time. However, it must be noted that 
in vivo binding does not necessarily lead to gene regulation, with it being likely that only a small 
fraction of these binding events impact on gene expression. ChIP-seq peaks displayed represent 
areas of enrichment, where protein interacts with DNA. D) As not all binding events result in 
gene regulations, functional binding assays are conducted to experimentally validate targets 
effects on promoter activity, usually by mutating the binding site or conducting overexpression 
or knockdown studies and determining the effect on the reporter activity. Using Figure adapted 
from Slattery et al., 2014 (502). 




Table 5.1. Overview of methods for analysis of transcription factor-DNA binding. TF = Transcription Factor. Table created and inspired by the following 
review articles:- (481,500,503,504) 












Way to determine how specific a known DNA-protein interaction 
is. Method uses epitope tagged TF which is incubated with binding 
and non-binding DNA probes in separate wells of an ELISA 
microplate. Proteins bound to the immobilised DNA are then 
measured photometrically. 
Main method available to 
allow DNA-motif analysis in 
a motif-by-motif way to 
determine DNA-protein 
interactions, low technical 
complexity, low cost. 
 
Doesn’t work for low 
protein amounts, prior 
knowledge on DNA-
protein interaction 




o  DNA Footprinting Confirming 
Predicted TF-DNA 
Binding 
DNA protection assay where DNA is incubated with TF and 
subsequently degraded. Pools of DNA fragments are generated. 
Areas bound by TF with be protected from degradation and can be 
compared to control pools using gel electrophoresis. 
 
Easy to perform, reliable, 
inexpensive. 
Pre-requisite of known 





o Electrophoretic mobility 




TF and labelled target sequence incubated to test if the specific 
DNA sequence is bound by the TF by observing a shift in the 
electrophoretic migration compared to unbound DNA or protein. 
Inexpensive, can be used to 
measure cooperative 
binding and analysis of 
mutated versions of a TF. 
 
Pre-requisite of known 







o Mechanical induced 





A microfluidic device is used to isolate TF-DNA complexes from 
free DNA instantaneously allowing capture of tens to hundreds of 
TF-DNA interactions in parallel. 
Transient and low affinity 
interactions better 
detected. 
Limited number of 
sequences assayed, not as 
good with TFs which have 










Optical method to monitor efficiency of binding of TFs to DNA in 
real time. 
Useful for determining TF 
binding association and 
dissociation kinetics. 
 
Limited throughput, prior 
knowledge of TF-DNA 
binding required. 













TF expressed as a fusion to a subunit of RNA-polymerase and a 
randomised library of oligonucleotides representing potential TF 
binding sequence containing selectable markers are cloned into 
bacterial or yeast cells. Positive and negative selection are then 
used to enrich for sites that bind the TF tested. 
No requirement for specific 
antibodies, low tech 
alternative to microarray-
based techniques, capable 
of de novo motif discovery. 
Limited capacity to 
determine binding 
specificities of TFs with 
lengthy binding sites, 
some eukaryotic factors 
don’t function in bacterial 
or yeast system, not good 











TF-binding assay where a DAP-seq guide DNA library, containing 
adapter DNA sequence, is added to an affinity capture bead-bound 
TF. Following incubation, the TF bound DNA is then eluted and 
amplified with PCR primers to introduce an indexed adapter and 
the DNA is sequenced. 
De novo motif discovery, 
high throughput. 
Limited by skewed 
distribution of genomic 
sequences, peaks are not 







Systematic evolution of 






A TF is added to a pool of DNA containing many randomised 
sequences and allowed to bind. Through a series of selection steps 
TF-bound-DNA is captured, using methods such as affinity tags, 
molecular trapping or EMSA, with the subsequently bound DNA 
fragments amplified by PCR and sequenced. 
High throughput, small 
sample size required, easily 
automated using liquid 
handling equipment 
allowing analysis of 
hundreds of TFs in parallel. 
 











Similar to SELEX but uses fragmented genomic DNA rather than 
synthetic random sequences. 
Useful for TFs which have 
long binding specificities. 
 
Not useful for TFs which 











Epitope-tagged/labelled TF is bound to double-stranded DNA 
microarray. Fluorescent-based detection then determines 
enriched binding motifs. 
Efficient and relatively 
economical, can be used to 
measure cooperative 
binding and/or multimers. 
Accessibility issues of 
DNA-binding domains to 
probe DNA, arrays 
contain limited numbers 
of sequence, requires 
freshly produced and 
purified proteins. 













Also known as reverse ChIP. Following crosslinking, a desthiobiotin 
conjugated DNA probe is used to hybridize to a specific genomic 
region, the associated proteins are isolated and analysed by mass 
spectrometry. 
No prior knowledge about 
the proteins that bind to the 
locus of interest required 
Unable to distinguish 
direct from indirect 








(ChIP) based methods 
Discovery of 
Target Regions 
TF-DNA complexes are fixed in situ using formaldehyde 
crosslinking. Crosslinked DNA is sheared into pieces and 
precipitated with a TF-specific antibody. Bound DNA is the 
detected using qPCR (ChIP-qPCR), microarray (ChIP-chip), or 
sequencing (ChIP-seq). 
ChIP-qPCR offers a simple, 
inexpensive method to 
determine if TF binds 
certain regions of DNA. 
ChIP-chip and ChIP-seq offer 
genome wide profiling of TF 
binding. Can be used to 
determine cooperative 
binding (Co-IP). 
For ChIP-qPCR specific 
probe regions need to be 
designed to determine 
binding, hence is low 
throughput. ChIP-chip 
and ChIP-seq limited by 
skewed distribution of 











TF is fused to bacterial DNA adenine methyltransferase and 
transfected as a hybrid-fusion protein in mammalian cells. The 
enzyme methylates a consensus sequence near the TF binding 
sites, which can then be mapped by NGS. 
Fewer artifacts than ChIP-
based techniques and no 
need for toxic 
formaldehyde. 
Cannot be used for 'snap-
shot' analysis or 
monitoring dynamic 
changes in TF binding, 
need to express DAM 
hybrid-fusion proteins 







Promoter Assays Identifying TF-
DNA binding of 
regulatory 
importance 
Assay where a TF drives the expression of a given promoter 
sequence that is fused to a downstream reporter gene. Reporters 
include galactosidase (GAL), fluorescent reporters (GFP, RFP) or 
luciferase (LUC) with the activity being detected by means such as 
photometrically, using flow cytometry or luminescence depending 
on the reporter system. 
Easy to perform, reliable, 
inexpensive. 
Limited to TFs that 
activate gene expression, 
variable copy number 
integrations of the 
reporter DNA can affect 
results. 
 




In this chapter chromatin immunoprecipitation (ChIP) techniques are utilised. This is a 
powerful yet relatively easy and cost-efficient method for identifying transcription factor 
target gene binding across different cell types or cellular developmental stages at one 
moment in time. An in vivo approach was desired over an in vitro one as this would allow 
for direct comparison of SCX binding in all three of the different cell type of interest; 
adult, fetal and ESC-derived tenocytes, across the entire genome and, using the RNA-seq 
results generated in chapter 4, would provide evidence as to whether SCX was directly 
regulating candidate genes or not. This method was preferred over other in vivo 
techniques such as DamID, in which cells are transfected with plasmid containing the 
transcription factor of interest fused to the Escherichia coli DNA adenine 
methyltransferase (DAM), as it does not require cell line manipulation with an artificial 
construct which can be cumbersome and lead to a degree of cellular stress (505). 
Unfortunately, due to cost reasons and the expense of the RNA-seq conducted throughout 
this project, ChIP-qPCR was conducted rather than ChIP-ChIP or ChIP-seq, which limits 
our investigation to only a small number of target genes rather than being genome wide. 














5.1.5. Chapter aims 
In chapter 4 RNA-seq profiles of SCX knockdown adult and fetal tenocytes were 
generated, providing an insight into potential genes which may be under SCX regulatory 
control. However, additional techniques are required to determine if any of the candidate 
genes are directly bound by SCX, potentially leading to the changes observed. Therefore, 
the aim of this chapter is to identify novel genes which are the direct targets of SCX 
regulation in tenocytes isolated from different stages of development. 
The specific objectives were to: 
1) Optimise a ChIP assay to identify SCX target genes in tenocytes using a candidate 
gene approach based on known target genes and those identified in chapter 4. 















5.2.1. Optimisation of ChIP-qPCR protocol  
Prior to conducting the ChIP experiments several steps needed optimisation. Chromatin 
shearing, which is one of the most critical steps in the protocol was optimised first, with 
varying cycle lengths compared to determine the optimum shearing time required to 
generate fragments between 100-600 base pairs (bp). Three different cycle lengths were 
tested, namely 23 cycles, 30 cycles and 40 cycles of 20 seconds on and 20 seconds off, 
and the fragment sizes compared using agarose gel electrophoresis (Figure 5.4.A). Using 
23 or 30 cycles resulted in fragments between 100-600 bp as depicted by the strong 
concentration of DNA in this region. Using 40 cycles produced a weaker smear, likely 
due to over-sonication leading to fragments of less than 100 bp. Over-sonication can lead 
to a drop in ChIP-efficiency, therefore the shortest sonication time of 23 cycles was used 
in the subsequent experiments, with shearing assessments via agarose gel electrophoresis 
conducted on all replicates prior to their use.  
In addition, of upmost importance for successful ChIP experiments is the selection of 
appropriate antibodies. The successful use of an antibody in another experiment, such as 
immunocytochemistry or western blotting, does not necessarily mean the antibody will 
work in ChIP experiments (506). A literature search was therefore conducted to find a 
SCX antibody which had previously been used in ChIP experiments (termed ChIP-new) 
(507). This antibody was then compared to a SCX antibody which was routinely used in 
our laboratory for immunocytochemistry and western blotting (termed ChIP-old) (140) 
which had not previously been shown to work in ChIP experiments, alongside a histone 
H3 positive control (Figure 5.4.B). TNMD gene specific primers were then designed to 
encompass the E-box binding sites CAGATG and CATCTG, located around the TATA 
box of the TNMD promoter, which have previously been demonstrated as preferential 
binding sites for SCX in mature mouse tenocytes (422). qPCR was then conducted using 
the TNMD primers and immunoprecipitated DNA from adult tenocytes, isolated using 
each of the aforementioned antibodies.  
Following qPCR, the data was then normalised. As numerous different normalisation 
strategies can be found in the literature, including background subtraction (508), fold 




enrichment (509), percentage input (%IP) (510), normalisation relative to nucleosome 
density (511), normalisation to a control sequence (512) as well as combinations of the 
aforementioned (506), a strategy needed to be determined and used throughout. For this 
chapter a combinatory normalisation strategy was utilised. Firstly, the data was 
normalised to the amount of input chromatin (%IP) where the sample precipitation 
efficiency is measured relative to the total input signal (513). This method is generally 
preferred over the other commonly used ‘fold enrichment over IgG control’ method as 
IgG control reactions can have quite differing levels of background signal (513). 
However, caution needs to be taken with the handling of input and ChIP samples to ensure 
the input is a true representation of the amount of chromatin in each reaction. Following 
this the data was then normalised to the average of a panel of negative control genes 
(514), consisting of four genes, two of which qPCR assays designed to target intronic 
regions which contained no E-boxes within a 1.5 Kb span, and assays were also designed 
for two genes which are known not to be expressed in tenocytes and which had no E-
boxes within 500 bp of the promoter region. In doing so this reduced the number of false 
positives by accounting for background signal which can occur through differences in 
reproducibility of chromatin washing and purification steps. IgG controls were still 
performed for all experiments as a further internal negative control however, the data was 
not normalised to these values.   
Following normalisation, no enrichment of the target DNA sequence as a consequence of 
SCX binding in adult tenocytes was found when using the SCX (old) antibody which 
binds to the N-terminal region of the SCX protein (Figure 5.4.C), whereas an enrichment 
of > 5 fold was determined using the SCX (new) antibody, which binds to the C-terminal 
region. The SCX (new) antibody was therefore used in subsequent experiments. It should 
be noted, that as a result of the COVID-19 pandemic (see preface) this antibody was not 
validated by western blotting to determine its specificity in the horse. However, this 
antibody is made from a keyhole limpet hemocyanin (KLH) carrier protein conjugated 
with a synthetic peptide made from the 172-201 amino acids located at the C-terminal 
region of the human SCX protein, which as shown in Figure 4.1 has 100% homology to 
the equine SCX protein within this region, therefore it is highly likely to be cross-reactive.  
 
 







Figure 5.4. ChIP-qPCR protocol optimisation. A) Optimisation of chromatin shearing in one 
adult tenocyte line as determined by agarose gel electrophoresis. Lane A shows a programme of 
23 cycles (20 seconds on, 20 seconds off), lane B a programme of 30 cycles (20 seconds on, 20 
seconds off) and lane C a programme of 40 cycles (20 seconds on, 20 seconds off) using a Misonix 
Sonicator XL2020 Ultrasonic Liquid Processor. B) Chromatin immunoprecipitation was 
performed on adult tenocytes using two different anti-scleraxis antibodies (old vs new) alongside 
a histone H3 control at a concentration of 2 µg of antibody per reaction, as per the supplier’s 
recommendation. Immunoprecipitates were subjected to qPCR using primers flanking E-box 
binding sites within the TNMD gene promoter region. Genomic DNA was used as a positive input 
control. Results represent the fold enrichment of the ratio of SCX- or H3- bound DNA to the 
average of the negative controls (TEX33, RNASE9, Intronic #1 ad Intronic #2) normalised for 
input DNA. C) Diagram of the SCX bHLH protein demonstrating where the two SCX antibodies 
(old vs new) bind.  
 




The final optimisation step was to determine the most efficient amount of antibody to use 
per reaction. It is known that too low a concentration of antibody can lead to failed binding 
of all the target protein in the immunoprecipitated sample, whereas too high an antibody 
concentration can result in saturation of the assay leading to lower specific signal and 
high background noise. Therefore, the SCX antibody concentration was titrated from 1 
µg to 10 µg to determine the optimum concentration for use in subsequent reactions. 
Using an antibody titration curve, 4 µg was determined to be the optimal concentration, 
giving the lowest signal over background ratio, and was used for subsequent experiments 




Figure 5.5. SCX antibody titration curve. Immunoprecipitates isolated from reactions using 
varying antibody concentrations were subjected to qPCR using primers flanking E-box binding 
sites within the TNMD (positive control), IGF2BP1(candidate gene) and TEX33 (negative 
control) gene promoter region. Crosslinked chromatin was used as a positive input control. The 
quantified DNA is expressed as a percentage of the total input chromatin. IgG antibody (4 µg) 
can be seen on the graph as a negative control. Reactions containing varying IgG concentration 
were also conducted however for simplicity are not shown. 
 
 




5.2.2. Identification of SCX targets in adult and fetal tenocytes 
Following optimisation ChIP-qPCR was conducted on two genes previously 
demonstrated to be regulated by SCX, namely COL1A2, which has been shown to be 
directly bound by SCX in cardiac fibroblasts, and TNMD, which has been identified as 
being directly regulated by SCX in adult tenocytes (422,443,446). ChIP-qPCR 
demonstrated significant enrichment of SCX binding to the COL1A2 promoter in both 
adult and fetal tenocytes, despite this gene not being DE in either cell type following SCX 
knockdown (Figure 5.6). TNMD showed significant enrichment in both adult and fetal 
tenocytes, despite this gene again not being DE in either cell type following SCX 
knockdown (Figure 5.6). 
 
 
Figure 5.6. ChIP-qPCR on genes unaffected by SCX knockdown. Chromatin 
immunoprecipitation was performed on adult and fetal tenocytes using an anti-scleraxis antibody 
(4 µg). Immunoprecipitates were subjected to qPCR using primers flanking E-box binding sites 
within the gene’s promoter regions. Crosslinked chromatin was used as a positive input control. 
Results of n = 3 biological replicates are presented as a fold enrichment of the ratio of SCX-bound 
DNA to the average of the negative controls (TEX33, RNASE9, Intronic #1 and Intronic #2) 
normalised for input DNA, with error bars representing the SEM. Grey bars represent the fold 
change in enrichment of SCX-bound DNA for the average of the negative control genes. Blue 
bars represent the fold change in enrichment of SCX-bound DNA for each gene analysed. * p< 








Next were tested genes that showed significantly decreased expression in both adult and 
fetal tenocytes following SCX knockdown (Figure 5.7). IGF2BP1, which was the top 
downregulated gene in both adult and fetal tenocytes was significantly enriched in both 
adult and fetal tenocytes, however, at different E-box binding sites (IGF2BP1 #1 in fetal 
tenocytes and IGF2BP1 #2 in adult tenocytes). FGF19, another gene which was 
significantly downregulated in both adult and fetal shSCX expressing cells, showed a 
trend of enrichment (> 2-fold) in fetal tenocytes only, yet this was not significant. KLF15 
and NOV, which were significantly downregulated in both fetal and adult tenocytes 
showed a trend of enrichment (> 2-fold) in both adult and fetal tenocytes however again 
this was not significant.  
 
 
Figure 5.7. ChIP-qPCR on genes downregulated following SCX knockdown in both adult 
and fetal tenocytes. Chromatin immunoprecipitation was performed on adult and fetal tenocytes 
using an anti-scleraxis antibody. Immunoprecipitates were subjected to qPCR using primers 
flanking E-box binding sites within the gene’s promoter regions. Crosslinked chromatin was used 
as a positive input control. Results of n = 3 biological replicates are presented as a fold enrichment 
of the ratio of SCX-bound DNA to the average of the negative controls (TEX33, RNASE9, 
Intronic #1 and Intronic #2) normalised for input DNA, with error bars representing the SEM. 
Grey bars represent the fold change in enrichment of SCX-bound DNA for the average of the 
negative control genes. Blue bars represent the fold change in enrichment of SCX-bound DNA 
for each gene analysed. * p< 0.05 using a two-tailed Student’s t-test. 




Following this, genes which were differentially affected by SCX knockdown in adult and 
fetal tenocytes were then tested (Figure 5.8). PDGFB, which was significantly 
downregulated in fetal tenocytes only following SCX knockdown was significantly 
enriched in fetal tenocytes. Adult tenocytes also showed substantial enrichment (7.66-
fold) however this was not significant due to the high variability between biological 
replicates. CLDN16, which was significantly downregulated in adult tenocytes only 
following SCX knockdown, showed significant enrichment in SCX binding in adult 
tenocytes but not fetal tenocytes. ACTA1, which was significantly downregulated in fetal 
shSCX expressing cells only following differential expression analysis, showed no 
significant enrichment in either cell type (within E-box region #1 or #2). FGF9 which 
was similarly significantly decreased in fetal tenocytes only, clearly showed no 
enrichment of SCX binding.  
 
Figure 5.8. ChIP-qPCR on genes differentially affected by SCX knockdown in adult and 
fetal tenocytes. Chromatin immunoprecipitation was performed on adult and fetal tenocytes 
using an anti-scleraxis antibody (4 µg). Immunoprecipitates were subjected to qPCR using 
primers flanking E-box binding sites within the gene’s promoter regions. Crosslinked chromatin 
was used as a positive input control. Results of n = 3 biological replicates are presented as a fold 
enrichment of the ratio of SCX-bound DNA to the average of the negative controls (TEX33, 
RNASE9, Intronic #1 and Intronic #2) normalised for input DNA, with error bars representing 
the SEM. Grey bars represent the fold change in enrichment of SCX-bound DNA for the average 
of the negative control genes. Blue bars represent the fold change in enrichment of SCX-bound 
DNA for each gene analysed. * p< 0.05 using a two-tailed Student’s t-test. 




Finally, although SCX has only been demonstrated to be a transcriptional activator, the 
genes that showed the largest upregulation following SCX knockdown in adult and fetal 
tenocytes, MMP3, was investigated to see if SCX bound within the MMP3 gene promoter 
(Figure 5.9). MMP3 (within E-box region #2) showed a trend of enrichment (> 2-fold) in 
both adult and fetal tenocytes however this was not significant. No enrichment was found 
in either of the other E-box regions investigated (#1 or #3).  
 
 
Figure 5.9. ChIP-qPCR on gene upregulated by SCX knockdown in adult and fetal 
tenocytes. Chromatin immunoprecipitation was performed on adult and fetal tenocytes using an 
anti-scleraxis antibody (4 µg). Immunoprecipitates were subjected to qPCR using primers 
flanking E-box binding sites within the gene’s promoter regions. Crosslinked chromatin was used 
as a positive input control. Results of n = 3 biological replicates are presented as a fold enrichment 
of the ratio of SCX-bound DNA to the average of the negative controls (TEX33, RNASE9, 
Intronic #1 and Intronic #2) normalised for input DNA, with error bars representing the SEM. 
Grey bars represent the fold change in enrichment of SCX-bound DNA for the average of the 
negative control genes. Blue bars represent the fold change in enrichment of SCX-bound DNA 










5.2.3. Identification of SCX targets in ESC-derived tenocytes 
ChIP-qPCR was being conducted to determine the direct targets of SCX in ECS-
tenocytes, however as a result of the COVID-19 pandemic this could only be conducted 
in one biological replicate (see preface). Although no statistically significant conclusions 
can be drawn from this data, if we consider those with fold enrichment of > 2 to be 
potentially bound, enrichment of SCX binding was observed in the promoter region of 
IGF2BP1 (within E-box region 2), PDGFB, NOV and TNMD in this biological line 
(Figure 5.10).  
 
Figure 5.10. ChIP-qPCR in ESC-tenocytes. Chromatin immunoprecipitation was performed on 
one biological line of ESC-tenocytes using an anti-scleraxis antibody. Immunoprecipitates were 
subjected to qPCR using primers flanking E-box binding sites within the gene’s promoter regions. 
Crosslinked chromatin was used as a positive input control. Results are presented as a fold 
enrichment of the ratio of SCX-bound DNA to the average of the negative controls (TEX33, 
RNASE9, Intronic #1 and Intronic #2 –labelled as negative) normalised for input DNA. Blue bars 









In the previous chapter, through the generation of SCX knockdown ESCs, fetal, foal and 
adult tenocytes lines, it was demonstrated that SCX regulation of gene expression differs 
during different stages of development. However, whether the genes identified were 
regulated directly via SCX or not was unclear. To further explore this concept, candidate 
genes which were differentially affected by SCX knockdown were investigated using 
ChIP-qPCR to determine whether they were directly bound by SCX. Identification of 
SCX downstream targets at different developmental stages will yield valuable insight into 
how adult reparative and fetal regenerative tenocytes act to facilitate scleraxis-dependent 
processes which may provide new targets for therapeutics. The results in this chapter have 
been published (471).  
5.3.1. Differences in SCX binding in adult and fetal tenocytes 
Following ChIP optimisation, 11 genes were analysed using ChIP-qPCR in three 
biological lines of adult and fetal tenocytes. COL1A2 has been confirmed as a direct 
downstream target gene of SCX in cardiac fibroblasts (242,446). Yet despite no 
significant difference in mRNA expression being determined following SCX knockdown 
in both adult and fetal tenocytes, significant enrichment of SCX binding to the COL1A2 
promoter was detected. This could suggest, that although SCX binds to the COL1A2 
promoter it does not activate transcription in tenocytes. This may be due to the lack of 
availability of the required SCX interacting partners at this site, which may indicate that 
SCX directs similar but discrete signalling programs in a tissue-dependant manner that 
are modified by tissue specific interacting partners (444).   
IGF2BP1 expression on the other hand was significantly decreased in both adult and fetal 
tenocytes following SCX knockdown confirming for the first time that SCX can directly 
bind to the IGF2BP1 gene promoter in both adult and fetal tenocytes, although at different 
E-box binding sites. IGF2BP1 is a member of the IGF-II mRNA binding protein family 
which regulates the growth factor IGF2. IGF2BP1 knockout (KO) studies in mice have 
identified its essential role in normal growth and development, with KO mice exhibiting 
severe dwarfism and impaired gut development (515). KO mice also displayed impaired 
extracellular matrix formation within the organs tested (intestine, liver, and kidneys) with 




reduced expression of LGALS1, LUM, TNC and several other procollagen transcripts. 
Although IGF2BP1 has not currently been implicated in tendon development, evidence 
suggests it plays a role in periodontal ligament (PDL) tissue and dental development 
(516). Further functional studies to determine the effects of altering IGF2BP1 expression 
in tenocytes would therefore be of interest.  
FGF19, KLF15 and NOV expression was also significantly decreased in both adult and 
fetal tenocytes following SCX knockdown. Low levels of enrichment of SCX binding 
was observed in both adult and fetal tenocytes in the KLF15 (3.24- and 2.1-fold 
enrichment in adult and fetal respectively) and NOV (3.21- and 2.7-fold enrichment in 
adult and fetal respectively) E-box promoter regions, although this was not significant. 
Further biological replicates are therefore required in order to determine if SCX is directly 
regulating these target genes. FGF19 E-box showed a trend of enrichment in fetal 
tenocytes only (3.66-fold enrichment), however this again was not significant and further 
replicates would be required.  
A selection of genes which had differing subsequent expression in adult and fetal 
tenocytes following SCX knockdown were then investigated. PDGFB was significantly 
decreased following SCX knockdown in fetal tenocytes only. PDGF proteins are 
produced by a variety of cell types including platelets, macrophages, endothelial cells and 
smooth muscle cells and are heavily implicated in tendon wound healing (517,518). 
PDGFB in particular is also proposed to promote ECM production in muscle cells during 
limb development (519). Significant enrichment of SCX binding to PDGFB was detected 
in fetal tenocytes, which taken along with the RNA-seq results, provides evidence that 
SCX directly activates PDGFB expression in fetal tenocytes. Enrichment was also 
detected in adult tenocytes; however, this was not significant due to the large variation in 
fold changes. This suggests SCX, although bound, may not actively promote transcription 
in adult tenocytes. ACTA1 and FGF9 were also only significantly decreased in fetal 
tenocytes following SCX knockdown, however no enrichment in SCX binding was 
detected in either gene in either adult or fetal tenocytes, indicating that the effect on gene 
expression may be due to an intermediate interactor.  
CLDN16 was the most significantly downregulated gene in adult tenocytes following 
SCX knockdown yet it was unchanged in fetal tenocytes. Little is known in regard to 
CLDN16, a claudin protein that is an important component of tight junctions between 




cells. Direct interaction between SCX and the CLDN16 gene sequence was confirmed in 
adult tenocytes, having significant enrichment in SCX binding, whereas no binding was 
observed in the fetal tenocytes. Functional studies to determine the role of CLDN16 in 
tendon cells is therefore warranted.  
The final investigation focused on whether SCX regulated the expression of MMP3, the 
most significantly upregulated gene in both adult and fetal tenocytes following SCX 
knockdown. Although SCX has only been reported to be a transcriptional activator, over 
two-fold enrichment of SCX binding was detected in both adult and fetal tenocytes 
around one MMP3 E-box binding site (MMP3 #2), although no significant binding was 
detected to confirm the binding of SCX to any of the three E-box regions within the 
MMP3 promoter. This could suggest that either SCX has some previously unreported 
repressive effects, or that it is passively binding the promoter region which is blocking 
the binding of a different transcriptional activator for MMP3. Identifying histone 
modifications around this promoter site alongside SCX binding may help determine if 
SCX is indeed involved in MMP3 regulation.  
5.3.2. Differences in SCX binding in ESC-tenocytes 
Unfortunately, investigation into SCX binding in ESC-tenocytes could not be completed, 
with only one biological replicate having been examined. Although this data is 
preliminary it appears that IGF2BP1 (around E-box region 2), PDGFB and NOV show 
enrichment in SCX binding, like that of the TNMD positive control. These genes also all 
showed enrichment in adult and fetal tenocytes. Although these genes were DE in adult 
and/or fetal tenocytes following SCX knockdown, whether they would be affected in 
ESC-tenocyte SCX knockdown lines was not determined and would be worth further 
investigation. To do so ESCs would first need to be differentiated into tenocytes and SCX 
knockdown performed on the differentiated cells in order to match that of the adult and 
fetal tenocyte data.  
In chapter 4, several chondrogenic genes were found to differ in their expression 
following tenogenic differentiation of shSCX expressing ESCs which could signify 
SCX’s role in determining tenogenic versus chondrogenic lineage specification. To 
investigate this hypothesis high throughput methods could be employed to help decode 
the temporal changes in gene expression patterns that occur during both tendon and 




cartilage differentiation. For example, by combining RNA-seq, histone modification 
ChIP-seq and transcription factor ChIP-seq experiments; the changes in global gene 
expression, the chromatin state and transcription factor occupancy at multiple distinct 
stages of tendon differentiation from ESCs to tenocytes or chondrocytes could be 
captured. By combining these features, dynamic regulator networks could then be 
inferred using computational modelling such as that which has been conducted in 
haematopoietic specification and cardiac differentiation (520,521).  
Finally, it should also be noted that ChIP-qPCR was not conducted on the foal tenocytes 
lines either, which would also be of interest, particularly to look at potential binding of 
SCX in the COMP gene promoter region as this was significantly affected by SCX 
knockdown in the foal samples alone.  
5.3.3. Theoretical mechanisms for differences in SCX binding & gene 
regulation 
When one considers the size of the equine genome, being around 2.7 billion DNA bp in 
length, searching for potential SCX binding sites using an E-box motif of only 6 bp long 
will result in hundreds of thousands of potential binding sites. Not all of these sites are 
actually bound in vivo (502,522), so what is it that allows transcription factors to so 
precisely bind to specific DNA sites and not others? And of those bound sites, as only a 
small number are suggested to be functional i.e. have an impact on gene expression 
(502,522,523), what determines this functionality? Predicting and interpreting in vivo 
transcription factor-DNA binding events and their regulatory consequences is therefore 
quite a sizable task.  
It is now recognised that several features contribute to transcription factor-DNA binding 
preferences beyond that of the core nucleotide sequence, which in this study is the E-box 
motif. These include the 3D structural features of the binding sites, where variations in 
DNA groove width or DNA bending for example, as indicated in Figure 5.3.B, can alter 
the preference for transcription factors to bind to specific DNA sites (502,524,525). 
Considering this fact, such shape changes at transcription factor binding sites may 
account for the lack of enrichment in SCX binding observed for many of the primer pairs 
tested in this study, even though they were designed to encompass E-boxes. Similarly, 
how accessible the E-box binding regions are could also account for the lack of 




enrichment observed. Chromatin accessibility and nucleosome occupancy can impede 
transcription factor binding and increase transcription factor-DNA dissociation rates, 
therefore many of the primer pairs generated may have been unknowingly designed to 
inaccessible E-box regions (Figure 5.11). In order to determine DNA accessibility, 
methods such as ATAC-seq (assay for transposase-accessible chromatin using 
sequencing) would need to be conducted, however this was outside the scope of this 
thesis.  
 
Figure 5.11. Differences in accessibility of E-box binding regions. The accessibility of E-box 
regions can explain the binding affinity shown. For example, in A) the E-box may be accessible 
therefore SCX can readily bind and result in activation of gene transcription. B) However, many 
E-boxes may be accessible yet remain un-bound due to other factors such as the DNA context 
surrounding the motif, with it being predicted that on average 99.8% of binding sites in the 
genome are not bound by their respective transcription factor (526). C) One widely accepted 
reason is due to the accessibility of the binding sites, with many transcription factors preferentially 
binding to regions of open chromatin rather than inaccessible condensed chromatin (527). Figure 
inspired by Gomes & Wang et al., 2016 (528).  
Consideration should be given to the possibility that SCX might be bound within a 
particular gene regulatory region in one cell type, or a developmental stage within a cell 




type, but not in another. It is well described that gene regulatory networks are plastic, 
being able to direct distinct patterns of gene regulation in relation to different spatial, 
temporal and environmental cues (502). One way in which this type of regulatory 
specificity is achieved is similar to that described previously, where the chromatin 
environment and DNA accessibility across cell types or developmental stages within a 
cell type can dynamically change based on the cellular context (502,529–531). Such 
changes can therefore impact the binding of transcription factors in a context specific 
manner. For example, BAFT (basic leucine zipper transcription factor) and IRF4 
(interferon regulatory factor 4) are two transcription factors which have been 
demonstrated to be capable of remodelling the chromatin landscape by altering chromatin 
accessibility for other transcription factor to bind, thus providing T cells with plasticity 
to differentiate into multiple lineages depending on cytokine environmental cues (532). 
It may be the case therefore that SCX is able to bind to DNA made accessible in one 
developmental stage due to other ‘pioneer’ transcription factors altering the accessibility 
of the E-box binding site, whereas at another developmental stage it remains inaccessible 
due to lack of these cooperative transcription factors.  
So, what about the case in which SCX is found to bind to a certain gene promoter region 
in both adult and fetal tenocytes, but only appears to cause a regulatory effect in one of 
the two? It is well recognised that cell-type or cell-stage specific regulation is likely to 
occur through binding of a combination of different transcription factors, with differences 
in combinatorial occupancy resulting in differing effects (533). For example, one study 
which looked at the binding patterns of three transcription factors, CTCF, RNA 
polymerase II (RNAPII) and MYC, across 11 different human cell types, revealed the 
expression level of genes whose promoters were bound by different combinations of the 
three factors changed depending on the occupancy (533). When certain genes were 
occupied by both MYC and RNAPII higher expression levels were detected than when 
the genes were bound by either MYC or RNAPII alone (533). Whereas when these genes 
were occupied by both MYC and CTCF they exhibited lower expression than those 
occupied by MYC without CTCF (533). Therefore, by altering the cohort of transcription 
factors present genes can be regulated differently. It could therefore be hypothesised that 
SCX is able to regulate, for example, IGFBP1 but not COL1A2 in the same cells due to 
the presence or absence of other proteins which bind cooperatively to regulate the genes 
expression in a cell-type specific way. The E2A splice variants E47 and E12 have been 




identified as common binding partners of SCX, therefore it would be beneficial to 
determine whether the DE genes are co-activated with either of these by comparing ChIP-
seq profiles or using Co-immunoprecipitation or ESMA techniques. 
5.3.4. Summary 
Taken together it therefore appears that SCX is developmentally regulated, having age 
specific transcriptional programmes in tenocytes which lead to differences in gene 
expression and SCX binding preferences in the developmental stages investigated. Whilst 
SCX is known to be the first robust marker for tendon progenitor formation, its expression 
pattern is not limited to tendon, being expressed in many highly ECM rich tissue 
precursors such as ligaments, bronchial cartilage and pericardium (428,479). It is 
becoming increasingly apparent that the ECM undergoes age related changes, with such 
age-related declines in the ECM having a bearing on how wounds heal at different 
developmental stages (534). Pathway and enrichment analysis of genes whose expression 
in adult tenocytes changed significantly following SCX knockdown identified an 
enrichment of genes involved in cell adhesion and ECM remodelling (Section 4.2.5). 
Consequently, it could therefore be hypothesised that SCX may present as one of the key 
developmental-specific transcription factors involved in coordinating such changes in the 
ECM. The specific occupancy of SCX on the promoters of ECM genes may, with 
interaction with other factors such as E12 and E47, influence the particular pattern of 
expression of these genes at different developmental stages. As differences in the healing 
model of adult and fetal tendons have been observed, with many studies indicating 
changes in ECM constituents between the reparative and regenerative tissues 
respectively, further understanding of SCX ECM gene regulation and its impact on cell-
matrix interactions could be instrumental in understanding these different wound healing 
mechanisms.  
It should be noted that in this chapter only a handful of DE genes were investigated using 
ChIP-qPCR and thus I was unable to investigate all of the DE genes resulting from the 
RNA-seq experiment detailed in chapter 4. Using this approach primers were designed 
within what was determined as the promoter regions of the genes investigated, however 
evidence is emerging that some genes are regulated by introns with genes still being 
regulated when promoter regions are deleted (535). This emphasises the need for larger 




scale studies such as utilising genome-wide chromatin immunoprecipitation-sequencing 





Chapter 6 – Summary, Discussion and 
Future Perspectives  
6.1 Summary 
The overarching goal of this thesis was to explore the suitability of using ESC-derived 
tenocytes as a cellular therapy. More specifically it aimed to determine if ESC-tenocytes 
were more similar in their global gene expression profile to fetal or adult tenocytes, as 
well as to determine how SCX, a key gene in tendon development and healing, regulates 
gene expression in these different developmental stages. By using an RNA-sequencing 
approach to tackle both questions, ESC-tenocytes were found to be transcriptomically 
more similar to fetal as opposed to adult tenocytes, supporting the concept of using them 
as a cellular therapy and thereby endorsing the need for future in vivo efficacy and safety 
studies. Fetal regenerative and adult reparative cell types were also compared and large 
distinctions in gene expression were detected. The expression patterns of many 
chemokine, cytokines, growth factors and ECM proteins, which typically present in the 
injured adult tendon, differed between these two developmental states. Similarly, SCX 
was also shown to have differing regulatory effects in these stage specific cell types, 
differentially interacting with several novel genes involved in ECM remodelling. Taken 
together this data opens up future avenues of research to determine whether modulation 
of such factors in vivo could enhance adult tendon repair. The transcriptomic data 
presented in this thesis therefore provides an unprecedented insight into the fundamental 
differences between regenerative and reparative tendon cells which are likely to be 









6.2.1. Comparing regenerative and reparative cells  
Tendon wound healing is a complex process which has amassed much scientific and 
financial interest in an effort to try and harness the properties of fetal regenerative healing 
as a means to improve adult injury repair. Whilst scientific inquiry and the clinical 
application of mesenchymal stem cell therapies in horses abounds in research labs and 
veterinary practices worldwide, thus far few adequately powered clinical trials evaluating 
the clinical outcome of MSC treated SDFT injures has been conducted (39,536,537). In 
one such study, 113 racehorses considered to have career ending tendinopathy were 
treated with BMSCs and followed up over a 2-3 year period (39). Of those treated, 98% 
of horses returned to work, with re-injury rates being lower than those with alternative 
treatments (39). Although ultrasonographical examination of MSC treated horses showed 
rapid filling-in of the injured lesion, the longitudinal striated patterns of the tendon 
architecture did not return to normal suggesting a degree of scarring remained (39,537). 
Other studies have similarly demonstrated a reduction in re-injury rates following MSC 
treatment as well as enhanced regeneration (538–540), however completely scarless 
wound healing like that observed in the fetus remains elusive (541).  
Our understanding of fetal scarless healing leaves much to be desired, however as 
discussed in chapter 3, this appears to be in part due to the intrinsic properties of fetal 
tenocytes themselves (255). This highlights the need to better characterise fetal and adult 
cells, as these fundamental differences may be important in uncovering their differing 
mechanisms of wound repair and may help in the development of cellular or biological 
therapies. Therefore, in an attempt to better understand the core differences between adult 
and fetal tenocytes, in this thesis, their transcriptional profiles were compared in both 2D 
and 3D culture. 
Through this work, one finding of particular interest was that the gene expression 
signature of adult and fetal tenocytes when cultured in a 2D static environment was not 
significantly different. Only when their environment was perturbed, be that by three-
dimensional forces or gene modulation via SCX knockdown, did differences in adult and 
fetal transcriptional profiles occur. Although no other study to date has compared the 




global transcriptome of adult and fetal tenocytes, two studies have demonstrated 
significant global transcriptional differences in 2D cultured human adult and fetal cardiac 
and skin fibroblast cells (542,543). Yet these studies compared cells which had a much 
larger age window, with fetal cells being from around 35-50% of the way through 
gestation and adult cells being from very elderly patients (50-75 years old). In this thesis 
I compared equine fetal cells of around 80% of the way through gestation and young, 
skeletally mature, adult horse (2-10 years old) tenocytes. Although as described in section 
3.1.1, regeneration appears not only to be age specific, but also tissue and species specific, 
it must be noted that the tenocytes used in this study are therefore outside the range 
typically employed for regenerative studies, which is typically at 60-70% of the way 
through gestation in fetal sheep models (254,255,544). Similarly the majority of studies 
published however instead compare cells either directly from adult and fetal tissue 
collected post-mortem or from 3D cultures, rather than 2D cultures (344,396,545–549). 
In fact, studies which compare freshly isolated tissue of the limbs (tendon, ligament, 
cartilage and bone) compared to their 2D cultured counterparts have shown that even 
between tissues, 2D cultured cells cluster and have fewer differences than their native 
counterparts further highlighting that, when unperturbed, culturing primary cells in 
monolayers can result in a loss of their native gene expression profile (240).  
Yet despite this lack of transcriptomic difference detected in 2D, the results of previously 
published research indicate that adult and fetal tenocytes can still respond differently 
when subjected to different environmental factors when cultured in this manner. For 
example, when investigating the differences in equine adult and fetal cells’ migratory 
response to growth factors, TGF-β3, which is heavily involved in the wound repair 
process (306,412,413), is found to significantly inhibit fetal tenocyte migration, yet has 
no effect on adult tenocytes when cultured in 2D (376). Similarly, sheep fetal tendon 
fibroblasts were shown to have significantly greater rates of migration, producing more 
collagen type I when cultured in 2D wound healing scratch assays compared to adult 
tenocytes (550). The results presented in chapter 4 demonstrated that knocking down the 
gene SCX results in different global gene expression changes in adult and fetal tenocytes 
cultured in 2D. Therefore, taken together this suggests that it is how adult and fetal 
tenocytes respond to different stimuli that is important, and if we can better understand 
how they act in response to injury we are likely to be able to uncover how fetal tenocytes 
are able to orchestrate regenerative healing.  




Differences in gene expression detected in 3D versus 2D have mainly been attributed to 
the differences in how the cells are able to form connections between each other, which 
in 3D is thought to more accurately represent the cell junctions seen in vivo which allow 
for better exchange of molecules between cells (551–555). Cells cultured in 3D have also 
been demonstrated to have a greater capacity to deposit ECM, with both ECM proteins 
and growth factors consistently being increased as a result of 3D culture (551–555). In 
this study significant changes in gene expression were detected between adult and fetal 
cells cultured in a 3D environment and the results presented demonstrate that ESC-
tenocytes have a more similar transcriptomic profile to fetal as opposed to adult tenocytes 
when cultured in this way. However, to accept that the actions and responses of the cells 
to an injury environment, and not solely their gene expression profiles, demarcate the 
regenerative and reparative phenotypes, then more research is required to unequivocally 
determine if ESC-tenocytes would act in a fetal regenerative manner.   
The balance of pro- and anti-inflammatory activity, which is coordinated through 
cytokines, chemokines and growth factors has been shown to be altered in fetal and adult 
wounds. Whereas adult wound healing is accompanied by high levels of inflammation 
(556–561), fetal wounds have minimal inflammation (562). Furthermore, inducing 
inflammation in fetal wounds, such as through the injection of pro-inflammatory 
cytokines and growth factors typically present in the adult injury environment, has been 
shown to stimulate scar formation (330,335,563,564). Although ample evidence exists 
demonstrating the importance of the local wound environment on wound healing, it 
appears to not be the major reason for the different healing outcomes of adult and fetal 
tissue, as in contrast fetal tendons transplanted into an adult environment retain their 
regenerative capacity (255–259). It has therefore been suggested that instead it is the 
differences in cellular behaviour in response to injury signals that effects whether scarring 
ensues, with fetal cells ability to rapidly migrate towards an injury thought to be critical 
in limiting damaging inflammatory mediator induction that leads to scarring (296,562).   
Interestingly, upon comparing the adult and fetal gene expression profiles generated in 
this thesis, it was apparent that many genes involved in cell migration and inflammatory 
functions were DE, as indicated by the gene ontology (GO) analysis. Migration of 
resident cells is an important early tissue injury response that is critical for correct tissue 
repair (565). In skin, fetal fibroblast migration is increased in response to injury compared 




to adult fibroblasts, which is in part due to the differential balance of inflammatory 
signalling and growth factors within fetal and adult wounds (36,258,373–375,565,566). 
Chemokines, growth factors and growth factor binding proteins, all of which have been 
shown to play a role in cellular migration during wound healing (372–375), were amongst 
the genes associated with the enriched GO terms. In fact several of the genes identified 
are upregulated in adult tendon injuries including IGF-1 (insulin-like growth factor 1), 
bFGF (basic fibroblast growth factor), PDGF (platelet derived growth factor) and SDF-1 
(stromal cell derived factor 1) (404–407), all of which can influence cell migration (407–
411).  
Understanding how these factors produced in adult injuries regulate cellular activity is 
therefore an important next step and would help to determine whether ESC-tenocytes 
share some of these properties with fetal tenocytes, thereby strengthening the evidence 
for their clinical use. To do so would require the generation of extensive wound models, 
which could allow us to determine how adult, fetal and ESC-tenocyte act to close a 
wound, as well as model if and how an ESC therapy would work in practice. This could 
be done by determining how adult, fetal and ESC-tenocyte migration rates compare in 
2D wound healing assays. The effect of several of the growth factors and inflammatory 
mediators, identified in this thesis as DE and known to be present in the adult injury 
environment, on wound closure could then be compared (Figure 6.1).  
This could then be developed into a 3D system, where punch wounds could be made in 
cell seeded 3D collagen artificial tendon gels (154) to represent the typical central core 
lesion presented (567), and the rate of wound closure again compared with and without 
the addition of the growth factors and inflammatory mediators (Figure 6.1). Such a system 
could then be used to model the clinical scenario of applying ESCs to an adult tendon 
injury, by utilising fluorescently labelled adult tenocytes seeded in co-culture with either 
ESCs or fetal tenocytes labelled with different fluorophores (46) and the rate and effect 
on wound closure and matrix remodelling compared. Such in vitro tools would minimise 
the extent of future in vivo animal models needed.  





Figure 6.1. Tendon wound modelling. Schematic of potential wound healing assays which could 
be conducted to better understand the differences in how adult and fetal tenocytes respond to adult 
injury signals. Assays could be conducted using both 2D scratch assays as well as using 3D 
collagen gel hole punch assays. The responses could then be compared to that of ESC-tenocytes 
to give further evidence of their use as a cellular therapy.  
However, this simplified wound assay outlined above fails to account for the complexities 
of the real in vivo wound environment. In particular, the effect of immune cells, which 
play a large role in the wound healing process are not taken into account (568). Therefore, 
further optimisation of this wound healing assay could be conducted by seeding the assays 
with stimulated peripheral blood mononuclear cells to better recapitulate the inflamed 
adult in vivo environment. Once this system was established, further alterations could be 
performed such as looking at the effect of conditions known to alter the rate of healing 
including altered glucose levels and hypoxia (569,570). The effect of fetal or ESC-
tenocytes addition to the adult artificial tendons could again be examined to see how it 
impacts wound closure. Finally the application of a cyclic external strain could also be 
investigated to mimic the physical properties experienced in the tendon during healing; 
another key aspect which is missing in existing in vitro wound models (571). This could 
be done by seeding the 3D collagen gels in a bioreactor and performing the 
aforementioned punch assay, a system previously utilised in our laboratory (233).  




6.2.2.  Heterogeneity of the tendon cell population 
As discussed in chapter 3, although ESC-tenocytes have fewer DE genes when compared 
to fetal tenocytes as opposed to adult tenocytes, this study does not account for the 
heterogeneity of our sample populations. Cellular heterogeneity within various tissue and 
cell populations is being increasingly recognised as important for understanding how 
different tissue subpopulations function during development and disease, with studies 
using single cell RNA-seq (scRNA-seq) rising exponentially within the last decade (572). 
Prior to the advent of scRNA-seq, the sparse, heterogeneous and auto-fluorescent nature 
of the tendon cell population limited our ability to interrogate their diversity fully (573). 
Yet even with the introduction of scRNA-seq, few studies have been conducted using 
normal adult tendon tissue, with the numbers of bulk RNA-seq data available similarly 
being limited, particularly in terms of the number of biological replicates, developmental 
stages and species sequenced (397,573,574). This lack of transcriptomic data available 
highlights the need for greater collaborative efforts to be made. Having access to larger 
cohorts of tendon tissue and cellular transcriptomic and proteomic datasets at differing 
developmental stages would allow for a more accurate picture of tendon cell development 
and heterogeneity to be obtained. Taken together this could provide vital information for 
the development of reliable selective markers for key tendon cell populations.  
Looking at the limited scRNA-seq studies which have been conducted, it is clear that at 
least three distinct populations exist within the healthy adult tendon of humans and mice 
(397,573,574). The first reported scRNA-seq, which was conducted using only 71 
individual human tendon cells, isolated from a single healthy adult male which had 
undergone one passage in culture, described three main populations (397). The first 
expressed the endothelial cell-specific marker CD3 and nestin (NES), the second which 
was also NES positive had high tendon-related gene expression (COL1A1, TNC, Fmod) 
suggestive of a progenitor population, and the third, which contained the biggest 
proportion of cells, was composed of a NES negative population which expressed high 
levels of tendon lineage genes (THBS4, MKX) and CD146, suggestive of a mature 
tenocyte population. A more recent study of human tendon, which contained a data set of 
over 6,000 cells obtained immediately ex vivo from 8 healthy adult tendons, instead found 
eight distinct transcriptomic clusters, made up of five so called tenocyte populations 
which expressed collagen matrix genes, monocytes, T cell lymphocytes and endothelial 




cells, with NES positive cells being predominantly found in the endothelial cell cluster 
(573). These differing results were suggested to be due to the differences in the numbers 
of cells analysed, as well as due to potential unintentional preferential selection of cells 
during monolayer passaging (397,573).  
Consistent with this, a study of healthy 6-week old mouse Achilles tendon scRNA-seq 
identified 11 distinct populations, comprised of three tendon fibroblast-like groups, three 
endothelial cell groups, two nerve cell groups, immune cells, red blood cells and pericytes 
based on the analysis of four independent replicate datasets of over 1,000 ex vivo tendon 
cells (574). Interestingly, whilst all of the tendon fibroblast populations expressed 
COL1A1 only a small subset expressed the routinely described tendon specific marker 
SCX, a result which was confirmed with RNA in situ hybridization and SCX lineage 
tracing using SCX:R26tdTomato mice (574). Similarly, some populations were found to 
express TNMD but not SCX, whilst others were found to express both SCX and TNMD 
together. Differences in SCX expression in tendon subpopulations were also noted in the 
human scRNA-seq study, with only two out of the five having high SCX expression (573).  
In this thesis, using bulk RNA-seq data of in vitro passaged cells, SCX was found to be 
DE between adult and fetal tenocytes, with TNMD not being expressed at the mRNA 
level in either cell type. Considering, based on the scRNA-seq data available (573,574), 
that SCX and TNMD expressing cells appear to be limited to certain subpopulations of 
tendon cells this could suggest that the proportions of these different subpopulations 
differ in adult versus fetal tenocytes which could account for the differential expression 
observed in our bulk RNA-seq data. Similarly, it is unknown how the selective in vitro 
pressures change the ratios of these populations, with some potentially being 
unintentionally selected for during routine passaging. As our adult and fetal tenocytes 
were passaged multiple times prior to sequencing, it is unclear whether some populations 
are overrepresented as a result, which would alter the gene expression profiles obtained. 
Similarly, the ESC-tenocytes were not passaged following ESC tenogenic differentiation, 
and given it is likely that only one main population of immature tenocytes would arise 
following this relatively short differentiation protocol, having access to scRNA-seq data 
of equine adult and fetal tendon would be of great use to determine which tenogenic 
population arises following this differentiation protocol.  




Computational methods already exist which use deconvolution algorithms to infer 
scRNA-seq cell type and cellular state compositional information from bulk RNA-seq 
data (575). The bulk data generated in this study could therefore be of great use to help 
deconvolve the different cell types present in the adult, fetal and ESC-tenocyte 
populations (Figure 6.2). Similarly, this data could be used to uncover the cell populations 
present in RNA-seq profiles of injured tendon tissue from different developmental stages 
to deconvolve the cell-type gene signature present during injury. Together this 
information could help determine if different populations respond to injury in fetal 
regenerative healing, whether a small subset of these cells are present within the adult 
tendon, and how best to select for this population of interest for use as a cellular therapy. 
Although the scRNA-seq datasets currently generated are of great value, limitations arise 
due to technical differences between the donors used, batch variation, anatomical site 
sequenced, sex of the donors, as well as donor age (573,574). Similarly, concerns have 
also been raised over the methods required to prepare single cells from tissue, with some 
suggesting this could result in preferential selection of certain populations over others 
(573). As cellular heterogeneity is likely to change between individuals as well as 
throughout tendon development, this further highlights the need for more sequencing data 
to be generated, with additional insight likely to be obtained by analysing tendons across 
many different sites, developmental stages and injury timepoints (574) (Figure 6.2). 





Figure 6.2. Theoretical experiment using scRNA-seq. Schematic showing a theoretical 
workflow for determining the gene expression signature and population dynamics in different 
stages of tendon injury and development. 1) A tendon tissue biopsy from the SDFT obtained from 
fetal, young postnatal and adult horses would be prepared by dissociating the tissue into single 
cells immediately ex-vivo. Resulting cells would then be subjected to scRNA-seq and clustering 
and cell type annotation performed. 2) The cell type clusters identified would then be validated 
using data from other scRNA-seq experiments of the same tissue. 3) The bulk RNA-seq data 
presented in this thesis could then be used to deconvolve and confirm the cell types present in the 
tendons from the different developmental stages which could then be compared to the ESC-
tenocytes to determine which population fraction they appear to be. This could also inform as to 
which populations may be unintentionally selected for in culture. 4) Previously published datasets 
or newly published studies looking at the RNA-seq profiles of injured tendon tissue from different 
developmental stages could then be used to deconvolve the cell-type gene signature present 
during injury. This information could help determine if different populations respond to injury in 
adult reparative and fetal regenerative healing. Figure inspired by Rubenstein et al., 2020 (576).  
 




6.2.3. SCX as a therapeutic target 
As described in section 6.2.2 although SCX has always been thought of as a selectable 
marker for tendon cells, it is clear that its expression is actually quite heterogeneous 
within the tendon cell population (573,574). Glimpses of this heterogeneity have also 
been indicated in adult injury repair models, with various SCX tracking systems showing 
that SCX positive cells are the main players in the injury repair process (161,429–
431,577), playing a key role in the induction of fibrosis in various adult tissue types (see 
chapter 4). However, the role of SCX in fetal injury repair has not been reported.  
In this thesis, using SCX knockdown it was apparent that in adult and fetal tenocytes SCX 
regulated ECM genes and fibrillar collagens differently. This mechanism of SCX 
dependant modulation of ECM and collagen gene expression is being increasingly 
documented, and appears to be conserved across tissues (428,444,578). Changes in the 
ECM and collagen synthesis are well recognised as important factors in wound healing, 
the composition and arrangement of which determines if scarring presents (278). Taken 
together, if SCX differentially regulates ECM production and degradation in adult and 
fetal injuries, could this affect whether or not tendon fibrosis ensues? If this is the case, 
the ability to modulate SCX function may therefore provide a mechanism to fine tune the 
rate of ECM production and degradation to improve wound healing, thereby preventing 
unwanted tissue fibrosis (578).  
A recent study, which has not yet undergone peer-review, has described that SCX 
depletion in adult mice improves tendon healing, with injured tendons displaying reduced 
stiffness, increased maximum load to failure and differential expression of matrix related 
gene expression post injury compared to wild type littermates (579). SCX therefore 
presents as an interesting target for therapeutic drug design. However, several factors 
need to be considered when designing drugs to target transcription factors which have 
historically been considered ‘undruggable’ (578,580,581). These include the fact that 
transcription factors function via protein-protein or protein-DNA interactions and so 
typically lack active sites, unlike enzymes for example which have ligand-binding sites 
which make them more suitable for binding of small molecules (578,582). Similarly 
transcription factors lack pores or channels and generally have shallow surface 
involutions which again prohibit small molecule binding (578,582). Strategies to 
modulate transcription factors are being developed, which include manipulating 




transcription factor DNA binding domains using peptidomimetics or blocking protein-
DNA binding by compounds that compete with the transcription factor, which may allow 
SCX to be targeted (581).  
However, SCX has the added challenge of being intracellularly expressed, therefore it is 
likely that any therapeutic would first have to target tenocytes prior to being internalised 
which, due to the lack of specific markers defining the tendon cell population, is likely to 
prove difficult (583). This further highlights the need for collaborative efforts to generate 
more transcriptomic data to allow reliable tendon cell markers to be determined. Another 
translational barrier includes our limited understanding of the effects of inhibiting or 
activating SCX in vivo. As described in chapter 4 and 5, SCX is highly expressed across 
a variety of ECM rich tissue types, with its role likely to be highly context specific, 
therefore off-target effects need to be considered during drug design. Further studies 
using pre-clinical models of tendon fibrosis are therefore required to evaluate the effects 
of SCX interference in a clinical setting across tissues. 
An alternative strategy for modifying SCX expression therapeutically may be to target 
another candidate or pathway upstream of SCX. TGF-β is a key mediator of tendon 
remodelling and has been demonstrated to be an upstream regulator of SCX expression 
(140,154,175,182,446–448,457,465). Three main TGF-β isoforms are involved in the 
wound repair process, the expression of which differs in adult versus fetal wounds 
(41,278,544). In fetal wounds TGF-β3 is elevated in comparison to TGF-β1, whereas in 
adults TGF-β3 has a delayed expression with TGF-β1 showing more rapid induction and 
slower clearance from the wound (41,278,544). As such TGF-β3 has been postulated as 
being anti-fibrotic, with the addition of exogenous TGF-β3 in some animal models 
showing decreased scar tissue formation (584,585). Conversely, TGF-β1 has been 
considered as pro-fibrotic, with studies blocking its expression showing some reduction 
in scar tissue formation (584,586). Attenuation of TGF-β expression, such as through the 
use of a TGF-β receptor inhibitor, may therefore provide a means to augment SCX 
expression as described in vitro (587). However, due to the huge variety of roles played 
by TGF-β across many cell and tissue types caution would again need to be exercised.  
Considering that alteration of SCX and potential upstream targets of SCX expression may 
have such wide-ranging effects in vivo, the data presented in this thesis acts as a crucial 
resource to help bridge the gap in our understanding of SCX-dependent gene regulation. 




By carefully comparing and contrasting the biology between fetal and adult tendon cells 
and how SCX may differentially affect gene expression and ECM composition during 
injury repair it is possible that new targets for therapeutics may be determined (Figure 
6.3).  
One potential candidate for further investigation is platelet derived growth factor subunit 
B (PDGFB). PDGFB was significantly decreased following SCX knockdown in fetal 
tenocytes, with SCX being demonstrated to directly bind to an E-box within its promoter 
region suggesting that SCX directly regulates fetal tenocyte PDGFB expression. In adult 
SCX knockdown tenocytes however, no significant difference in PDGFB expression was 
found. SCX did appear to be bound to the PDGFB gene promoter in adult tenocyte, 
however the lack of effect on PDGFB gene expression following SCX knockdown 
suggests that SCX may only be passively binding, requiring other co-activators to activate 
its expression. As described in section 6.2.1, growth factors are known to play a key role 
in tissue healing, having multiple functions including stimulating cell proliferation, aiding 
angiogenesis, orchestrating cellular differentiation and stimulating chemotaxis (588). 
PDGF is one such growth factor which is heavily implicated in wound healing, being a 
potent chemoattractant and mesenchymal cell mitogen (589–592). Furthermore, PDGF 
has been demonstrated to increase fibroblast proliferation, migration and collagen 
synthesis, with its in vivo application into incised skin wounds showing enhanced ECM 
deposition during the wound healing process (593–598).  
In chapter 3, PDGFB mRNA expression was significantly increased in both 3D cultured 
fetal tenocytes and ESC-tenocytes compared to adult tenocytes. Fetal rat lung fibroblasts 
and fetal rat skin have also been demonstrated have increased PDGFB expression, which 
decreases with gestational age (589,599). The levels of PDGF and its receptors are 
similarly decreased in diabetic and aged mice which display delayed wound healing, as 
well as being reduced in nonhealing human ulcers (600–602). In fact, PDGF-BB, the 
protein product encoded by the PDGFB gene, is already approved for topical treatment 
of diabetic non-healing foot ulcers (603), with clinical trial data showing as much as a 
39% increase in wound healing compared to the placebo (604,605). The use of PDGFB 
gene delivery into rat Achilles tendons has also been investigated, with treated tendons 
demonstrating accelerated healing compared to untreated controls. PDGFB induction 
resulted in tendons with significantly greater maximum load to failure, maximum stress 




and Young’s modulus as well as higher structural organisation as observed by histological 
analysis (606). Likewise in vivo induction of the PDGFB gene in healing rat ligaments 
resulted in enhanced collagen and ECM deposition, enhanced angiogenesis and 
accelerated healing (593).  
Taken together with the results demonstrated in this thesis, PDGFB therefore presents as 
an interesting candidate for future studies. It would therefore be worth further 
deconvolving this potential pathway between SCX and PDGFB, as well as determining 
if PDGFB is DE during fetal and adult wound healing. Using the aforementioned wound 
healing models (section 6.2.1) altering PDGFB expression via gene delivery could also 
be conducted to determine its effect on the rate and degree of wound healing in adult 
equine tenocytes. As ESC-tenocytes had similar high expression of PDGFB compared to 
adult tenocytes it would also be worth determining if SCX knockdown also alters PDGFB 
expression like that of fetal tenocytes, and whether ESC-tenocyte addition to the wound 
healing model would result in increased PDGF levels and effect the rate of wound 
healing.  
 





Figure 6.3. Theoretical model of adult injury/repair and potential therapeutic interventions. 
Damage and physical force have been demonstrated to induce both the expression of growth 
factors, as well as SCX expression in the injured tendon. How this induction occurs is not fully 
understood. Injury-induced induction of growth factors, including TGF-β, have been 
demonstrated to increase SCX expression in tenocytes. Up-regulation of SCX in response to TGF-
β, and potentially other factors as represented by the dashed lines, leads to changes in the 
expression of various downstream target genes, including collagens and ECM proteins. Which 
collagens and matrix proteins are affected may result in whether scarring ensues. It has therefore 
been hypothesised that scarring may occur due to inappropriate SCX expression. This indicates 
SCX or genes upstream of its regulation as potential therapeutic targets. Or similarly, by carefully 
examining the data produced in this thesis to identify genes that are downstream of SCX 
regulation in fetal regenerative and adult reparative cells, other potential candidate genes or 
pathways involved in the scarring phenotype could be determined. 
6.2.4. Are ESCs now safe for therapeutic use?  
Given the information generated in this thesis, the question remains: Where do we now 
stand on using ESCs therapeutically? As suggested in section 6.2.1 more work is still 
required to determine if ESC-tenocytes function like that of fetal tenocytes in a wound 
injury environment, but there is still another key factor which needs to be considered. 




Although tendon injuries have historically been characterised as degenerative conditions 
devoid of inflammation, our understanding of the disease paradigms have shifted (607). 
In both horses and humans evidence now indicates a strong inflammatory response is 
present, with a range of inflammatory cells and cytokines being induced following tendon 
injury, some of which are described in chapter 1 (558,608–610). In contrast, one of the 
hallmarks of scarless fetal tendon healing is a dampened inflammatory response, with the 
fetal wound microenvironment having fewer resident and recruited circulating 
inflammatory cells as described in chapter 3 (284,324,326–333). Many of these 
inflammatory cells and released factors have negative impacts on local tendon cells, 
resulting in the production of inappropriate levels of collagens and matrix proteins which 
can ultimately results in fibrosis (610). Considering the negative consequences of 
inflammation on endogenous tendon cells, this leads to the question: Will the same occur 
to those applied during a cell-based therapy? 
Equine ESCs and ESC-derived tenocytes have been demonstrated to be immune 
privileged, with allogeneic immune cells showing no proliferation in response to their 
addition in vitro (72,107). Similarly, in vivo studies in the horse have shown high survival 
rates of injected ESCs into mechanically induced SDFT injuries with a gradual decrease 
in leukocytes at the injection site, suggesting that they do not induce immune cell 
stimulation over a 90 day period (91). More recently they have also been demonstrated 
to possess a degree of protection from the effects of inflammatory cytokines, including 
IL-1β, due to a failure to activate the NF-kappa B signalling pathway which regulates 
multiple aspects of the innate and adaptive immune system (608,611,612). Studies using 
human and mouse ESCs have also demonstrated that the interferon system, another 
fundamental component of the innate antiviral immunity in differentiated cells (613), is 
underdeveloped in ESCs which similarly contributes to the lack of immune response 
observed by pluripotent cell types (612,614–618).  
ESCs lack of inflammatory response is likely due to the fact that during early 
development any negative changes in proliferation and differentiation, as a result of 
negative inflammatory regulators, could severely impact embryonic development, and as 
ESCs reside within the womb the maternal immune system likely acts as the main source 
of protection (612). The lack of inflammatory response by ESCs and ESC-derivatives 
may provide an advantage for ESC-derived cellular therapeutics as the implanted cells 




would not respond to the inflammatory response already present in the wounded area, 
thus preventing additional damage caused by the host’s immune system (612). However 
it remains unclear whether over longer periods transplanted ESC-derivatives would 
develop the ability to respond to inflammation and lose their immune privileged status 
leading to their rejection (608).  
Unlike MSCs, ESCs do not appear to be capable of modulating the immune environment 
(72,107). As such, although they themselves may be protected from inflammation upon 
therapeutic injection, the endogenous adult cells will remain unprotected and will 
therefore likely still contribute to scar tissue formation. It may be the case that therapeutic 
strategies using cell therapies in conjunction with other pharmaceuticals which can reduce 
inflammation, may be a better solution for treating tendon injuries. Further 
characterization of ESC-tenocytes long term response to inflammation, and to what 
degree the hosts immune response may affect them if they were applied therapeutically 
is therefore required (612). The data collected in this thesis may help in this objective, 
allowing immune response pathways which potentially facilitate this immune protection 
to be uncovered.  
Data from this thesis has already assisted other work within our laboratory, looking at the 
effects of the inflammatory cytokine IL-1b on adult, fetal and ESC-tenocytes. IL-1b is a 
key inflammatory cytokine which is upregulated rapidly following tendon injury (619) . 
It has been shown to induce tendon fibroblasts to increase expression of inflammatory 
and catabolic enzymes including IL-6 and MMP-13 (34), and reduce expression of type 
I collagen leading to tendons with reduced elastic and tensile strength (620). Molecules 
which regulate IL-1 signalling include the IL-1 receptor antagonist IL-1RA, encoded by 
the IL-1RN gene. IL-1RA competitively binds to the IL-1R1 receptor, which is 
responsible for IL-1 signal transduction, preventing IL-1b from inducing an 
inflammatory, angiogenic or haematopoietic response (621). Interestingly, from the 
RNA-seq data presented in this thesis, it is evident that ESC-derived tenocytes were found 
to have significantly lowered expression of the IL1-R1 receptor gene as well as a 
significant increase in IL-1RN expression, relative to adult tenocytes. This suggested that 
IL-1b could be being blocked from interacting with the IL-1R1 receptor and thus 
potentially not eliciting as substantial an inflammatory response through this system. 
Similarly, the ESC-tenocytes, in comparison to both fetal and adult tenocytes, showed 




significantly increased expression of IL-1R2, the gene which encodes what is known as 
the decoy receptor which acts as an endogenous inhibitor of the IL-1 signalling pathway 
(621). This finding was further explored at the protein level and taken together helped to 
strengthen the evidence that ESC-tenocytes are protected from the detrimental impact of 
IL-1b (608). As many other inflammatory genes and receptors including several members 
of the interferon gamma (IFN-γ) and tumour necrosis factor (TNF) families were also 
found to be DE in ESC-tenocytes compared to adult tenocytes, further investigation into 
the effects of such inflammatory factors on these different cells types may shed more light 
on ESC-tenocytes inflammatory protection.  
Other obstacles in the way of clinical translation of ESC-derived cells include concerns 
about their safety and ability to be produced commercially in line with good 
manufacturing practice (GMP) (622). Safety and toxicity studies should be carried out to 
ensure that the stem cell derivatives are nontoxic and clinical trials should be conducted 
to test for any acute infusion toxicity resulting from the damage at the injection site as 
well as in the adjacent tissue (622). Similarly karyotyping stability analysis should be 
conducted on ESCs and ESC-derivatives to minimise potential tumour development 
(623). The inherent genetic and epigenetic variability of ESCs also needs to be taken into 
consideration, as it can lead to variability in the differentiation potential and purity of the 
final cell product. Therefore extensive safety and purity testing would need to be 
conducted on a cell line to cell line basis (622). Although the clinical requirements for 
animal and human therapeutics differ, equine pluripotent cell derivatives would likely be 
held to similar regulatory scrutiny, including adherence to current GMP and rigorous 
quality control. For human cell therapies, the use of defined culture systems which avoid 
using chemically undefined materials or those of animal origins are required, which 
would present an issue for equine ESC culture which relies on the use of fetal bovine 
serum and mouse embryonic feeder cells to support them (622,623). Ongoing advances 
to improve equine ESC culture and insurance of reliable cellular differentiation into the 
desired cell population for therapeutic use are therefore required before considering their 
use clinically. 




6.2.5. Concluding remarks  
Overall the data presented in this thesis provides an important insight into the 
fundamental differences between adult reparative and fetal regenerative cells. Further 
mining of these data sets alongside comparison to other publicly available data is likely 
to help identify key factors involved in the scarring process and highlight if ESC-derived 





















List of additional data contained in appendix A: 
 
1. List of 441 genes identified as differentially expressed between adult and fetal 3D 
cultured tenocytes using both HISAT2 and Salmon mapping pipelines.  
 
2. List of 113 genes identified as differentially expressed between adult and fetal 3D 
cultured tenocytes using HISAT2 mapping only. 
 
3. List of 101 genes identified as differentially expressed between adult and fetal 3D 
cultured tenocytes using Salmon mapping only.
  198 
Table A1. List of DE genes between adult and fetal tenocytes cultured in 3D identified using 
both alignment-based and alignment-free mapping. 441 genes identified as being DE in adult 
and fetal tenocytes cultured in 3D using both HISAT2 alignment-based and Salmon alignment-
free mapping using a p-adj of < 0.01 and ±2 Log2FC.
Ensemble Gene ID 
 
Gene name 
HISAT2 mapping Salmon mapping 
Log2 FC p-adj. Log2 FC p-adj. 
ENSECAG00000000136 FERMT1 -2.341533 0.00019245 -2.2928457 1.5161E-05 
ENSECAG00000000178 RUNX1T1 3.67764308 0.00040125 3.90848913 2.3893E-06 
ENSECAG00000000197 TLR3 -4.2669688 0.00129345 -4.2296717 0.00130197 
ENSECAG00000000207 ACTA1 4.77285617 0.00014215 4.58471547 0.00047126 
ENSECAG00000000239 FNDC1 4.26812098 0.00054429 4.9822643 3.6938E-08 
ENSECAG00000000250 CILP2 6.41796104 7.1199E-09 6.23329495 2.8782E-08 
ENSECAG00000000353 HPSE2 2.7564817 0.00128162 2.84937111 0.00635759 
ENSECAG00000000487 SYNM 3.60778085 8.1415E-16 3.71384156 3.876E-14 
ENSECAG00000000599 PCDH7 -2.2547179 1.3041E-06 -2.279693 1.3714E-06 
ENSECAG00000000607 TRIB3 2.15943662 0.00037732 2.16287566 0.00012748 
ENSECAG00000000627 PDZRN4 4.36965886 0.00093755 4.42726835 0.00229385 
ENSECAG00000000734 HMGA1 -3.4200441 5.2784E-16 -3.2671461 2.3321E-14 
ENSECAG00000000794 EMB -3.2597391 0.00015949 -3.4919696 0.00033872 
ENSECAG00000001021 ARL4D 2.188635 8.6134E-07 2.07512549 2.3981E-06 
ENSECAG00000001688 PCSK6 2.50487687 0.00015877 2.55598718 5.4715E-06 
ENSECAG00000001716 PLXNA2 2.76268237 6.4402E-06 2.76037931 5.1934E-07 
ENSECAG00000001775 RAB38 -2.1486168 0.00049394 -2.009058 0.00560114 
ENSECAG00000001845 P2RY1 5.45203974 0.00530962 4.71114096 0.00823615 
ENSECAG00000002211 CD80 -4.0564748 0.00018706 -4.2007679 6.6853E-05 
ENSECAG00000002225 SLC6A9 2.25208921 3.5192E-06 2.32291777 5.6812E-08 
ENSECAG00000002523 SOWAHB -3.6340245 0.00220145 -3.7663331 0.00810117 
ENSECAG00000002918 BMP7 -5.9741652 5.8711E-08 -5.8157359 1.0491E-07 
ENSECAG00000003072 TCIM -2.9589384 2.8621E-05 -2.995744 4.9934E-08 
ENSECAG00000003106 C3AR1 -4.6097727 0.0013045 -4.8672658 0.00041079 
ENSECAG00000003201 PRSS35 2.4574136 0.00771137 2.46807185 0.00019981 
ENSECAG00000003260 ITIH5 3.82392471 0.00052453 3.79864558 0.00145321 
ENSECAG00000003266 PIRT -3.5618165 4.3714E-05 -4.2829499 0.0037617 
ENSECAG00000003277 REL -2.5969253 7.9618E-11 -2.5127539 5.3694E-10 
ENSECAG00000003563 BST2 -6.2736958 0.00090832 -5.8053981 0.00092009 
ENSECAG00000003748 PYROXD2 3.30303158 7.4154E-07 4.23272918 3.0215E-07 
ENSECAG00000004234 MMP28 3.93778509 4.0577E-07 4.06595303 4.7699E-06 
ENSECAG00000004274 IQGAP2 -2.7727862 0.00085209 -2.8559454 0.00186826 
ENSECAG00000004408 GPR1 3.78414544 0.00204524 4.28532415 0.00457052 
ENSECAG00000004433 
 
-5.835328 0.00807216 -5.0445845 0.00886545 
ENSECAG00000004501 FDCSP -6.6847223 0.00118253 -5.6575216 0.00105275 
ENSECAG00000004678 CYSLTR2 -6.5306547 6.8525E-07 -6.2679821 2.5762E-11 
ENSECAG00000004913 LPAR6 -3.9495141 7.0539E-06 -3.8467496 1.0309E-12 
ENSECAG00000005046 MAB21L2 6.43702054 1.5675E-11 6.58767315 1.2007E-09 
ENSECAG00000005302 GJB5 -2.3111674 0.00520971 -2.3417413 0.00238449 
ENSECAG00000005384 SPRY4 -2.5111307 3.831E-05 -2.5309516 8.2592E-06 
ENSECAG00000005468 PTPRN -4.6703276 9.662E-05 -4.8962991 2.1748E-07 
ENSECAG00000005515 GCNT4 -3.9371659 0.0058059 -4.5854534 0.00019981 
ENSECAG00000005573 LOXL4 4.21243948 2.3676E-51 5.03891971 1.0896E-55 





ENSECAG00000005704 CARD11 -5.3134338 3.7108E-07 -5.3185911 3.0493E-06 
ENSECAG00000005794 MYRIP -3.5737136 1.4054E-05 -3.7798034 1.2321E-08 
ENSECAG00000005814 NEDD9 -2.0598726 0.00013424 -2.0359116 0.00020861 
ENSECAG00000005880 RIMKLA 2.76506368 0.00044877 2.65204752 0.00151916 
ENSECAG00000006011 RALGPS2 -2.0452634 9.2724E-06 -2.0344183 5.6856E-08 
ENSECAG00000006269 SHISAL1 -2.62105 0.00081358 -2.8407084 0.00319114 
ENSECAG00000006288 
 
-2.570234 0.00058339 -2.6747484 0.00026787 
ENSECAG00000006290 TGM2 -3.5348761 7.2032E-10 -3.6121988 5.1433E-12 
ENSECAG00000006338 ANKH 2.95687034 1.9182E-17 3.0175591 1.2121E-17 
ENSECAG00000006466 CLDN4 -3.0147664 1.0353E-05 -3.2621497 2.9936E-10 
ENSECAG00000006482 CRISP2 -8.1319114 0.00017186 -7.3133794 0.0003983 
ENSECAG00000006511 MCHR1 -2.743014 0.00090744 -2.7767734 0.00025378 
ENSECAG00000006554 PRRG4 -4.6587619 4.3413E-07 -4.377222 2.5967E-06 
ENSECAG00000006567 SLITRK4 -8.3325272 1.2582E-21 -8.5344888 1.8443E-31 
ENSECAG00000006646 MUC1 2.11697132 0.00093599 2.14480336 0.00114485 
ENSECAG00000006669 ACSM3 3.69286944 1.5798E-07 5.38751195 1.0778E-05 
ENSECAG00000006764 CCL20 -2.8715593 8.7989E-09 -2.6258628 7.1817E-05 
ENSECAG00000006829 KAZN -2.0180576 1.8215E-16 -2.0064087 8.1567E-15 
ENSECAG00000006867 CDC42EP2 -2.2710903 0.00288405 -2.1874499 0.00618302 
ENSECAG00000006880 WNT16 -4.3050993 0.00040771 -4.4414496 0.00097527 
ENSECAG00000006914 ELFN2 -2.6759538 4.505E-05 -2.5701959 0.0001013 
ENSECAG00000007066 RASSF4 2.59247127 6.7751E-05 3.14052841 0.0006905 
ENSECAG00000007242 DUSP2 -4.4615291 0.00523304 -4.6905128 0.00369096 
ENSECAG00000007246 CDH8 -4.008536 0.00033632 -3.6375474 0.00246826 
ENSECAG00000007379 KCNE3 -5.2660709 1.8237E-11 -5.1955568 4.966E-18 
ENSECAG00000007388 ADCYAP1R1 -7.0114935 0.00026051 -6.471501 0.00058952 
ENSECAG00000007395 FAM160A1 2.55876033 1.0627E-07 2.48034315 4.9623E-06 
ENSECAG00000007432 PTGDR -5.5693061 0.00022851 -5.5555118 0.00033709 
ENSECAG00000007540 CYP7B1 -2.0151221 3.9474E-05 -2.048868 0.00011698 
ENSECAG00000007584 HCN1 -5.5369906 0.00095178 -5.5094149 0.00342251 
ENSECAG00000007588 EREG -4.2632313 0.00018887 -4.0866166 1.5956E-06 
ENSECAG00000007761 DSC2 -4.3958865 1.0372E-15 -4.5078975 4.1397E-10 
ENSECAG00000007825 CALCA -4.5051221 0.00483056 -4.0089898 0.00690374 
ENSECAG00000007918 TNS4 -4.0066786 3.5253E-06 -4.2496032 2.6796E-08 
ENSECAG00000007960 LIMD2 -2.4057232 0.00484533 -2.416066 0.00357234 
ENSECAG00000007974 GALNT3 -5.0255001 0.00151866 -4.5100546 0.00673051 
ENSECAG00000008049 EPOR 2.81617619 9.496E-07 2.84468637 3.3667E-05 
ENSECAG00000008193 UPP1 -2.086778 0.00015394 -2.038898 0.00049095 
ENSECAG00000008270 FABP5 -2.1524375 0.00075842 -2.3238343 5.6519E-05 
ENSECAG00000008330 RIPK4 -2.0948989 0.00031084 -2.0457534 2.0722E-05 
ENSECAG00000008335 PDK4 -2.7938745 0.00649576 -2.8267977 0.00384434 
ENSECAG00000008425 LURAP1L 5.08907931 1.3715E-13 5.2726881 8.1444E-18 
ENSECAG00000008483 GXYLT2 3.34432413 8.0214E-06 3.64031273 2.1748E-07 
ENSECAG00000008512 ANKRD33 -3.6948136 0.00130399 -3.7434643 0.0002711 
ENSECAG00000008569 TMTC1 3.42818595 0.00274336 3.93095053 5.2856E-06 
ENSECAG00000008799 ENPP4 3.02171643 0.00025991 2.9104868 0.00059637 
ENSECAG00000008830 WNT5A -4.0419136 3.0943E-05 -3.8792772 2.7193E-05 
ENSECAG00000008871 ALDH1A3 2.6073234 0.00075395 2.51436654 0.00139635 
ENSECAG00000008923 THBS1 2.18960517 0.00490194 2.14916222 1.2916E-08 
ENSECAG00000008940 TMEM40 3.04498252 0.00128661 3.31016443 0.00169943 
ENSECAG00000008993 HIP1R 2.21529678 1.345E-17 2.17187095 8.0079E-19 
ENSECAG00000009011 FLRT2 2.24841091 0.00114766 2.45109542 5.8731E-05 
ENSECAG00000009038 TMEM255A 2.6311439 0.00017987 2.94093408 4.2899E-06 





ENSECAG00000009047 RIBC2 -4.7224658 2.5204E-06 -4.5845932 0.00025694 
ENSECAG00000009067 SLC16A6 -5.5676769 3.7676E-07 -5.9149941 8.2221E-07 
ENSECAG00000009136 PRXL2A -4.6277029 9.4944E-14 -4.2801895 7.1607E-19 
ENSECAG00000009165 IZUMO1 3.64902062 3.9633E-07 3.33655966 2.387E-05 
ENSECAG00000009316 EYA4 3.00456923 0.00804752 3.1398433 0.00333294 
ENSECAG00000009375 GASK1A 4.68501483 1.5155E-12 4.72476752 8.8428E-13 
ENSECAG00000009398 STS -2.0444101 1.9376E-09 -2.0081254 2.0003E-07 
ENSECAG00000009485 GPT2 2.11337777 0.00109661 2.20648848 0.00013745 
ENSECAG00000009515 ATRNL1 2.35322392 0.00147208 2.31114589 0.00205616 
ENSECAG00000009668 SCRG1 4.53657908 1.2452E-07 4.18998061 0.00023604 
ENSECAG00000009700 ANK3 -3.5194349 1.3541E-14 -3.6583586 8.5835E-16 
ENSECAG00000009707 PTGS1 -4.3359346 0.00193875 -4.6026289 0.00030653 
ENSECAG00000009723 IGF2BP1 -2.8319188 0.0020927 -2.6387243 0.00352383 
ENSECAG00000009742 S100A12 3.0176703 0.00105832 2.83512666 0.00286727 
ENSECAG00000009755 EPHB3 3.00741512 3.4378E-08 3.02931323 3.418E-08 
ENSECAG00000009779 SORCS2 2.9808972 0.00868468 4.07109889 4.2899E-06 
ENSECAG00000009839 VAT1L 3.81505934 6.2386E-06 3.76611532 5.6519E-05 
ENSECAG00000009887 COL21A1 -4.4545224 0.00038728 -4.5500276 0.0038423 
ENSECAG00000009916 GRIA4 -6.6105951 4.7445E-07 -6.5254339 0.00041079 
ENSECAG00000010048 IGSF11 -5.7392746 5.9224E-05 -5.4670265 0.00064118 
ENSECAG00000010098 GDPD5 2.17176242 2.4356E-06 2.15792352 1.161E-06 
ENSECAG00000010109 IGF1 5.31887202 6.6283E-07 5.70035693 4.9803E-07 
ENSECAG00000010118 SRGAP3 3.81657047 0.00015877 3.99716856 0.00176502 
ENSECAG00000010145 LPL -5.7381072 0.00015877 -5.5681756 7.6401E-05 
ENSECAG00000010238 CECR2 -4.3201175 1.3706E-17 -4.267903 1.1368E-16 
ENSECAG00000010558 PTGFR 2.73634194 6.6408E-06 2.75284184 7.7624E-06 
ENSECAG00000010573 CELSR1 -2.2120294 0.001453 -2.1848833 0.00187295 
ENSECAG00000010617 VGLL3 2.32801133 0.00077699 2.33876467 1.0732E-07 
ENSECAG00000010619 F12 2.42612524 4.7637E-10 2.38144394 1.565E-08 
ENSECAG00000010695 FGF21 5.22773832 7.4154E-07 5.09499831 5.0172E-11 
ENSECAG00000010700 CREG2 -2.1170458 0.00080862 -2.1167863 0.00523199 
ENSECAG00000010739 ITGA2 -3.0156319 0.00128661 -2.7468713 0.00187814 
ENSECAG00000010760 MEOX2 3.93970992 3.5408E-09 3.92542584 5.8459E-08 
ENSECAG00000010773 PLAG1 -3.811448 2.1066E-08 -3.7144938 1.6585E-08 
ENSECAG00000010778 VWF 4.45980086 0.006166 4.74931544 0.00881557 
ENSECAG00000010791 LMCD1 4.96197127 1.5667E-05 5.9484775 2.1667E-09 
ENSECAG00000010880 SOX6 2.82292549 3.6676E-05 2.59480777 0.00093069 
ENSECAG00000010917 HR 3.45912199 3.1047E-20 3.41467206 1.997E-18 
ENSECAG00000010928 MMP25 -4.2625304 0.00203897 -3.6161254 0.00881557 
ENSECAG00000011217 INHBE 3.74620239 0.00439768 5.12677257 1.9758E-05 
ENSECAG00000011229 SLC1A4 2.77792158 7.4501E-09 2.81862572 2.3929E-12 
ENSECAG00000011246 GLI1 3.1877193 3.4858E-05 3.36024139 0.0010811 
ENSECAG00000011404 SAA1 3.92059635 3.6676E-05 3.14671498 0.00056136 
ENSECAG00000011449 ANKS1B -3.9406144 0.00104941 -3.9969337 0.0019183 
ENSECAG00000011626 S1PR1 -4.4899513 0.00085209 -4.5430344 0.00070264 
ENSECAG00000011774 APCDD1 -3.6291738 3.5421E-05 -3.6803379 4.4259E-06 
ENSECAG00000011994 CYFIP2 -3.7137695 0.00026136 -3.3362598 0.00025378 
ENSECAG00000012061 CES2 2.4194751 0.0032751 2.89749544 0.00294133 
ENSECAG00000012189 PDE8B -4.474614 2.6939E-10 -4.6424131 3.3699E-09 
ENSECAG00000012212 LRP1B 6.88623685 0.00564666 7.87559141 0.00290038 
ENSECAG00000012229 BIRC3 -2.9177185 5.2775E-08 -2.7884153 1.3149E-08 
ENSECAG00000012253 CXCL11 -11.082013 0.00340506 -10.170191 0.00714945 
ENSECAG00000012282 MPP7 3.21352824 4.5591E-06 3.14332021 0.00014574 





ENSECAG00000012330 LRRC31 4.55384338 0.00148158 5.01789975 0.00261895 
ENSECAG00000012370 NPTX2 -5.6616042 0.00130399 -6.0744933 0.00393692 
ENSECAG00000012476 PROSER2 2.25472502 1.9074E-05 2.34852927 2.5322E-06 
ENSECAG00000012619 CASP14 4.61030456 1.3766E-05 4.97392359 3.9315E-05 
ENSECAG00000012662 SEMA3A -2.1879658 0.00409295 -2.0967904 0.00826553 
ENSECAG00000012734 BAIAP2L1 -2.5271569 4.9862E-14 -2.8539484 3.1362E-20 
ENSECAG00000012742 CXCL6 -2.8005259 8.1725E-05 -2.7496189 0.00027203 
ENSECAG00000012799 COL8A2 2.74091557 1.5798E-07 2.72025264 9.5808E-06 
ENSECAG00000012861 TBX3 -2.2270779 7.836E-05 -2.2219292 7.7681E-05 
ENSECAG00000012862 LYN -2.5401625 2.4484E-06 -2.5116837 5.5958E-10 
ENSECAG00000012887 CPZ 3.09730212 5.0165E-10 3.12447622 8.0309E-09 
ENSECAG00000012955 CD163L1 -6.8621826 0.00330189 -6.8290589 0.00222121 
ENSECAG00000013151 RGCC -2.848275 1.7963E-21 -2.7812529 2.182E-19 
ENSECAG00000013176 MEGF6 2.57832397 7.5613E-05 2.57033894 0.00022715 
ENSECAG00000013300 CXCL10 -9.1320788 0.00028358 -7.5602863 0.00115525 
ENSECAG00000013422 SLC12A2 -2.1150272 1.1343E-07 -2.1118252 3.4961E-07 
ENSECAG00000013515 SEMA3B 2.58766669 0.00118766 2.92254743 0.00051024 
ENSECAG00000013566 PKP2 5.36293348 1.5798E-07 5.18898846 1.8108E-07 
ENSECAG00000013582 DHRS3 3.10205658 5.9779E-09 3.16664357 7.3351E-12 
ENSECAG00000013584 PSAPL1 6.09640446 0.00043858 5.63803817 0.00295386 
ENSECAG00000013597 DAB2 2.06192089 2.3656E-05 2.20840572 1.7256E-10 
ENSECAG00000013677 FRY -2.8504223 5.2403E-05 -2.9054275 5.8487E-05 
ENSECAG00000013749 MBOAT1 2.69040878 1.0049E-07 2.7450555 3.5299E-09 
ENSECAG00000013771 PDE4D -2.1155845 6.8708E-09 -2.2243225 1.2271E-08 
ENSECAG00000013788 ARHGDIB -4.1692158 6.0393E-09 -4.1113517 1.0732E-07 
ENSECAG00000013869 
 
3.1217982 0.00338856 3.76415206 0.00018639 
ENSECAG00000013952 CADM4 -2.352879 0.00013409 -2.3955103 0.00015165 
ENSECAG00000014017 PRKG1 -3.7305763 0.00094603 -3.6554 0.0017102 
ENSECAG00000014243 GATM 4.97324108 8.7192E-17 5.05890143 2.3321E-14 
ENSECAG00000014287 OMD 3.07235008 0.00311271 3.02817537 0.00316067 
ENSECAG00000014295 PI3 -2.6971065 0.0082286 -2.539022 0.00126437 
ENSECAG00000014357 DLL1 -3.0370686 1.7193E-12 -3.0183911 4.2929E-13 
ENSECAG00000014358 RERG -4.1697883 0.00044931 -4.4133738 0.00015339 
ENSECAG00000014372 SLC9A3R1 -3.7192229 0.00387964 -4.0891085 0.0004864 
ENSECAG00000014414 SPI2 7.34623534 0.0002379 7.20655131 0.00814425 
ENSECAG00000014504 KIF1A 3.59543011 0.00136511 3.9405549 0.00019101 
ENSECAG00000014672 TNFRSF11A -3.8805198 0.0003906 -4.3222208 0.00015426 
ENSECAG00000014708 PTHLH -2.2279872 1.368E-12 -2.1537588 5.1433E-12 
ENSECAG00000014750 ALDH1A2 -4.9608027 0.00439016 -4.8358033 0.00032984 
ENSECAG00000014783 FAM43A -2.677412 0.00166933 -2.7670033 0.00245651 
ENSECAG00000014812 KRT23 2.36779776 5.282E-05 3.26439099 5.5958E-10 
ENSECAG00000014921 GPRC5A -2.7257797 0.00640809 -3.2920221 0.00013745 
ENSECAG00000014962 FAXDC2 -2.3272309 0.00240682 -2.4827037 0.00192911 
ENSECAG00000015029 TGFB3 2.81502591 0.00531843 2.83707647 0.00734538 
ENSECAG00000015115 RHBDL1 2.67948903 1.7867E-05 2.77884425 0.00012385 
ENSECAG00000015140 LIPG -4.300185 8.985E-07 -3.8960175 1.5365E-06 
ENSECAG00000015189 FAM216B -7.3302274 2.2393E-10 -7.5929736 6.6394E-08 
ENSECAG00000015198 CPM -5.6139571 5.4363E-06 -5.8724844 0.00042108 
ENSECAG00000015255 ARMC4 3.93963389 0.00304154 3.97445895 0.00652436 
ENSECAG00000015261 IL18 -2.4406115 0.00018706 -2.3525853 0.00012186 
ENSECAG00000015273 IRX1 -3.8023149 0.00022826 -3.5841664 0.00553434 
ENSECAG00000015275 
 
4.43513525 0.00568562 3.7530901 0.00030426 
ENSECAG00000015342 CXCL8 -4.0728402 2.55E-05 -3.6244808 0.00013216 





ENSECAG00000015613 SCUBE3 -3.7884725 6.2038E-05 -4.1662414 1.0167E-06 
ENSECAG00000015621 ARHGEF16 -3.1102131 0.00259947 -3.5565822 6.3667E-06 
ENSECAG00000015692 SERTAD4 2.68347725 9.5526E-05 2.98790501 6.7031E-07 
ENSECAG00000015840 PODN 3.05442542 1.6843E-05 3.39806146 4.6168E-09 
ENSECAG00000015848 HHIPL2 3.9816694 0.00115401 4.91673451 0.00433019 
ENSECAG00000015853 SORT1 2.0442427 0.00070645 2.01272178 0.00119935 
ENSECAG00000015958 NKD1 -3.3062348 0.00052769 -3.2884295 0.00094328 
ENSECAG00000015959 MYBL1 2.18118485 2.019E-07 2.26605464 1.2343E-07 
ENSECAG00000016019 ST6GALNAC2 -5.0467937 1.4617E-08 -5.0709552 1.8871E-07 
ENSECAG00000016121 ADAMTS12 -2.2266142 0.00138173 -2.2268432 0.00186727 
ENSECAG00000016228 CA2 -3.2351399 0.00706704 -3.3765707 0.00103336 
ENSECAG00000016232 IL22RA1 -2.2211795 0.00167849 -2.1677255 0.00768791 
ENSECAG00000016251 
 
-3.1989535 2.393E-06 -3.2481457 9.0802E-07 
ENSECAG00000016277 SGCD 2.31668385 0.00065092 2.4199453 2.5389E-05 
ENSECAG00000016322 CYP24A1 -5.3131645 2.8558E-05 -5.146603 4.2935E-06 
ENSECAG00000016339 ADAMTS1 -3.1921274 2.115E-07 -3.0729508 4.0282E-08 
ENSECAG00000016362 DUSP16 -2.0251336 1.0372E-15 -2.0344399 2.3593E-15 
ENSECAG00000016596 RARG 2.1291855 6.2297E-07 2.18256759 1.1776E-07 
ENSECAG00000016661 NR4A1 -2.6733536 0.0003906 -2.7052808 0.00042496 
ENSECAG00000016662 MCF2L -4.3829736 0.00025785 -4.1544271 0.00144421 
ENSECAG00000016669 ANGPT1 -3.0764428 0.00137237 -2.9579362 0.00358404 
ENSECAG00000016710 UPK3B 3.31417362 2.5213E-07 3.48211803 9.8178E-09 
ENSECAG00000016768 GATA2 -2.1757568 6.9123E-07 -2.1779557 4.1397E-10 
ENSECAG00000016773 NABP1 -3.0089798 3.2241E-11 -2.9491457 5.1433E-12 
ENSECAG00000016778 MKX 4.48814625 1.5358E-05 4.57462131 5.126E-05 
ENSECAG00000016784 
 
-3.7465819 0.00810509 -3.112424 0.00018137 
ENSECAG00000016797 IGF2BP3 -3.1757805 6.7268E-20 -4.5291167 3.0313E-21 
ENSECAG00000016829 ABTB2 2.21790673 0.00167849 2.25752889 0.00335875 
ENSECAG00000016997 KIAA1324L 3.5740961 0.00115401 4.21780782 7.4389E-10 
ENSECAG00000017059 OTULINL 2.05890446 5.4229E-05 2.0227202 0.0001583 
ENSECAG00000017157 IER3 -2.6425156 4.8036E-06 -2.7052895 1.1215E-09 
ENSECAG00000017172 IFI27 -3.1501309 0.00126092 -2.9046235 0.0031657 
ENSECAG00000017181 PTGS2 -5.9907409 4.2211E-11 -5.7665288 1.5272E-10 
ENSECAG00000017185 ZBP1 -7.735991 0.00563246 -7.1258264 0.00888139 
ENSECAG00000017294 SNTB1 2.726692 0.00381863 3.11931571 1.265E-08 
ENSECAG00000017379 CYP27C1 -2.5469988 0.00378897 -2.6740555 0.00191538 
ENSECAG00000017460 ATP12A -4.1783136 0.00393531 -3.8609243 0.00013207 
ENSECAG00000017468 TFAP2A -3.7010434 0.00011277 -3.8116969 0.00026364 
ENSECAG00000017495 NALCN 8.62648614 5.4088E-07 8.5012262 7.2438E-06 
ENSECAG00000017566 MVB12B 2.08344532 2.287E-07 2.0195273 2.187E-05 
ENSECAG00000017588 MMD -3.2595323 0.00015877 -3.1874601 3.9207E-05 
ENSECAG00000017615 CDH17 -5.1460809 3.4515E-09 -4.8809094 1.0348E-09 
ENSECAG00000017625 ITGB3 -2.4053428 0.00611135 -2.3808069 0.00427029 
ENSECAG00000017816 ADORA1 -3.330035 0.00197938 -3.4245937 5.8731E-05 
ENSECAG00000017826 TMEM26 -2.7942236 9.161E-06 -2.8136503 0.00026861 
ENSECAG00000017905 LTBP4 2.45433916 0.00079077 2.65486635 2.2117E-05 
ENSECAG00000017921 SUSD1 -2.5843441 3.355E-10 -2.6405919 1.5095E-09 
ENSECAG00000017988 FRMD7 4.00113699 2.7332E-06 4.3160619 3.4738E-16 
ENSECAG00000018067 ITGBL1 7.84294538 4.245E-17 8.34924268 1.4601E-20 
ENSECAG00000018104 IGFBP3 -4.9589598 7.3003E-07 -4.9641739 0.00014791 
ENSECAG00000018160 TBX21 -5.3078156 0.00294721 -4.7214316 0.00241451 
ENSECAG00000018182 TBX20 2.89190779 0.00097838 2.78345378 0.00504736 
ENSECAG00000018218 SYNPO2 3.51498464 2.5726E-05 3.8166235 5.0672E-07 





ENSECAG00000018472 PDGFB -5.6669401 9.5924E-12 -5.7883103 3.9319E-08 
ENSECAG00000018498 ERMP1 -2.3063207 1.9376E-09 -2.285986 5.1353E-08 
ENSECAG00000018514 ADAM23 -3.418859 0.00277703 -3.4105241 0.00238449 
ENSECAG00000018533 SALL4 -3.5686032 3.6676E-05 -3.437253 0.00015087 
ENSECAG00000018579 F11R -3.5782062 1.9099E-05 -4.1289729 2.3656E-11 
ENSECAG00000018670 ALCAM -2.2985035 1.0271E-07 -2.3386917 1.4411E-08 
ENSECAG00000018716 FGF9 4.68040105 1.563E-05 5.06502884 2.7934E-05 
ENSECAG00000018784 NIM1K 2.24362833 0.00257355 2.39199472 6.8E-07 
ENSECAG00000018841 CGA -6.1650069 3.4515E-09 -6.4359983 5.2923E-15 
ENSECAG00000018863 ADGRL3 3.31394473 6.4266E-33 3.30640822 5.5044E-34 
ENSECAG00000018961 ACTN3 2.18970844 2.9149E-06 2.41495301 7.1171E-07 
ENSECAG00000018963 COLEC12 3.28651032 7.7953E-05 3.70323525 1.3395E-06 
ENSECAG00000019055 TSGA10 -2.6720524 0.00011659 -3.2893851 1.4376E-05 
ENSECAG00000019060 ESYT3 -2.6418899 0.00148875 -2.7338254 0.00071148 
ENSECAG00000019148 TNFRSF25 2.17423901 1.4481E-06 2.54910759 0.00626309 
ENSECAG00000019193 NCAM1 -2.4898118 0.00123311 -2.2981031 0.00352383 
ENSECAG00000019378 KCNV1 -5.9694181 0.00105832 -6.1176314 0.0028497 
ENSECAG00000019391 TNFSF10 -3.1088043 0.00088706 -2.6656163 0.00169943 
ENSECAG00000019398 TFPI2 -5.4437248 0.00359148 -5.32566 0.00242609 
ENSECAG00000019408 CAT 2.83412886 6.8065E-08 2.79457432 7.5397E-08 
ENSECAG00000019431 RPS6KA6 -3.0645401 0.0001578 -2.9568484 0.0001583 
ENSECAG00000019460 MPPED2 -2.7762209 0.0055796 -3.0549174 0.00440466 
ENSECAG00000019549 CERS6 2.1668193 6.6475E-06 2.07605515 2.2969E-06 
ENSECAG00000019565 DLX5 2.26748915 0.00032301 2.38401066 8.6492E-07 
ENSECAG00000019617 ATP8B4 -2.2220791 1.3741E-07 -2.2032897 1.5634E-08 
ENSECAG00000019665 THBS4 5.76774627 2.4339E-06 6.44347205 0.0011023 
ENSECAG00000019677 EPHX1 2.83869295 0.00085631 2.90125826 0.00069936 
ENSECAG00000019805 WSCD2 6.75530299 1.2528E-16 6.69980512 3.3161E-15 
ENSECAG00000019940 AKAP6 -2.463918 0.00025456 -2.5162478 0.00121462 
ENSECAG00000019948 TNFRSF4 -4.0967582 0.00093407 -4.0489967 0.00300139 
ENSECAG00000019949 
 
2.7061962 1.2856E-05 2.62730017 0.00045342 
ENSECAG00000019958 ARHGAP20 -3.5421188 1.3789E-05 -3.4221145 1.797E-06 
ENSECAG00000019992 PIP5K1B 4.24182139 0.00047061 3.99378764 0.00124638 
ENSECAG00000020129 
 
4.25368184 9.7282E-18 4.34283464 5.1749E-43 
ENSECAG00000020311 BCO2 -2.7022472 5.02E-06 -2.7273886 1.7436E-05 
ENSECAG00000020407 MYBPC2 3.72171281 2.3319E-08 4.00085065 5.7237E-06 
ENSECAG00000020437 BCL2 2.56303207 0.00095178 2.56983569 0.00772621 
ENSECAG00000020456 ZBTB7C 3.90278988 5.1661E-10 3.7593439 9.1057E-07 
ENSECAG00000020489 SLITRK2 -4.1563859 0.00287016 -4.9622653 0.00244816 
ENSECAG00000020685 IGF2BP2 -3.841327 0.00020484 -3.9210676 0.00010719 
ENSECAG00000020693 HIF3A -5.9074552 8.5178E-05 -6.4815614 0.00014485 
ENSECAG00000020769 FGF1 -4.5542899 1.3355E-08 -4.6793649 7.2906E-07 
ENSECAG00000020810 TNFRSF18 -5.2712075 5.0064E-09 -5.5514838 8.4504E-10 
ENSECAG00000020956 SERINC2 -3.2007313 7.0217E-08 -3.2838639 1.8316E-25 
ENSECAG00000021009 GUCY1B1 -3.8498584 0.00037722 -3.970919 0.00015424 
ENSECAG00000021075 FGD6 -2.9484234 4.9862E-14 -2.9030196 8.3567E-15 
ENSECAG00000021108 RASIP1 3.21069958 1.0759E-09 3.01780652 5.9071E-12 
ENSECAG00000021125 TFAP2C -3.9438999 7.1326E-07 -4.2901833 5.2266E-08 
ENSECAG00000021326 NRAP -2.707811 3.0985E-07 -2.7860464 5.9075E-06 
ENSECAG00000021413 ADGRG1 -2.0482964 0.00019245 -2.2304588 3.352E-07 
ENSECAG00000021446 GRID1 -7.0965265 5.7545E-05 -6.8309753 3.4886E-05 
ENSECAG00000021448 PADI1 -2.4051672 0.00105012 -2.3580987 1.2635E-06 
ENSECAG00000021545 MTSS1 -2.0997918 5.4829E-07 -2.0676252 1.0916E-06 
ENSECAG00000021580 
 





ENSECAG00000021604 PDGFRL 3.99742933 1.4304E-09 4.21296254 1.4376E-05 
ENSECAG00000021634 SLC29A4 -3.7303842 3.089E-06 -3.9358127 1.4508E-06 
ENSECAG00000021700 FLT1 -6.1508998 7.8235E-10 -5.5456631 1.456E-10 
ENSECAG00000021735 EPHA6 -3.1304639 1.5456E-05 -2.9945099 0.00749362 
ENSECAG00000021778 SLC16A7 2.02553444 0.00057212 2.12166712 0.00032441 
ENSECAG00000021849 TFPI -3.690721 7.0593E-05 -3.5357114 3.9629E-05 
ENSECAG00000021903 LAMC2 -2.2495481 0.00030142 -2.1065809 0.00034167 
ENSECAG00000021914 PDE1C -3.5081494 0.00040724 -3.4234302 0.00044482 
ENSECAG00000022007 SCN9A -5.9368465 6.1308E-05 -5.9235494 5.4784E-05 
ENSECAG00000022015 ALOX12 -6.0709358 3.5674E-11 -7.1280942 2.8351E-26 
ENSECAG00000022141 TSLP -4.6653101 3.4628E-05 -4.5747041 4.0186E-05 
ENSECAG00000022232 SASH1 2.20123356 8.3682E-09 2.28112227 1.5635E-12 
ENSECAG00000022279 SERPINF1 2.9118206 0.00042524 2.92335337 0.00047418 
ENSECAG00000022291 CCDC69 -3.8393631 0.00010545 -3.5878058 0.00069832 
ENSECAG00000022333 MFSD4A -2.3869625 0.00820203 -3.6495821 0.00105375 
ENSECAG00000022515 MYO5B 3.25744484 4.54E-05 3.37509913 9.1221E-06 
ENSECAG00000022555 KLC3 4.08487287 1.1493E-05 3.87515622 3.9207E-05 
ENSECAG00000022618 INAVA -2.3955029 6.4333E-09 -2.3780334 3.3513E-08 
ENSECAG00000022659 CCL26 -4.09336 0.00128661 -4.1479729 3.4886E-05 
ENSECAG00000022703 LY5 -4.0154893 7.1326E-07 -3.5199995 3.9319E-08 
ENSECAG00000022724 CYP26B1 -2.873045 0.000216 -3.0349599 8.2387E-05 
ENSECAG00000022741 CDC42EP3 2.6872654 0.00066342 2.56500986 0.00608059 
ENSECAG00000022742 APBB1IP -2.3521725 0.00411546 -2.3543352 0.00641195 
ENSECAG00000022900 RAP1GAP -2.556878 0.00034106 -2.4670789 0.00130297 
ENSECAG00000022919 SIX1 2.27113681 1.4304E-09 2.25900589 2.6229E-10 
ENSECAG00000022924 EEF2K 2.0855619 1.6617E-11 2.1301541 4.732E-16 
ENSECAG00000022939 S100A1 3.09712772 5.9961E-12 3.08477339 1.0348E-09 
ENSECAG00000022944 THSD4 -2.4296467 0.00461336 -2.3030582 0.00088652 
ENSECAG00000023134 KCNK5 -4.6899962 2.2301E-08 -4.5607363 7.9194E-25 
ENSECAG00000023170 STAT4 -3.5500834 0.000788 -3.5642089 1.4027E-05 
ENSECAG00000023264 RTP4 -3.988211 0.00233288 -3.6846611 0.00426569 
ENSECAG00000023423 PRX 5.28349385 1.4273E-08 5.39235151 3.7198E-06 
ENSECAG00000023458 OLFM2 -5.934918 0.0020927 -5.1852642 0.00386807 
ENSECAG00000023472 KCNK2 3.2241896 2.6494E-08 3.18004797 2.9038E-07 
ENSECAG00000023607 DOCK5 3.58764123 5.2086E-06 4.00137502 1.5015E-08 
ENSECAG00000023663 LRP4 2.97420372 0.00085209 2.98320898 0.00151393 
ENSECAG00000023874 SPINT1 -2.343804 0.00011277 -2.4224244 1.3767E-07 
ENSECAG00000023888 ALDH1L2 2.04331711 0.000788 2.04672838 2.2986E-05 
ENSECAG00000023893 SERPINB5 2.19587457 0.0029746 2.07603771 0.0048333 
ENSECAG00000023908 OLFML2A -2.5125735 8.374E-06 -2.6864469 1.9373E-07 
ENSECAG00000023946 SDC3 2.14378568 3.6297E-05 2.11679881 7.1379E-05 
ENSECAG00000024011 ADGRF4 -5.8029086 0.00134012 -5.0959245 0.00290038 
ENSECAG00000024082 ITGAX -2.966916 0.00154815 -2.8224583 0.00213905 
ENSECAG00000024185 GNG11 -2.5911632 0.00024547 -2.6121683 0.00021977 
ENSECAG00000024232 A2ML1 2.20626745 0.00643461 2.38884075 0.00219589 
ENSECAG00000024287 MAP3K9 2.3688072 0.00083042 2.20071631 0.00668234 
ENSECAG00000024288 SLC27A2 -4.0222032 4.0935E-08 -4.1480246 5.3724E-07 
ENSECAG00000024374 ERBB3 -3.2972383 0.00195682 -2.7824123 0.00123976 
ENSECAG00000024385 PIWIL4 -4.7981782 0.00246968 -5.1191088 0.00796328 
ENSECAG00000024387 PRKG2 -8.2263631 1.4163E-06 -7.2193365 1.5161E-05 
ENSECAG00000024399 FGF12 -3.5593341 1.8131E-05 -3.6052741 4.6916E-06 
ENSECAG00000024536 NFE2 3.25748473 0.00488029 3.44746426 0.00985863 
ENSECAG00000024542 ATP1A4 -2.3630611 0.00175021 -3.6859946 0.00705477 







-4.3474566 0.0006147 -4.0112757 0.00098639 
ENSECAG00000024674 TTLL7 2.40487 6.6138E-10 2.50373907 2.3656E-11 
ENSECAG00000024705 MAFB 3.26634555 3.4515E-09 3.17012239 1.8233E-08 
ENSECAG00000024764 ARHGAP18 -2.4194871 2.7189E-08 -2.3869083 2.8168E-07 
ENSECAG00000024810 PLA2G4A -2.6146686 3.4515E-09 -2.6033319 3.3919E-10 
ENSECAG00000024851 EDNRB -3.5435174 3.831E-05 -3.6295675 1.1269E-05 
ENSECAG00000024861 DLX1 -2.9817831 0.0003906 -3.0989414 0.00015339 
ENSECAG00000024870 CWH43 2.5816429 0.00044381 2.88495937 9.4669E-06 
ENSECAG00000024888 CCL5 -4.1804473 0.00254427 -4.3857992 0.00186958 
ENSECAG00000024906 SPOCK3 -7.9372926 2.4339E-06 -7.7998319 2.2158E-05 
ENSECAG00000024951 SERPINB7 -5.6165265 0.00129312 -5.6380678 0.00333779 
ENSECAG00000024992 HSD17B7 -2.1167203 3.2743E-05 -2.154261 7.1817E-05 
ENSECAG00000025020 FHL1 2.47472491 0.00429237 2.90825574 2.2837E-06 
ENSECAG00000025109 EEF1A2 -4.6846479 0.00246968 -4.6677601 0.001764 
ENSECAG00000025171 HS3ST3A1 -6.7552988 0.00135218 -6.3220018 0.00804473 
ENSECAG00000026819 NTN1 3.60482099 3.7728E-08 3.56207493 6.1712E-08 
ENSECAG00000026863 EFS 2.1369118 8.7258E-09 2.222296 7.7283E-13 
ENSECAG00000026984 GPSM3 -2.9912217 0.0011337 -3.6211824 0.00239279 
ENSECAG00000027719 
 
-3.7059477 5.1005E-05 -3.8265987 0.00663305 
ENSECAG00000028369 GRIN3B 2.51559851 6.0352E-13 2.58084444 2.3049E-10 
ENSECAG00000028889 
 
5.33919832 0.00235867 5.48672777 0.00142053 
ENSECAG00000029062 PRNP -2.8085069 0.00052497 -2.6097475 0.00076656 
ENSECAG00000029287 
 
8.0369476 2.4339E-06 7.88559562 0.00069936 
ENSECAG00000029428 DLK1 -6.109829 0.00050141 -5.8499562 0.00288007 
ENSECAG00000030290 TTC9 6.92811655 6.4984E-06 7.52560989 2.7809E-05 
ENSECAG00000030554 LIF -3.9904499 2.3296E-11 -3.9665182 1.2261E-10 
ENSECAG00000030644 PALM3 2.23866059 0.00362624 2.19333134 0.00174301 
ENSECAG00000030850 FGF18 2.53965678 0.00049265 2.52884832 0.00205446 
ENSECAG00000031322 
 
-8.219668 0.00130399 -6.0515986 0.00162307 
ENSECAG00000031442 FGF16 8.44045634 3.6676E-05 8.34984188 0.00042925 
ENSECAG00000031983 MTUS1 2.49212065 6.6475E-06 2.634851 4.5421E-09 
ENSECAG00000032416 APC2 2.00396644 0.00936522 2.47600749 9.7446E-07 
ENSECAG00000032515 CEBPA 2.55601841 0.00363472 2.88770415 0.00408581 
ENSECAG00000032623 TMEM158 -3.8230468 2.245E-05 -3.9864453 0.00075747 
ENSECAG00000032959 
 
-5.4326121 5.7383E-05 -7.0926593 4.2591E-10 
ENSECAG00000032992 TIAM1 -2.7299671 0.00156249 -2.8392356 0.00297582 
ENSECAG00000034242 
 
-2.4247444 1.1082E-05 -2.0316611 0.00071148 
ENSECAG00000034300 RASD1 -3.4161744 6.2165E-05 -3.5730921 0.00029279 
ENSECAG00000034308 TRIM6 -2.0721281 0.00355762 -2.4337465 0.00021615 
ENSECAG00000035324 HAS3 -3.6122185 0.00031713 -4.4687797 0.00040641 
ENSECAG00000035548 
 
-5.5242707 6.0393E-09 -6.3491358 2.6982E-09 
ENSECAG00000035667 
 
2.98994285 1.533E-08 3.00287498 0.00088291 
ENSECAG00000035706 SMCO4 -2.217128 1.0071E-06 -2.1279943 1.8233E-08 
ENSECAG00000036634 CCDC3 7.58685027 2.4886E-13 7.61328712 1.7657E-11 
ENSECAG00000036638 SLC6A12 -3.2719713 0.00068409 -3.4694103 0.00048409 
ENSECAG00000036646 FGF19 3.48745894 3.4874E-08 3.2934258 2.6061E-09 
ENSECAG00000036997 
 
-2.8411139 0.00210782 -3.02044 0.00414732 
ENSECAG00000037060 SCX 2.90519135 0.00053303 3.28870599 3.7439E-06 
ENSECAG00000037831 SOX11 -4.5113325 2.7707E-05 -4.7297265 5.6072E-06 
ENSECAG00000037859 ERICH4 -2.5068279 0.00420376 -2.5854117 0.00241451 
ENSECAG00000038005 
 
-4.6371588 0.00128661 -4.5701944 0.00135646 
ENSECAG00000038178 HEY2 -3.0847903 8.546E-07 -3.1208347 2.5876E-05 
ENSECAG00000038313 MT2A 2.80863949 0.00058611 2.8115114 0.00065399 





ENSECAG00000039651 RNF208 2.05344658 0.00609264 2.14541577 0.00622987 
ENSECAG00000039865 
 
-4.9970128 0.0064076 -4.4592034 0.00124768 
ENSECAG00000040252 
 
-3.3643973 8.4702E-05 -3.3873436 7.277E-05 
ENSECAG00000040532 
 
-7.0614382 0.00106893 -6.1095264 0.00188811 
ENSECAG00000040631 GADD45A 2.97598998 6.6156E-07 2.88055323 2.3981E-06 
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Table A2. List of DE genes between adult and fetal tenocytes cultured in 3D identified using 
alignment-based mapping. 113 genes identified as being DE in adult and fetal tenocytes using 
HISAT2 alignment-based mapping only. Based on a p-adj of < 0.01 and ±2 Log2FC.  
 
Ensemble Gene ID 
 
Gene name 
HISAT2 mapping Salmon mapping 
Log2 FC p-adj. Log2 FC p-adj. 
ENSECAG00000000758 CAPN11 3.15496627 0.00224538 3.09830907 0.02176647 
ENSECAG00000001481 SAMD9L -5.2047511 0.00456344 -4.6602804 0.01386661 
ENSECAG00000003078 OXGR1 -5.0168761 0.00409423 -5.076409 0.03743207 
ENSECAG00000003193 BAMBI -2.0156985 0.00083641 -1.8890176 0.00156998 
ENSECAG00000004942 RGS1 -6.3542033 0.00337147 -6.8050318 0.01598007 
ENSECAG00000005126 TRIM22 -9.1744934 0.00531843 -7.3980057 0.01211602 
ENSECAG00000005405 BDKRB2 -3.1774411 0.0044009 -3.2466137 0.15885089 
ENSECAG00000005577 GPR39 3.70291607 0.00609264 2.3923296 0.03955876 
ENSECAG00000006175 PGBD5 -2.2394364 0.00628199 -2.0256107 0.03076012 
ENSECAG00000006178 TRH -3.1586886 0.00845454 -3.4004568 0.04541126 
ENSECAG00000006703 
 
-6.8846975 0.00360284 -6.5382462 0.01407504 
ENSECAG00000006991 PECAM1 -3.2812738 0.00646998 -3.0118702 0.01788761 
ENSECAG00000008059 
 
2.07133801 0.00807216 2.10092386 0.01102352 
ENSECAG00000008112 EPGN -4.981002 0.00349097 -3.7675741 0.06123986 
ENSECAG00000008564 MAGI2 4.3350489 0.00409423 3.67277741 0.03032404 
ENSECAG00000008624 CCL28 -2.0907807 0.00513794 -1.8497515 0.02226176 
ENSECAG00000009660 PLEKHA6 2.07538683 3.4515E-09 1.97239258 2.1631E-08 
ENSECAG00000010131 CPLX1 -7.0561848 0.00058594 -6.3104424 0.01390672 
ENSECAG00000010206 SMTNL1 -3.3541863 0.00114766 -0.2277101 NA 
ENSECAG00000010537 HECW1 -3.7308502 0.00868415 -3.8866447 0.07817924 
ENSECAG00000010648 GPR143 -5.0343682 0.00833521 -3.4619438 0.15943615 
ENSECAG00000011067 CAPN3 6.19092278 0.003769 5.47839591 0.29120912 
ENSECAG00000011406 ST8SIA4 -2.5037637 0.00542982 -2.5741989 0.02285188 
ENSECAG00000011439 DHX58 -3.4075018 0.00526951 -2.9065186 0.01879227 
ENSECAG00000011794 C20H6orf141 -2.4100135 0.00134346 -1.9407632 0.04408123 
ENSECAG00000011854 CFB 3.33787585 0.00173836 3.6591285 0.05507649 
ENSECAG00000011934 LGR6 -4.7646084 0.00286369 -4.4256775 0.01964908 
ENSECAG00000012150 SHROOM2 -2.013765 8.2604E-06 -1.9138102 8.0022E-06 
ENSECAG00000012514 
 
-6.5726344 0.00092689 -5.472098 0.01421732 
ENSECAG00000012695 DBX2 7.35191547 5.0721E-05 6.97031326 0.01635939 
ENSECAG00000012791 GBP6 -5.5338595 0.00731023 -4.6403105 0.03574442 
ENSECAG00000012825 ARHGAP24 -2.3933327 2.9964E-05 -1.4585228 1.2321E-08 
ENSECAG00000013681 GRHL2 -2.1182002 0.00259947 -2.0364382 0.01069774 
ENSECAG00000013883 ICAM1 -2.1219122 0.00291118 -1.9678908 0.00862649 
ENSECAG00000014149 NETO1 -2.9748136 0.00281415 -2.8553719 0.01274405 
ENSECAG00000014200 TMEM178B -4.0274733 0.00414113 -4.337663 0.01654865 
ENSECAG00000014992 JAM2 2.26655685 0.00258792 2.23109665 0.01489417 
ENSECAG00000015102 MYOZ3 2.51376139 0.00523984 2.48322109 0.04157201 
ENSECAG00000015382 NLRP3 -3.7014158 0.00308472 -3.3781294 0.01291967 
ENSECAG00000015894 ANGPT2 -4.3283919 0.00233288 -4.4699853 0.02393851 
ENSECAG00000016312 CD274 -4.7443637 0.0055796 -4.1456002 0.06648712 
ENSECAG00000016564 RPRML 6.09334049 0.0005971 5.35525532 0.02357524 
ENSECAG00000016713 TESMIN 5.77049749 0.00105677 4.18396154 0.12196016 
ENSECAG00000017450 CMTM8 -3.6785984 0.00612132 -3.2443785 0.02860968 
ENSECAG00000018674 CEMIP 2.56811092 0.00706704 2.7727815 0.07011718 
ENSECAG00000019084 DLX6 2.93719348 0.00556316 3.22214801 0.03344219 





ENSECAG00000019298 FER1L6 -2.1547555 0.00121528 -1.3944155 0.15967857 
ENSECAG00000019551 CXCL12 2.40992766 0.00313362 2.77755778 0.04533863 
ENSECAG00000020126 LGI3 2.31318306 0.00275405 2.40584765 0.01481823 
ENSECAG00000020201 GCNT1 -2.0256484 2.5863E-08 -1.9791658 7.5397E-08 
ENSECAG00000020449 PARVG -4.4467043 4.349E-05 -4.6613435 0.03180037 
ENSECAG00000020552 GPR83 -2.237192 0.00300301 -2.3608536 0.01101184 
ENSECAG00000020808 TRIL -3.2019669 0.00734464 -2.7247225 0.03007736 
ENSECAG00000020974 RTP3 3.40229862 0.00225973 3.59256623 0.01022927 
ENSECAG00000021078 GRB14 -2.1885793 0.0018955 -2.0405071 0.0112897 
ENSECAG00000021392 COL26A1 -4.6007733 0.00691737 -4.800369 0.01192905 
ENSECAG00000021395 CLDN19 -4.2547343 0.00744684 -3.7053767 0.14535147 
ENSECAG00000021654 SLC10A4 -2.5622286 0.00731777 -2.4258814 0.04440647 
ENSECAG00000022443 GPR87 -4.8511785 0.00612534 -4.2329937 0.01062557 
ENSECAG00000022873 ATP8A1 -3.3897927 0.00975674 -3.2733133 0.04205545 
ENSECAG00000023321 ELF5 3.99511829 0.00647054 3.77387669 0.06062318 
ENSECAG00000023531 RAD21L1 -4.5907208 0.00718967 -4.3497345 0.01828717 
ENSECAG00000023963 NMNAT2 -2.015238 0.00168286 -1.9521989 0.00017472 
ENSECAG00000024312 RORB -6.1999958 0.00445682 -5.191208 0.0202141 
ENSECAG00000024358 ZBTB16 3.37335164 0.00576439 3.34476026 0.01766532 
ENSECAG00000024389 TEC -2.1601352 2.3198E-08 -1.9939932 2.4934E-07 
ENSECAG00000024599 KIRREL3 2.44204496 0.00568562 2.43956027 0.02703237 
ENSECAG00000024961 XAF1 -7.0997631 0.00483482 -5.6398282 0.02853514 
ENSECAG00000027765 
 
-4.4045495 0.00282604 #N/A #N/A 
ENSECAG00000028085 
 
-3.4736869 0.0020927 -2.4546557 0.0541678 
ENSECAG00000029156 
 
-2.5343909 4.229E-05 #N/A #N/A 
ENSECAG00000029578 
 
-2.2136632 1.4764E-06 #N/A #N/A 
ENSECAG00000031122 
 
-2.9490136 0.00328681 #N/A #N/A 
ENSECAG00000031668 
 
3.21313841 0.00121528 2.63930849 0.09071631 
ENSECAG00000032667 INA -3.6823527 0.003769 -3.6536755 0.01205033 
ENSECAG00000033252 
 
4.38380613 0.00093452 #N/A #N/A 
ENSECAG00000033385 LGALS3BP -5.7343131 0.00798943 -4.8574649 0.01650681 
ENSECAG00000033730 
 
-5.0586768 0.00363024 -3.661806 0.19953431 
ENSECAG00000033856 
 
-3.9710316 2.8359E-10 #N/A #N/A 
ENSECAG00000034127 CRACR2A -5.8715142 0.00734513 -5.3840241 0.01952886 
ENSECAG00000034535 
 
-2.7986235 0.00530962 #N/A #N/A 
ENSECAG00000035544 
 
4.67384823 0.00479277 #N/A #N/A 
ENSECAG00000036059 FAM155A -3.9875843 0.00150844 -3.8943619 0.01609996 
ENSECAG00000036178 TMEM238 -3.6475014 0.00240682 -0.595895 0.54645876 
ENSECAG00000036860 eca-mir-9149 4.713375 0.00845454 #N/A #N/A 
ENSECAG00000037593 
 
-7.1732853 0.00322037 -6.1569948 0.02387106 
ENSECAG00000037901 
 
2.53613613 0.00045104 #N/A #N/A 
ENSECAG00000038391 
 
-3.3080144 0.00490194 -2.440336 0.04706489 
ENSECAG00000038552 
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Table A3. List of DE genes between adult and fetal tenocytes cultured in 3D identified using 
alignment-free mapping. 101 genes identified as being DE in adult and fetal tenocytes using 
Salmon alignment-free mapping only. Based on a p-adj of < 0.01 and ±2 Log2FC.  
 
Ensemble Gene ID 
 
Gene name 
HISAT2 mapping Salmon mapping 
Log2 FC p-adj. Log2 FC p-adj. 
ENSECAG00000000046 FAM13C -1.6195041 0.18222154 3.17125249 0.00730174 
ENSECAG00000000203 TRPA1 2.1646631 0.08099268 -3.5232629 0.00370842 
ENSECAG00000000271 APBA1 -1.8065572 0.30333891 3.56234098 0.00222121 
ENSECAG00000000651 SPINK5 3.18019455 0.0104386 -3.989795 0.00986419 
ENSECAG00000000852 SGIP1 1.84240495 0.11687374 -2.0474441 0.0004334 
ENSECAG00000000903 RASGRF2 -2.5150523 0.01011661 2.50183667 0.00407105 
ENSECAG00000001004 TMEM74B 2.93858106 0.00662523 -3.0271051 5.8443E-05 
ENSECAG00000002548 RNF182 3.16312232 0.01445254 -2.5000881 0.00835456 
ENSECAG00000002867 F2RL1 2.92600133 0.01103188 -3.1685806 0.00016149 
ENSECAG00000005379 HPGD 5.35744968 0.04496436 -5.103158 0.00277089 
ENSECAG00000006337 RAB11FIP4 1.51444165 0.08369467 -2.0359288 0.00290499 
ENSECAG00000006756 MYH14 1.80239384 0.01535388 -2.4475078 0.00632022 
ENSECAG00000006853 UBD 7.34828784 NA -6.2136332 0.00933036 
ENSECAG00000007414 SV2A 2.06608734 0.07781021 -2.1665391 0.00436056 
ENSECAG00000007647 COL5A3 2.09960722 0.01722894 -2.3739564 0.00096409 
ENSECAG00000007985 GOLGA7B 4.07914208 0.00030544 -4.8635145 0.00886039 
ENSECAG00000008079 BEND6 -1.4334732 0.03305331 2.03137612 0.00256839 
ENSECAG00000008135 TRPM3 2.43795859 0.00262167 -2.9022584 0.00258056 
ENSECAG00000008596 THEMIS2 3.73614838 0.00303572 -4.1731665 0.00144851 
ENSECAG00000008782 RPH3AL -1.970219 5.7411E-05 2.35470365 0.00256009 
ENSECAG00000009026 CYP2S1 2.28479085 0.06556274 -2.5694729 0.000998 
ENSECAG00000009042 
 
NA NA -4.0068776 0.00156998 
ENSECAG00000009133 ACVRL1 2.76522529 0.03216413 -2.7281562 0.0048333 
ENSECAG00000009139 CFTR 3.48826572 0.00523645 -3.2386151 7.1626E-06 
ENSECAG00000009306 NECTIN2 2.1646416 0.02263529 -2.5166024 8.4842E-07 
ENSECAG00000009989 CHAC1 #N/A #N/A 2.3427651 0.00307592 
ENSECAG00000010120 SNAI2 -1.9139682 0.00067985 2.0093063 0.00051476 
ENSECAG00000010178 ITGB4 2.09878486 0.06240864 -2.4954798 2.6127E-05 
ENSECAG00000010184 
 
-3.0048909 0.0924961 4.00873623 0.00124638 
ENSECAG00000010579 
 
-1.2889062 0.00738851 2.11643134 0.00017701 
ENSECAG00000010748 MPZL3 1.7495965 0.01258474 -2.0105522 9.5064E-05 
ENSECAG00000010990 
 
1.90261998 NA -7.4623965 0.00639229 
ENSECAG00000011177 TESC 5.22444417 0.18090472 -3.8380927 5.8044E-05 
ENSECAG00000011335 ITM2A -0.1078833 0.99438765 -3.7638186 0.006914 
ENSECAG00000012004 PIP4P2 -3.1824575 0.00128917 2.49840814 0.00213905 
ENSECAG00000013106 ESM1 5.3933586 0.00652517 -4.9035206 0.00156998 
ENSECAG00000013387 WNT7B 2.33097955 0.00345521 -2.6707273 9.0445E-05 
ENSECAG00000014486 CADPS -3.3018163 0.18708899 3.79905652 1.5845E-06 
ENSECAG00000014566 CCN5 -2.7399377 0.03684869 4.05688157 2.3163E-05 
ENSECAG00000014769 ITPKB 1.92503293 3.9054E-05 -2.0514857 1.1232E-08 
ENSECAG00000014891 NRCAM -3.0816552 0.02074947 3.18643187 0.00482873 
ENSECAG00000015194 RHBDL2 0.85112493 0.27911246 -2.0843913 3.6674E-05 
ENSECAG00000015758 IRX2 -2.3726504 0.12541428 2.54724085 0.00784876 
ENSECAG00000016161 SLPI -3.2296102 0.10218686 4.60357672 0.00692976 
ENSECAG00000016219 KANK1 -1.9695887 1.1943E-05 2.00608053 3.7963E-08 
ENSECAG00000016360 PDE3A 3.16358245 0.00583577 -3.1876073 0.00081982 





ENSECAG00000017027 SFRP2 -2.9622792 0.1854791 3.57905336 0.0002415 
ENSECAG00000017191 SPP1 3.67423204 NA -3.3416806 0.00054884 
ENSECAG00000017274 KRT13 -2.2108775 0.13558616 4.84462662 8.5696E-07 
ENSECAG00000017407 MOXD1 2.50573701 0.01080127 -2.724922 0.00033618 
ENSECAG00000017793 NGFR 7.2352042 NA -4.9972198 0.00020873 
ENSECAG00000017802 OGN NA NA 5.0111161 0.00444675 
ENSECAG00000017925 CD200 5.59208777 0.03798189 -5.1950422 2.0052E-05 
ENSECAG00000018429 WDFY1 NA NA 7.45178495 0.00247244 
ENSECAG00000018752 APOL6 7.35821682 0.01175625 -6.2500103 0.00096409 
ENSECAG00000018814 BCAM 1.91611287 0.00661066 -2.1249601 4.9563E-05 
ENSECAG00000018954 NCCRP1 2.33355553 0.02745427 -2.353994 0.00202729 
ENSECAG00000019278 GREB1L 1.31211967 0.00168529 -3.6912685 2.5322E-06 
ENSECAG00000019637 LGALS12 3.22001286 0.04046191 -4.6844119 3.3873E-06 
ENSECAG00000019881 PARP10A 2.86965184 0.03522834 -2.7645911 0.00236697 
ENSECAG00000019895 LRRC32 2.76286041 0.04435391 -3.1020272 0.00636883 
ENSECAG00000019932 
 
2.6639955 0.04423472 -2.7948001 0.00691739 
ENSECAG00000020612 SLC7A3 -2.4386783 0.1419941 3.21409851 0.0003427 
ENSECAG00000020778 FBLN7 -2.1186831 0.10409519 2.96054324 0.00143612 
ENSECAG00000020869 FGFR4 2.93681835 0.00335286 -2.9972336 0.00714945 
ENSECAG00000021277 LAMA3 -2.3801577 0.00720673 2.40472009 0.00020203 
ENSECAG00000021796 
 
5.60343379 NA -4.3705291 0.00910203 
ENSECAG00000022166 AKAP12 2.25538142 0.0117464 -2.539386 0.00105505 
ENSECAG00000022241 CACNA1H -2.7208091 NA 3.74362523 0.00025727 
ENSECAG00000022263 STC2 -1.8717579 0.00330739 2.05849039 7.1171E-07 
ENSECAG00000022420 LSR 1.3665071 0.00294167 -2.1057867 0.00505393 
ENSECAG00000022525 AREG 5.18439586 0.01131359 -4.3535474 0.00784876 
ENSECAG00000022705 IL16 -2.4271738 0.03956992 3.2734059 8.2994E-05 
ENSECAG00000022867 TSPAN18 -1.6664324 0.34736634 2.25746627 0.00210023 
ENSECAG00000022950 NDRG2 1.6616239 0.01453637 -2.0800866 5.8872E-05 
ENSECAG00000023149 SCIN 4.0219047 0.0070395 -3.640528 0.00302622 
ENSECAG00000023241 SCRN1 -1.849233 0.18811295 3.72879837 0.00409267 
ENSECAG00000023308 
 
-1.9383997 0.00738851 2.09604288 0.00127729 
ENSECAG00000024367 CASP1 5.30741816 0.00414637 -5.1503224 0.00436056 
ENSECAG00000024467 SH3RF2 -1.7499529 0.03330243 2.00994316 0.00051413 
ENSECAG00000024824 ADGRL2 2.16344977 0.01918242 -2.5757158 0.00011694 
ENSECAG00000025065 COL12A1 -2.0296011 0.05650654 2.11338892 0.00275924 
ENSECAG00000025098 CRHR2 4.52110424 0.00047195 -6.0095615 0.00737558 
ENSECAG00000025101 NELL2 -2.5433028 0.04770242 3.58504878 0.00069319 
ENSECAG00000029196 
 
#N/A #N/A -5.7282807 0.0038423 
ENSECAG00000030119 
 
#N/A #N/A 2.79196068 0.00433052 
ENSECAG00000030636 
 
NA NA -2.0104213 3.39E-08 
ENSECAG00000030750 
 
#N/A #N/A -6.3972951 0.00034055 
ENSECAG00000030891 
 
NA NA -7.6285948 0.00130927 
ENSECAG00000032131 
 
2.41646375 0.01289439 -2.2333961 0.0081493 
ENSECAG00000032479 
 
#N/A #N/A 2.28261287 0.00241451 
ENSECAG00000034476 
 
1.71245249 0.329305 -2.6085748 0.00632882 
ENSECAG00000034839 
 
#N/A #N/A -2.1558908 0.00041765 
ENSECAG00000036014 
 
NA NA -5.0505276 0.00187259 
ENSECAG00000036610 CALY 2.90667392 0.01315119 -3.045238 0.00765603 
ENSECAG00000036649 
 
#N/A #N/A -6.1491852 0.00714945 
ENSECAG00000037853 
 
#N/A #N/A 2.84437647 0.00567969 
ENSECAG00000038379 
 
4.08360737 0.01566214 -3.2178031 0.00382732 
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